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ABSTRACT
The Interaction of Platelets and Exogenous Anti­
genic Factors in the Causation of Atherosclerosis 
and Coronary Heart Disease
This work describes aspects of the role of platelets 
in the development of atherosclerosis and coronary heart 
disease (CHD)• Emphasis is on the involvement of "young" 
platelets, which are metabolically more active than the 
other population of these cells and are consequently termed 
"active" platelets. Aggregation investigations were used to 
detect an increase in this fraction of the platelet popula­
tion and electron microscope studies confirmed that these 
aggregation results reflected the total activity of the 
platelets. Surveys performed in conjunction with the 
Medical Research Council Epidemiology Unit showed abnormal 
results in approximately 18% of the normal population and 
in approximately 90% of CHD patients. This la tte r  group 
was tested at least twelve months after recovery from the 
heart attack (myocardial infarction).
There are immunological factors which may be important 
and are investigated in this work. The involvement of these 
factors are indicated by the report relating antibody to 
whole dried milk with CHD. This original observation was 
confirmed in surveys performed in collaboration with the 
Medical Research Council Epidemiology Unit. Because of the 
large number of specimens involved in these surveys, an 
automated method was developed. This method was also used 
to survey the distribution of food antibodies in the normal 
population.
It was found that the milk antibody originally related 
to CHD was produced in response to an antigen present in 
the cream portion of milk. I t  was determined that the 
antigen resided in the bovine milk-fat globule-membrane. 
Because i t  has previously been shown that cross-reactivity 
exists between membranes of different species, the possibility
—of antibody to bovine milk-fat globule-membrane reacting 
with human platelets was considered and the resulting 
investigations, which demonstrated this occurrence, are 
described.
The possibility is considered that increased platelet 
turnover in this disease, with an increased percentage of 
"active" platelets, may well be the result of the action of 
antibody to bovine milk-fat globule-membrane. Interaction 
between membranes may therefore play a role in the develop­
ment of atherosclerosis.
- 1-  
CHAPTER 1 
GENERAL INTRODUCTION
1.1 Introduction
This thesis discusses and examines the role of platelets 
in the development of coronary heart disease (CHD). The in­
volvement of certain immunological factors is also described.
There is evidence to show that a higher percentage than 
normal of "active" platelets are present in the circulation of 
hospital-based CHD patients in the acute phase of the disease. 
Controversy remains regarding their role and significance and 
their presence in the circulation has been attributed to the 
action of atheromatous tissue and subsec[uent ulceration. The 
work described in this thesis investigates the platelet acti­
vity in "long-term" CHD patients and also in apparently healthy 
control subjects. I t  also examines the hypothesis that an in­
creased percentage of "active" platelets in the circulation 
could be one important contributory factor responsible for in­
itiating the process which eventually leads to atherosclerosis.
\
The immunological aspect of CHD concentrates on the repor­
ted involvement of antibodies to whole dried milk in this con­
dition. An experimental programme was designed to elucidate 
the role of this phenomenon in CHD. The results obtained are 
reported and discussed.
The involvement of the platelets and the new immunological 
approach to CHD are detailed in the following sections.
1.1.1 The platele-tÿ-morpholoqy and function. In the circulat- 
ing blood the platelets appear as disc-shaped cells with an 
average longitudinal diameter of approximately 2-3pn (1) and 
0.5-lpm in thickness (2). An historical review by Tovantins 
(3) describes how the platelets were recognised as cells early 
in the f i r s t  quarter of the 19th century but most workers failed
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to appreciate their importance until Bizzozero in 1882 (4) 
related their function to the coagulation of blood. Wright 
in 1910 (5) established that platelets are detached portions 
of the cytoplasm of a cell produced in the bone marrow called 
the megakaryocyte. Although megakaryocytes are frequently 
found in the lungs (6), in the marrow they mature from the multi- 
potential stem cell which differentiates into the erythrocytic, 
myelocytic and megakaryocitic series (7). The earliest recog­
nisable member of the megakaryocytic series is the megakaryo- 
blast. In contrast to other cells these divide by a process 
termed endomitosis (8), a term describing nuclear division with 
the absence of cytoplasmic division. This cell develops into 
the promegakaryocyte and subsequently into the mature megakary­
ocyte. In the marrow, these cells are situated close to the 
sinusoidal membrane (9) and Wintrobe (10) describes how, from 
the megakaryocyte "platelet formation begins by the development 
of numerous long cytoplasmic pseudopods that extend through 
apertures in the sinus membrane into the lumen, much in the 
manner of an octopus. These pseudopodia become thinner and 
ultimately filiform and granular masses, the size of platelets, 
form within them. These are probably caught in sinusoidal 
capillaries, segments are broken off by their contraction, 
and the platelets thus formed are swept away by the blood 
streairf*. I t  has been calculated (11, 12) that one megakaryo­
cyte is capable of releasing between 2,000 and 7,000 platelets.
The mechanism that controls the turnover of platelets in 
humans has not been fully explained (13), however i t  has been 
postulated that the hormone called thrombopoietin regulates 
the release of the platelets from the megakaryocytes (14, 15). 
I t  is not clear what stimulus is responsible for the action of 
this hormone, but i t  has been suggested that i t  may depend more 
on the to tal body content of platelets than upon their concen­
tration in the blood (16, 17). I t  has been estimated that the 
platelet turnover rate in normal subjects is 35,000 ^4,300 
platelets/}il/day (18) and the platelet count in adults averages 
250 X 10^/1 and ranges from 140-440 x 10^/1 (10).
The normal life-span of the platelet, in normal subjects.
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has been reported to be between 9 and 12 days (19-21)• Shul- 
man and his co-workers (22) demonstrated that after leaving 
the marrow the platelets are stored in the spleen for approxi­
mately two days. On leaving the spleen the cells remain in the 
circulation for approximately 10 days. During this time i t  
appears that a proportion of the circulating platelets enter 
a splenic pool where they are exchanged with new cells, which 
in turn, re-enter the circulation. Although Shulman (22) 
states that approximately one third of the platelet are sequestr­
ated in the spleen. Aster and Jandle (20) demonstrated that 
the majority of circulating platelets are destroyed by the 
liver. Controversy remains regarding the exact mechanism con­
trolling the destruction of the platelets and i t  appears that 
platelets are removed from the blood stream by random destruc­
tion (23) and senescence (24). The newly-formed platelets 
released from the spleen appear to be metabolically more active 
than the other platelets present in the circulation (22, 25-30) 
but i t  has been suggested that these cells only show this 
activity for approximately two days (22). Section 1.1.3 (page 
15) of this thesis examines the relationship between an increase 
in the percentage of these platelets and the development of 
coronary heart disease.
The major function of the platelet is in haemostasis (31) 
which is a process in which the cell plays both a mechanical 
and biochemical role. Wintrobe (10) describes how vascular 
injury results in platelets adhering to the vessel wall, an 
action initiated by the exposed collagen fibres. Such adherent 
platelets release stored ADP (the release reaction) which results 
in the formation of further platelet aggregates. The activation 
of certain platelet factors and the initiation of blood coagula­
tion factors then follow, leading to the consolidation of the 
platelet plug by fibrin and subsequently to the phenomenon of 
clot retraction. In addition to their role in the process of 
coagulation, platelets act to maintain or support the vascular 
integrity of the vasculature by attaching to gaps which normally 
develop in the endothelium and as a result they actually enter 
and are incorporated into endothelial cells (32-35). This phen­
omenon is illustrated in Fig. 1.
Fig. 1. Diagram of the mechanism involved when a
platelet enters the endothelial cytoplasm.
Reproduced with permission of the publishers 
From Johnson, S. A. (1971), p.296, (13).
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Electron microscopy studies have shown that platelets are 
far more complex than suggested by their deceptively simple 
appearance when viewed by light or phase contrast microscopy. 
The ultastructure of the platelet is illustrated in Fig. 2.
Platelet anatomy can be divided into three main functional 
divisions
(a) the peripheral zone which includes the exterior coat,
unit membrane and submembrane area. This zone is 
responsible for adhesion and aggregation.
(b) The sol-gel zone which contains the microtubules and
the microfilaments. Their main function is contraction
and support.
(c) The organelle zone containing the granules, dense
bodies and mitochondria whose main function is storage 
and secretion.
(a) The peripheral zone is the interface between the 
platelet and the plasma (13). The outer "coat" surrounding 
the surface of the platelet is approximately 10-2Onm thick 
and is referred to as the "fluffy coat" or plasmatic atmos­
phere. The exact composition of this "fluffy coat" is not 
known, but i t  is considered to be important in the adhesion 
and aggregation of platelets (1).
"Adhesion" is the term used to describe the process by 
which platelets attach themselves to a non-platelet surface 
(36) and "aggregation" describes the attachment of platelets 
to each other (10). In vivo, platelets will adhere to collagen 
fragments, basement membrane and microfibrils which are associa­
ted with elastin (2, 37). Mayer (38) describes how both physi­
cal and chemical determinants are present on collagen fibres 
which together are responsible for platelet adhesion leading 
to platelet activation. The main physical factor involved is 
the triple helical shape of the collagen fibres and i t  appears 
that the chemical determinants recognised by the platelets on 
these triple helical surfaces involve some general features of
Fig. 2. Diagramatic representation of platelet anatomy.
Included is the peripheral zone, the sol-gel 
zone and the organelle zone. Structural elements 
of the peripheral zone include the exterior coat 
(fluffy coat) (EC), the unit meirbrane (CM) and a 
submembrane area containing submembrane filaments 
(SMP). The la tte r  are also included with the 
circumferential band of microtubules (MT) and 
microfilaments as the three major fibre systems 
constituting the matrix of the sol-gel-zone. 
Granules (G), dense bodies (DB), and mitochondria 
(M) are the formed organelle zone. The open 
canalicular system (CS) and the dense tubular 
system (DTS) are also illustrated together with 
a Golgi zone (GZ) present in approximately 10% 
of platelets. Glycogen particles (Gly) are 
usually concentrated in masses on the metrix.
Reproduced with permission of the publishers. 
From Johnson, S. A. (1971), p .48, (13).
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collagen composition, in particular the high pro1ine/hydroxy- 
proline content. This complex adhesion mechanism has also 
been ascribed to neuraminidase in the platelet membrane which 
exposes acceptor groups in the collagen by hydrolising sialic 
acid residues (39). The groups exposed in the collagen react 
with glycosyl transferases located in the platelet membrane 
(40).
Following adhesion, the platelets undergo a secretory 
process by which substances found in the dense bodies and the 
alpha granules are secreted. Grette (41) named this process, 
"the release reaction" and the ADP released results in the 
formation of the platelet aggregate. Aggregates became appa­
rent in experimental wounds within 15 seconds of the adhesion 
process (2). In v itro , platelet aggregation may be observed 
by an instrument called a "platelet aggregometer" (42). This 
instrument is a photo-optical instrument which is connected to 
a strip recorder chart. Platelet-rich plasma, which is turbid, 
is stirred in a cuvette and the transmittance of light through 
the sample, relative to a platelet-poor blank, is recorded.
When an aggregating agent is added, the formation of increas­
ingly large platelet aggregates is accompanied by a clearing 
in the platelet rich plasma, and therefore, light transmittance 
through the sample is increased. The light received through 
the sample is converted into electronic signals, sunplified 
and recorded on the chart recorder paper (Fig. 3).
The substances that induce platelet aggregation are many 
and varied. They are listed in Table 1. Platelet aggregation 
proceeds through three definite recognisable phases (1):-
(a) the change of shape of the cells after stimulus with 
the aggregating agent.
(b) primary reversible aggregation as the result of the 
stimuli.
(c) secondary or irreversible release action dependent on 
the concentration of the aggregating agent.
Fig. 3 showing typical aggregation curves produced by 
various aggregating agents.
Reproduced with permission of the publishers. 
From Triplett, D. A. e t. a l . (1978), p .114 (1),
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Table 1 showing substances that induce release in the 
platelets.
Reproduced with permission of the publishers. 
From Triplett, D. A. e t. al. (1978), p.16 (l)
Inducer
Inducer
Type
Shape
Change
Adhesion/
Aggregation
Release 1 
(Dense Body
Release II 
(Alpha Granule)
Low molecular weight 
Adenosine 
diphosphate (ADP) Weak + 4- 4"
Epinephrine Weak — 4- 4- —
Norepinephrine Weak + — 4- —
Serotonin Weak + — — —
Vasopressin Weak + +  ... + —
Proteolytic enzymes 
Thrombin Strong + + 4-
Trypsin Strong 4- + 4- 4-
Snake venom Strong + 4- 4* 4*
Papain Strong + 4- 4- +
Particulate matter 
Collagen Strong + 4- 4" 4-
Latex particles Strong? + 4-. + 4"
Fatt)' acids Strong? + 4- “4- +?
Endotoxin Strong? 4- 4* + 4-?
Thorium dioxide Strong? 4- 4- + +?
Viruses Strong? 4- 4- 4- _ +?
.\ntigen-
antibody Strong 4" 4- 4" - +
Strongly positive- 
charged ions 
Polylysine Strong 4* -h 4-
Ijmthanum Strong 4- 4- — +
Ristocetin 
Concanavalin A 
Bovine fibrinogen 
Distilled water
Strong 4- 4- 4-
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The f irs t  recognisable sign of platelet activation is 
their change of shape into disc-spiny spheres. This change is 
induced by a ll aggregating agents except adrenaline (See Table 
1)• This process is thought to involve the uptake of water 
resulting in a 30% increase in platelet volume. This phen­
omenon takes a few seconds to occur at 37°C and i t  is possible 
that hidden adhesive sites on the platelet membrane are exposed 
during this phase of the platelet response (43).
When platelets are stimulated, they undergo reversible 
or irreversible aggregation depending on the concentration of 
the agent involved. The direct aggregation of platelets by 
ADP and other aggregating agents is called the primary, f ir s t  
phase or reversible aggregation. Aggregation that is irre­
versible is achieved through the release of the dense bodies 
and is referred to as secondary or second phase aggregation 
(1). This process involving the release of the contents of 
the dense bodies is termed "release I" and the extrusion of 
the alpha granules is termed "release IP* (44).
The ADP store in the dense bodies accounts for approxi­
mately 60% of the total ADP in human platelets. This ADP is 
nonmetabolic or storage ADP, which is to be distinguished from 
the metabolic pool (45). This la tte r metabolic ADP actively 
participates in the metabolism of the blood platelets and 
provides energy for the maintenance of the membrane transport 
systems, various synthetic processes and the response to 
such stimuli as aggregation and retraction. MOst platelet 
aggregating agents can produce the biphasic or irreversible 
response though this depends on the concentration of the 
inducing agent (See Table 1). I t  is considered that this 
irreversible response is the result of the aggregation induced 
by the ADP released from the dense bodies of the platelets 
(41, 46). Strong inducers such as thrombin, collagen and 
latex particles trigger both release I and release II, whereas 
weaker inducers such as ADP and adrenaline are only able to 
cause release I (See Table 1). I t  is thought that once the 
platelet function has reached the stage where release occurs, 
the dense bodies are emptied. Only then, if  the in itia l
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stimulus has been sufficient, are the contents of the alpha 
granules released (47).
The exact process that triggers the release mechanism 
remains unclear (31, 46, 48-52) however, i t  is now recognised 
that the prostaglandin system plays a central role in in itia ­
ting the release I reaction (53, 55).
Prostaglandins were f irs t  discovered more than 40 years 
ago by Goldblatt (56) and the pure forms were isolated and 
identified in 1960 by Bergstron and Sjovall (57). They are 
biosynthesised from polyunsaturated fatty acids (58, 59), 
primarily by arachidonic acid, which is a major component of 
membrane phospholipids (60). This is released from cell mem­
branes by the action of phospho1ipase (61). The actual 
method by which this enzyme is activated is not fully under­
stood (60,62) but i t  is believed that simple mechanical stimul­
ation can result in the generation of prostaglandins from the 
platelets, and the lungs and the spleen (63-65). The diversity 
of the biological actions of prostaglandins became apparent in 
the studies of their effect on the cardiovascular and respira­
tory systems (66) and reviews (60, 66, 67, 68) confirm the 
complexity of their functions and structures. This thesis, 
however, describes the activity and aggregation of platelets 
and therefore only two products of prostaglandin synthesis are 
discussed and described. These are thromboxane a strong 
inducer of platelet aggregation, and prostacyclin, an inhibi­
tor of aggregation.
Figure 4 describes the complete metabolic-pathway of 
prostaglandin synthesis. Both thromboxane A2 and prostacyclin 
are derived from arachidonic acid and once this has been re­
leased by the action of pho spho1ipase Ag, i t  is metabolised by 
two enzymes (69). The f irs t  is lipoxygenase which forms an 
unstable compound 12-hydroperoxy-arachidonic acid (HPETE) and 
its  stable end product 12-hydroxy-arachidonic acid (HETE).
The other enzyme is cyclo-oxygenase which forms prostaglandin 
endoperoxide PGGg. This can be transformed enzymatically into 
two unstable products with potent biological activity called 
thromboxane Ag (TXA2 ) and prostacyclin (PCI2 ).
Fig. 4 showing metabolic pathway of arachidonic acid.
R ep rod uced  b y  p e r m is s io n  o f  t h e  a u t h o r s .
From Mono ad a, S. & Vane, J. R. (1978), p. 130, (69)
j)
3O
AA
M etabolic pathway of arachidonic acid 
HPET E HETE
■OOOH•COOH
HO
Cyclic e n d o p e r o x i d e s
COOH
0 0  H
PGG
COOH
OHP G I PG H TXA
HOOC
COOH
OH
OH OH
6 - o x o - P G F i a TXBz
COOH
HO'
OH OH
OH ■COOH
COOHCOOH
OH
Ci7 H y d ro x y a c id
OH OHOH
PGDg PGE
Abbreviations:
AA: arachidonic acid
HETE: 12-hydroxyarachidonic acid
HPETE: !2-hydroxyperoxyarachidonlc acid 
PGIj; prostacyclin
M a l o n d i a l d e h y d e
TXAz: thromboxane A% 
TXBi: thromboxane 3i
'«^here cyclo-oxygenase inhibitors (aspirin-like drugs), thromboxane synthetase inhibitors and prostacyclin synthetase 
inhibitors exert their action are indicated by the numerals I, 2 and 3, respectively
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In platelets, the prostaglandin endoperoxides exert 
their effect through the conversion of the arachidonic acid 
into thromboxane Ag (70). This is an unstable substance 
(half life  30 secs.) which is converted to thromboxane B2 
which plays no active role in platelet aggregation (69). 
Thromboxane is a strong inducer of platelet aggregation 
(71), which i t  achieves by triggering the release I reaction 
(1). This prostaglandin was so named because i t  was identi­
fied as the metabolite of arachidonic acid in the thrombocyte 
(platelet ). The metabolic-pathway of arachidonic acid in 
the platelet is summarised in Pig. 5.
In constrast to the thromboxane A^  metabolism in the 
platelets, prostacyclin (PGI2 ) is the major product of arach­
idonic ad.d metabolism in all vascular tissue (69, 72-76). I t  
is an inhibitor of platelet aggregation and its  role will be 
discussed in greater detail in the subsequent section des­
cribing coronary heart disease (1.1.2, page 10).
In summary, the "fluffy coat" of the peripheral zone of 
the platelets plays an important role in the adhesion and 
aggregation of blood platelets. The processes involved in 
these reactions have been detailed in this section.
Located beneath this "fluffy coat" is the platelet mem­
brane (1). Platelet specific proteins are arranged asymmetri­
cally within the membrane and i t  has been demonstrated that 
only a few of the membrane proteins, including the three 
major glycoproteins are exposed to the outer aspect of the 
membrane (77-78). Immunological investigations have demonstr­
ated that these glycoproteins play a major role in the adhesion 
of the platelets to the vessel wall (79-81).
Another aspect of the platelet membrane is the network 
of channels that burrow through the platelet cytoplasm (1).
This system, which has been called the surface connecting or 
open channel system, enlarges the total surface area of the 
platelet membrane and is thought to play a role in the rapid
Fig. 5 showing the role of prostaglandins in the platelet-  
release reaction and aggregation.
The arachidonic acid is released from the 
platelet phospholipids by the action of phospholi- 
pase A. I t  is subsequently metabolised by the 
enzyme cyclo oxygenase which forms the prostaglandin 
endoperoxide PGG^ or labile aggregation stimulating 
substance (LASS) which is the precursor of throm­
boxane A2 .
Also included is the action of aspirin on the 
platelet. This drug inhibits the cyclo oxygenase 
thus preventing the formation of thromboxane A^ and 
hence the release of the dense granules. This will 
be discussed in Chapter 2.
JReproduced with permission of the publishers.
From Triplett, D. A. e t. a l . (1978) , p. 10 (1).
3Membrane Phospholipids
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extrusion of granule-bound secretory products during the 
release reaction (82).
(b) The sol-gel zone contains at least three systems of 
fibres which are present in the matrix of the platelets.
These include the submembrane filaments, micro tubules and 
microfilaments. The most prominent of these systems is the 
circumferential band of microtubuJes (13). I t appears that 
the main function of these fibres is to maintain the discoid 
shape of the cells (1). During aggregation they migrate to 
the centre of the cell encircling the cluster of platelet 
granules (83-87). Their exact function in the release action 
is not well understood but the experimental removal of these 
tubules results in the impairment of the second or irrever­
sible stage of aggregation (1). There is evidence to show 
that the microtubules regulate the release of the platelet 
contractile protein called actin (88).
(c) Two types of granules have been identified within 
the organelle zone of the platelets. The dense granules are 
homogenous, containing ATP, ADP, pyrophosphate, a divalent 
metal and permeability increasing factor serotonin (89). The 
number of dense bodies per platelet can vary from two to ten 
(1) • The other granules located in the platelet cytoplasm 
are referred to as the alpha granules. These are heterogenous 
and only contain protein, namely, coagulation factors (fibrin­
ogen, factor V), platelet specific proteins (e.g. platelet 
factor 4 ), cationic proteins (growth factor, permeability 
factor, bacteriocidal factor, chemotactic factor) and also 
various glycoproteins (89). The role of these granules and 
the mechanism controlling their release have already been 
described in this section.
The cytoplasm also contains some mitochondria which 
contribute to the energy metabolism of the cell (1) and also 
glycogen particles which are usually concentrated in a single 
large mass (13).
The platelet is therefore a complex cell involved in the
—10-
coagulation process and vascular support. In vivo, i t  ini­
tiates this process by adhering to collagen and undergoing 
the release mechanism. This process is triggered by the 
formation of thromboxane and the released dense granules 
provide the ADP to induce further platelet aggregation and 
eventually, through the clotting system, the formation and 
contraction of the fibrin clot. During this process many 
platelet factors are released, including those which increase 
permeability.
1.1.2 Coronary heart disease. This is a term used to describe 
clinical heart disease due to lesions of the coronary arteries 
(90). The "Textbook of Anatomy and Physiology** (91) details 
the anatomy and diseases of the heart and its  arteries. The 
book describes how the coronary arteries supply blood to the 
heart-wall and their exact location is illustrated in Fig. 6. 
The heart wall is composed mainly of **thick, contractile, 
middle layer of especially constructed and arranged cardiac 
muscle called myocardium** (Fig. 7). These myocardial cells 
receive blood through two small vessels, the le f t amd right 
coronary arteries. When these arteries are diseased, the 
myocardial cells are deprived of oxygen (becone ischaemic) 
and subsequently catabolic metabolism is too low to ensure 
the survival of the cells. This impairs the operation of the 
heart which results in malfunction of the muscle. Ultimately 
this can lead to the death of the patient. However, anastom­
oses exist between the small arterial vessels in the heart 
and i t  is possible for new ones to develop which can provide 
collateral circulation to ischaemic areas.
The most common disease of the coronary arteries is 
atherosclerosis and the consequent disturbance in the blood 
supply to the myocardium constitutes the essential cause of 
coronary heart disease (91). Friedberg (90) describes ath­
erosclerosis as "hardening of the arteries" which is character­
ised by "intimai thickening due to lipid atheroma, fibrosis, 
calcification, necrosis and haemorrhage". These atheromatous 
plaques, or "tissue reaction to accumulated lipids", take
Fig. 6 showing the surface of the heart. The le ft 
and right coronary arteries are included in 
the illustration.
Reproduced with permission of the publishers.
From Davies, D. V. (Ed.) (1967). Grays 
Anatomy, 34th edition, p .643. Longmans, 
London.
DD
*
Fig. 7 showing a section of the heart wall. Included are 
the three main components
the outer pericardium (heart sac) 
muscle layer (myocardium)
inner lining (endocardium composed of a layer of 
endothelial cells).
Reproduced with permission of the publishers and of 
the medical illustrator, Mr. Ernest Beck. From 
"Anatomy and Physioloqy**, p. 374 (91)
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decades to form (90)• The lesions which characterise the 
early development of atherosclerosis in humans are called 
fatty streaks (92). Different stages of development are 
recognisable (93). The ultimate stage is ulceration associa­
ted with the damage to the muscle and elastic tissue caused 
by the adherent thrombi and fibrous tissue (94).
Basically the theories describing the formation of 
these atheromatous plaques have hardly changed during the 
past hundred years (95). The thrombogenic hypothesis, reform­
ulated by Duguid in 1949 (96) originated with the encrustation 
theory of von Rokitansky in 1844 (97). This theory involves 
the incorporation of thrombi into the arterial wall due to 
endothelial cells growing over the thrombus. Davies (95) 
suggests that this theory appears to be no more than a des­
cription of a process which may contribute to atheroma. An­
other hypothesis was originated by Virchow in 1862 (98).
This relates atheroma to an inflammatory reaction in the ar­
teria l wall in the areas surrounding absorbed and trapped 
plasma constituents such as lipids and fibrinogen. These two 
hypotheses have been extensively reviewed by Spaet and Gaynor 
(99) and also Mustard and Peckham (100, 101). These reviews 
discuss and describe a definite relationship between thrombosis 
and atherosclerosis and i t  appears that the three important 
areas for consideration are:-
(a) the mechanism of throrrbus formation.
(b) the relationship between this thrombosis and early 
changes in the vessel wall.
(c) the organisation of the mural thrombi and the develop­
ment of atherosclerotic lesions.
The normal blood vessel is lined with endothelial cells 
(Fig. 8) which present an effective barrier between the blood 
and the underlying thrombogenic vascular components (99). If 
these endothelial cells are separated by tissue injury, the 
subendothelia i tissues, such as basement membrane, are exposed 
(102). As previously described, the platelets can adhere to 
this membrane (2, 37) eind also to collagen exposed by the sep­
aration of the endothelial cells (38, 103). The platelet
Fig. 8 showing the structure of artery wall. This
varies with the size of the artery and its  function. 
The drawings show (at different scales) the wall of 
the aorta (top) and of a small muscular artery 
(bottom).
Reproduced with permission of the publishers.
From Johansen, K. (1982). Scientific American,
247, p .98.
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aggregate formed is referred to as a thrombus (104)• After 
the platelets adhere, the process is initiated resulting in 
the release of the dense bodies and therefore the ADP which 
cause aggregation to the platelets already adherent (10, 105). 
Further ADP for this release can be derived from injured cells 
in the vessel wall and also from red blood cells (106-109)•
The platelet rich thrombus formed is transformed into a fibrin 
mass and is subsequently organised into an intimai lesion 
which is rich in connective tissue (110, 111).
This incorporation of mural thrombi into the intima of 
arteries is a major and important factor in the build up of 
lesions that are involved in the development of atheroscler­
osis (112-114). In addition, during the formation of these 
thrombi the platelets release vaso active amines and these 
create areas of increased permeability.. This results in 
further damage to the endothelium and also in the increased 
absorption of plasma constituents including lipids and fib­
rinogen into the arterial wall with the subsequent development 
of atheromatous plaques (101).
The hypotheses discussed above describe how the mural 
thrombi can be incorporated into the blood vessel wall and 
in itiate a process which can eventually lead to the develop­
ment of atheromatous tissue. During the last decade the fac­
tors that regulate the adhesion and aggregation of blood 
platelets in vivo have been extensively studied. One hypothe­
sis, proposed by Moncada and Vane (69) suggests that the pro­
cess is controlled by maintaining a critica l balance between 
two metabolites of arachidonic acid - thromboxane A2 and 
prostacyclin. As previously detailed in Section 1.1.1., page 
7, thromboxane Ag is the metabolite that mediates aggregation 
and release (71) and i t  has also been demonstrated that i t  is 
a potent vasoconstrictor (60, 115). Conversely, prostacyclin, 
which is synthesised in the vascular tisse (66), is a strong 
inhibitor of platelet aggregation and is also a vasodilator 
(69).
—13—
The mode of action of this process is uncertain but i t  
appears that after the platelets adhere to the vessel wall 
the arachidonic acid in the surrounding vascular tissue is 
activated and the prostacyclin is produced (69)• Controversy 
remains whether any cross activity exists between the arachi­
donic acid and the prostaglandin endoperoxides in the platelets 
and the vessel wall but i t  appears that after stimulation the 
prostacyclin is produced independently and without any influ­
ence from the platelet constituents (69). The endothelial 
cells in the vessel walls are the most active producers of 
prostacyclin (116, 117) and i t  is therefore abundant in the 
intima, but i t  progressively decreases in concentration from 
the intima to the adventitia. In contrast, the pro aggregating 
elements increase from the subendothelium to the adventitia. 
These two opposing tendencies therefore render the endothelial 
lining antiaggregatory and the outer layer of the vessel wall 
thrombogenic (60, 118)• This mechanism allows the platelets 
to adhere and repair any vascular damage, but the formation 
of the thrombus is controlled by the formed prostacyclin.
The mechanism which initiates prostacyclin synthesis in 
the vessel wall, after the adhesion of platelets has not been 
fully elucidated. However, the mode of action of its  inhibitory 
effects on platelet aggregation has been established. Prosta­
cyclin inhibits aggregation by stimulating adenyl cyclase which 
leads to an increase in the cyclic AMP (cAMP) levels in the
Q  I
platelets (119, 120). Cyclic AMP enhances Ca sequestration 
(121) and the platelet bound Ca^  ^ is essential for the aggre­
gation process, detailed in the previous section (1.1.1.), to
proceed (122). A review by Luscher and his co-workers (122)
2 +describes how dytoplasmic Ca plays an important role in the 
contractile activity and the release reaction of the platelets, 
Aggregation is inhibited by the increase in cAMP levels because 
thromboxane A^ synthesis is dependent upon the availability of 
arachidonic acid which is cleared from phospholipids by the 
action of phospholipase A2 , an enzyme which requires Ca^  ^ for 
i ts  activity. cAMP accelerates the removal of Ca^  ^ ions from 
the cytoplasm and accordingly decreases phospholipase activity. 
Therefore, the potent aggregating effect of the thromboxane A2
- 1 4 -
in the platelet is regulated by the ability of the prosta­
cyclin formed in the vessel wall to increase the cAMP levels 
in the cells. This process is illustrated in Fig. 9.
I t  is therefore important that the body maintains this 
critical balance between the levels of thromboxane A2 and 
prostacyclin and any factor that inhibits the formation of the 
la tte r can result in a thrombotic state. For example, inhibi­
tion of the prostacyclin formation by lipid peroxides can lead 
to a condition in which platelet aggregation is increased and 
this could play a role in the development of atherosclerosis 
(60). I t  has been shown that lipid peroxidation takes place 
in plasma as a nonenzymic reaction (123) and is also known to 
occur in certain pathological conditions (124). Therefore the 
lipid peroxides present in these conditions could unbalance 
the system in favour of the thromboxane A2 and predispose to 
thrombus formation (60). I t  has also been reported (125) that 
human atherosclerotic tissue does not produce prostacyclin, 
whereas tissue obtained from a nearby normal vessel does.
Evidence therefore suggests that platelets can play a 
major role in the development of atheromatous tissue. This 
process can be initiated by the release of permeability factors 
from the platelets during the repair of vascular damage, thus 
encouraging the deposition of lipids and fibrinogen. The 
lipids deposited can also interfere with the thromboxane A2/  
prostacyclin balance which is thought to regulate the degree 
of thrombus formation in vivo.
One clinical manifestation of coronary heart disease is 
myocardial infarction (90). This signifies the necrosis or 
death of a portion of the heart muscle because of an interrup­
tion or curtailment in the blood supply to the myocardium. Myo­
cardial infarction can be diagnosed using clinical and laboratory 
tests and in this thesis only subjects fu lfilling  certain s tr ic t 
criteria , described later in the text, are included as patients 
with confirmed coronary heart disease.
Pig. 9 showing the role of adenosine 3*,5•-cyclic
monophosphate (cyclic AMP) in the inhibition 
of platelet aggregation.
Reproduced with permission of the publishers. 
From Triplett, D. A. e t. a l . (1978) p .11 (1).
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1.1.3 The role of "active" platelets in coronary heart disease. 
The previous section discusses the reported role of platelets 
in the formation of the thrombus and in the subsequent develop­
ment of atheromatous plaques. The platelet work described in 
this thesis is concentrated on the observations that coronary 
heart disease is one condition where an increased percentage of 
"active” platelets are present in the patient's circulation 
(126). Their presence has also been confirmed by the demon­
stration of an increased rate of platelet turnover in CHD 
(1, 127-130).
The presence of these "active” platelets could be related 
to the effect of the atheromatous lesions and subsequent ulcer­
ation, however, some workers believe (100, 105) that platelets 
may initiate the vascular damage and accelerate the formation 
of the subsequent atheromatous plaques. An attempt was made to 
avoid testing hospital-based patients in the acute phase of the 
disease. There is a possibility that changes found in such 
patients may be the result of the infarction. They can be due 
to, for example, ulceration of the endocardium near to the 
necrotic myocardium, or due to the patient being in a state of 
shock or to medication administered in the acute phase. In an 
attempt to elucidate their role, an experimental programme was ' 
devised which investigated the platelet activity in " long-term" 
confirmed coronary heart disease patients and in a large number 
of normal control subjects. The assumption was made that any 
damage present in the acute phase of the disease had healed in 
these patients and any differences found in case-control stud­
ies could be related to atherosclerosis. All the confirmed MI 
patients investigated in this thesis had suffered the infarct 
at least twelve months prior to the test.
In order to describe the role and relevance of an in­
creased percentage of these platelets in the circulation, the 
term "active" platelets must be explained and discussed.
The normal function of platelets has already been
—16—
detailed. The mechanism involved in maintaining the platelet 
metabolism in order to perform these roles should also be con­
sidered. The reviews by Wintrobe (10) and others (1, 13) des­
cribe how the energy metabolism of the platelet resembles that 
of the skeletal muscles. Both involve active glycolysis and 
the synthesis and utilisation of large amounts of glycogen. The 
mediator of intracellular energy utilisation is an actomyosin­
like adenosine tri-phosphate and the major energy source for 
the platelet is glucose which is rapidly taken up from the 
plasma. The glycolytic pathway with its  regulatory enzymes, 
the tricarboxylic acid cycle, the pentose-phosphate pathway 
and the NAD-NADH system are a ll active in the platelet (131). 
Approximately 90% of free platelet nucleotide consists of 
adenine nucleotides and are synthesised from both adenanine 
and adenosine. Platelet nucleotides are partitioned into at 
least two different pools (45, 132). The metabolic pool is 
utilised for the maintenance of the various energy consuming 
cell functions. This pool mainly consists of ATP in contrast 
to the storage pool which contains both ADP and ATP. The nuc­
leotides in this la tte r pool are metabolically inactive and 
are extruded from the cell during the release reaction. The 
ATP that has been used to provide the energy requirements of 
the cell is thought to be stored in a third compartment in 
equilibrium with the metabolic pool (45). ATP can also be 
converted into cyclic AMP which plays an important role in 
regulating platelet function. In the normal platelet a con­
stant and critical level of cAMP is maintained by the enzyme 
adenyl cyclase and only after platelet stimulation is the level 
changed. I t  appears that normal platelet activity is pre­
determined, the platelets being furnished with a level of nuc­
leotides to maintain their function for their 9 to 11 days of 
life (13, 133). The activity of the platelets also decreases 
steadily during this period terminating in the removal of the 
effete cell by the reticulo-endothelial system. Thereforë, 
when platelets f ir s t  enter the circulation, they demonstrate 
a higher degree of activity than that observed towards the end 
of their period in the blood stream when their energy providing 
mechanisms have expired. I t  has been shown that the "young" 
platelets entering the blood stream are the most metabolically 
active (30, 134-137). These cells are "larger and more dense.
— 17—
They adhere more readily to collagen, aggregate more rapidly 
with ADP and show increased aggregation with stimuli such 
as epinephrine , thrombin and collagen" (137). These larger 
platelets release a greater amount of ADP during the release 
process (30, 134) in addition to an increased level of per­
meability increasing factors at the site of aggregation.
Karpatkin and his co-workers (30, 134) l i s t  the properties of 
this population of platelets in comparison with the older less 
active cells. Shulman e t. a l . (22) suggest that only this 
newly formed population of platelets. Capable of synthesising 
proteins, are haemostatically effective. They comprise of 
20-25% of the total circulating platelet population and i t  ap­
pears that this level of activity is maintained for approxima­
tely 2 days. This thesis examines the importance and signifi­
cance of the presence of an increased percentage of these 
"young" platelets and in the text these cells are referred to 
as "active" platelets.
I t is known that coronary heart disease is one condition 
where platelet turnover is increased with no effect on the total 
platelet count (1). This has been confirmed by the demonstra­
tion of an increased percentage of "active" platelets in this 
condition (126). This thesis examines and explores the possi­
b ility  that the process of vascular repair and the regulatory 
balance between thromboxane A^ and prostacyclin function e ff i­
ciently when the population of platelets consists of the normal 
20-25% of "active" cells. I t  is hypothesised that a population 
of platelets with a higher number of "active" cells can unbalance 
the protective mechanisms resulting in the acceleration of the 
process which leads to the development of atheromatous plaques.
The effect of the "active" platelets on the normal process 
of vascular repair must be considered. These "active cells" 
"preferentially adhere to collagerf (138) and therefore more 
platelets than usual would be stimulated to respond to the 
vascular repair mechanism. In addition, each individual cell 
would release more ADP (30, 134) thus encouraging the formation 
of a larger and sturdier thrombus. An increased amount of per­
meability increasing factors would also be available and on
release from these platelets would encourage the deposition of 
plasma constituents such as lipids and fibrinogen. These 
large "active" platelets have more phospholipid content than 
the less active cells and i t  has been demonstrated that plate­
lets from CHD patients show a greater response to arachidonic 
acid stimulation when compared with normal control subjects 
(139). These cells must therefore produce more thromboxane 
Ag thus encouraging platelet aggregation and release on the 
damaged vessel wall. However, the prostacyclin response would 
not demonstrate the equivalent exaggerated stimulation, thus 
decreasing thé antiaggregatory effect and encouraging thrombus 
formation and its  subsequent organisation into the vessel wall.
The theories that platelets play an important role in 
the development of atherosclerosis has been reviewed by Bom 
(109) who believes that i t  is questionable whether platelets 
can remain on the arterial wall for a sufficient period of 
time to in itiate the process referred to in the previous sec­
tion. However, i t  has been established that platelets repair 
and are incorporated into the damaged vessel wall (32-35).
Wook and Carstairs (140) describe how platelet material has 
been isolated in atheromatous tissue. Ross and his co-workers 
(141) suggest that platelets are essential for the development 
of intimai hyperplasia seen in atherosclerotic plaques because 
they release a mitogenic factor that stimulates the prolifer­
ation of the smooth muscle. Evidence therefore suggests that 
platelets play a definite role in the development of atherom­
atous lesions. I t  could be speculated that a thrombus formed 
from a normal population of platelets could conceivably be 
removed from the vessel wall by the mechanical effect of the 
blood flow. However, the presence of an increased percentage 
of "active" platelets in a patient's circulation could exag­
gerate the response to vascular damage, form a sturdier throm­
bus which could be organised into the vessel wall and result in 
the process already detailed.
In this thesis the role of an increase!percentage of 
"active" platelets in the circulation of confirmed coronary 
heart disease patients has been approached in two ways.
- 1 9 -
The f ir s t  approach accepts that the increased percentage 
of "active" platelets is secondary to the atheromatous tissue 
and the subsequent ulceration. Coronary heart disease is a 
condition where the atheromatous deposits are created over a 
long period of time while the individual shows no evidence 
whatsoever of the disease (142). The presence of an increased 
percentage of "active" platelets in apparently healthy subjects 
could therefore be the only indication that such a process 
was occurring. A test was developed, suitable for use on a 
large number of subjects, capable of reflecting the presence 
of an increased number of these "active" platelets. The pres­
ence of an increased number of these cells and therefore a 
greater platelet turnover than normal could be the only recog­
nisable factor in detecting individuals who are undergoing a 
process which ultimately terminates in clinical symptoms of 
coronary heart disease.
Most of the workers who investigated the phenomenon of 
increased platelet activity in CHD based their observations on 
hospitalised patients in the acute phase of the disease. There­
fore, before investigating platelet activity in normal subjects, 
the activity in "long-term" patients should be established. 
Confirmed coronary heart disease patients included in the 
experiments described in this thesis have suffered from the 
myocardial infarction at least twelve months prior to testing. 
The significance of this time factor has been discussed on 
page 15. The result of such investigations should ascertain 
whether a higher than normal percentage of "active" platelets 
remain in the circulation of confirmed CHD patients.
The tests available for the detection of this population 
of platelets are time-consuming and some require expensive 
and specialised equipment (126, 128-130). I t was therefore 
essential to develop a test, suitable for use in a clinical 
laboratory, capable of detecting a greater than normal per­
centage of "active" platelets in a large number of individual 
subjects. The test developed and the results obtained are 
detailed in Chapter 2.
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The second approach to the presence of an increased per­
centage of "active" platelets explores the hypothesis that 
these platelets cein play a primary and causative role in in­
itiating the process that cumulates in the development of the 
atheromatous plaques. This hypothesis is based on the knowledge 
that an increased turnover of platelets can result from many 
factors to which every individual is susceptible and include 
viraemia, bacteraemia and antigen-antibody complexes (137, 143- 
145). Certain IgG class antibodies can sensitise the plate­
lets resulting in their removal from the circulation (146-153). 
This leads to an increased turnover of the platelet popula­
tion and therefore a higher percentage than normal of "active" 
platelets in the blood.
It has been demonstrated that vascular damage can be 
caused by the direct action of platelets. Mustard and Packham 
(100, 101) and others (96, 112-114, 154) describe how "there 
is considerable evidence that the organisation and incorpora­
tion of mural thrombi into the intima of arteries is the major 
factor in the build-up of stenotic lesions that are involved in 
the development of complications of atherosclerosis". One con­
tributory factor is the rate and pattern of the blood flow 
(blood rheology) (100, 101, 155, 156). The mechanical effect 
related to the pattern of the blood-flow could be the in itia ­
ting factor in the characteristic localisation of the early 
vascular changes. Oka (157) in his review of the current l i t ­
erature on this aspect of CHD states that any theory for the 
formation and growth of atherosclerotic plaques should take 
into account "the flow characteristics of the blood". He 
describes the current hypotheses which are classified as pres­
sure, wall shear stress, turbulence and flow separation rela­
ted. These hypotheses describe how the blood-flow pattern can 
in itiate the vascular damage (158, 159) and how the turbulent 
velocity fluctuations cause platelets to adhere to the vessel 
wall (160)• Blood-flow patterns can also in itiate the release 
of factors from the platelets and also the vessel wall which 
causes increased permeability at the site of reaction (101,
161). The direct action of platelets on the endothelium in 
these areas of disturbed blood flow is another contributory
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factor which can result in vascular damage (100, 101, 160). 
Thrombi formed in these areas can also fragment and shower 
the arterial wall with platelet fragments, thus causing fur­
ther endothelial damage (101). Intravascular platelet ag­
gregates can also be directly induced by stimuli such as 
endotoxins, viruses, bacteria and antigen-antibody complexes 
and these thrombi can be directly responsible for vessel injury 
(105, 162). I t  is to be expected that the enhanced effect and 
damage which is caused in the circulation when the platelet 
population consists of a greater than normal number of young 
"active" platelets will exaggerate the processes referred to 
above.
The study of the platelet populatbn in "long term", con­
firmed coronary heart disease patients and a large number of 
apparently healthy normal subjects should aid in elucidating 
the role of the "active" platelets in this condition. The 
results of the experimental programme designed and the conclu­
sions drawn are reported and discussed in the text.
1.1.4 The immunological theory of coronary heart disease. The 
immunological theory originated from the observation by Davies 
(163-165) that the negative charge on the erythrocyte suspended 
in plasma was reduced in the blood of patients with confirmed 
coronary heart disease. I t was demonstrated that this abnorma­
lity  was due to a factor present in the plasma of these patients. 
Further experiments demonstrated that the platelets and chyl- 
omicra showed a similar pattern in patients with this condition 
(166-168). The influence of the plasma in modifying the 
electrical charge on particulate matter was termed by Davies 
(169) as "plasma surface activity"• Work continued to identify 
and isolate the factors present in the plasma responsible for 
reducing the negative charge on the erythrocytes. I t  was 
shown by Davies and Clark (170) that the blood of confirmed 
coronary heart disease patients not only showed a reduced elec­
trophoretic mobility but xhe X G-globulin (IgG) level in these 
patients was also elevated. I t was postulated (142) that these
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immunoglobulins coated the cells, including the platelets, 
thus making them more adhesive. In addition, the authors 
suggest that the increased IgG levels in confirmed CHD pat­
ients reduce the plasma surface activity and point to the pos­
sib ility  of an immunological factor being involved in the 
disease. The higher level of IgG was observed in these pat­
ients over a period of time confirming that the findings were 
not secondary to the infarction. The raised immunoglobulin 
level in patients with confirmed CHD has subsequently been 
confirmed by other workers (171).
It was considered by Davies (142) that the aetiological 
factors that could be involved in this new approach could 
conceivably be endogenous or exogenous or both. As previously 
stated, atheromatous deposits and coronary artery disease are 
created over a period of time while the individual may show 
no evidence whatsoever of the disease. Davies (142) believed 
that the lack of any clinical symptoms suggested that any 
search for the antigens should in itia lly  be concerned with 
the exogenous factors. Relevant to this approach was the 
published evidence of the intestinal absorption of intact 
dietary proteins with the creation of specific antibodies to 
these antigens. This factor is discussed in detail in Chap­
te r 8. Recorded evidence (172-177) showed that a proportion 
of the apparently healthy population appeared to produce anti­
bodies, sometimes to a high t i t re ,  to various foods. The food 
most commonly implicated by these workers was milk.
This approach to coronary heart disease was pursued with 
a series of tests, in itia lly  concentrating on the levels of 
antibodies to milk protein in confirmed coronary heart disease 
patients and normal control subjects. The results of these 
investigations were reported by Davies e t. a l. (178) who con­
cluded that antibody titres  to whole dried milk were higher 
in patients with confirmed CHD than in the normal control 
subjects tested. The possible harmful effects of these anti­
bodies have been documented in respect of sudden death in 
babies (179) and in ulcerative co litis (177) but no relation­
ship had previously been reported relating the presence of
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bovine milk antibody to coronary heart disease.
Circumstantial evidence for the involvement of milk 
protein in the aetiology of atherosclerosis has been dis­
cussed by Davies (95). He describes the findings of Osbom 
(180), who studied coronary arteries of 109 young «individuals 
and found where there had been no breast feeding the coronary 
arteries were mainly abnormal. A similar conclusion was also 
drawn by Turner (181) and Osbom (182). Muir (183) refers to 
the work of Annand (184) who demonstrated that an increase in 
the incidence of ischaemic heart disease occurred soon after 
the introduction of Holder pasteurisation process. Annand 
(185) and Segall (186) correlated the consumption of milk pro­
teins to the incidence of coronary heart disease and referred 
to Finland which has the highest coronary mortality rate and 
the highest per capita intake of total milk. Recently (187), 
Seely reported that a "direct and reasonably accurate corre­
lation has been found between coronary heart disease mortality 
rates and the consumption of unfermented milk proteins". This 
correlation is illustrated in Fig. 10.
The hypothesis that the development of atherosclerosis 
was the result of an immunological disorder was f i r s t  published 
by Davies in 1969 (142). Evidence in support of this immunol­
ogical approach has since been collected and reviewed (95, 188) . 
These publications describe how the immunological hypothesis 
embodies the two long-standing theories of coronary heart 
disease already described in section 1.1.2. The direct action 
of immune antigen/antibody complexes can in itiate the vascular 
damage and the subsequent formation of the thrombus (189). In 
addition, antibodies and complement have a toxic action on 
the vascular endothelial cells (190). Mast cells present in 
the arterial wall are activated by antigen/antibody complexes 
resulting in the release of permeability-increasing factors 
(191). Davies (142) suggests that the excess lipids in ather­
omatous arterial lesions may be due to excessive filtra tion  
resulting directly from this increased permeability. Most of 
the factors that cause increased permeability results in the
Fig. 10 demonstrating the correlation between coronary
heart disease mortality rate and the consumption 
of unfermented milk proteins.
(Reproduced with permission of the author.
From Seeley, S. (1981), p .914 (187)).
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separation of the endothelium cells from each other thus 
exposing the subendothelia i tissue such as basement membrane, 
thus encouraging platelet adhesion (102). Serum sickness 
experiments in animals have demonstrated that some antigen/ 
antibody complexes are capable of causing vascular damage by 
being deposited directly in the arterial wall (188). As pre­
viously described, the development of an immunological dis­
turbance leads to platelet aggregation which can have several 
different results. Briefly, the platelet aggregates formed 
can cause vessel injury (96, 100, 101, 112, 114, 154), per­
meability increasing factors are released by platelets (89), 
certain immune antigen/antibody complexes and IgG antibodies 
not only cause platelets to aggregate, but they also result 
in the removal of the cells by the reticulo endothelial system, 
thus causing an increased platelet turnover (137, 143-153).
The importance of an increased percentage of "active" platelets 
has already been discussed in section 1.1.3.
More recent findings, as the result of heart transplan­
tation, offer further evidence that immunological factors 
play a major role in the development of atheroma. Gross ath­
erosclerosis developed in the coronary arteries of a trans­
planted heart, previously normal, in the 19 months before the 
death of the recipient (192). In a review similar findings 
have been described by Davies (193) who reported that "the 
main cause of death in long-term cardiac transplant patients 
is an accelerated- form of coronary heart disease (atheros­
clerosis)". (194).
In summary, the aims of this thesis are:-
1. To attempt to elucidate the role of "active platelets in 
coronary heart disease. To achieve this, a technique 
was developed capable of testing a large number of "long 
term" confirmed CHD patients and apparently normal healthy 
control subjects. This section of the work was approached 
in two ways:-
(a) The theory that the presence of an increased
- 2 5 -
percentage of "active" platelets is secondary to 
atheromatous tissue was provisionally accepted 
and a technique developed of sufficient sensi­
tiv ity  to detect these cells in the "long-term" 
confirmed CHD patients. The value of the test 
as a predictor of the presence of CHD in the 
apparently normal healthy subject is also examined 
and discussed.
(b) The data obtained was examined to ascertain if  any 
evidence existed to support the hypothesis that 
these "active" platelets could be one important 
factor in the initiation of the process which 
terminates in clinical coronary heart disease.
2. To confirm the observation that a relationship exists
between bovine milk antibody and coronary heart disease.
3. To isolate and identify this antibody, report the findings
and to relate any relationship to metabolically "active" 
platelets.
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CHAPTER 2
ADP "DISAGGREGATION RATIO"
2.1 Introduction
The tests currently available for measuring the rate of 
platelet turnover and hence the number of "active" platelets 
are unsuitable for the investigation of large numbers of 
subjects. Most of the studies u tilise  radioactive isotope
c  1 3  n
techniques, the main radio-nuclides used being Cr and P. 
These techniques are time-consuming and involve the manipul­
ation of platelets in vitro during the labelling procedure 
(195). The equipment used is also specialised and expensive. 
Shatz and Riddle (126) used electron microscopy studies to 
demonstrate an increased percentage of " active" platelets in 
the circulation of confirmed myocardial infarction patients. 
Another non-isotope method was described by Stewart and his co­
workers (196) . This test was based on the measurement of 
malondialdehyde (MDA), an end-product of platelet lipid per­
oxidation. This process has already been described on page 7 
and Table 5 illustrates the formation of thromboxane A2 and 
also malondialdehyde. De Haas and his co-workers (195) des­
cribe how lipid peroxidation is stimulated by adding collagen, 
thrombin, 1-epinephrine, ADP or N-ethylmaleionide to prepared 
platelet suspensions. The process is blocked irreversibly by 
acetyl sal icy lie acid (ASA) and this inhibition persists for 
the remaining life  span of the circulating platelet . ASA 
prevents the formation of MDA by interfering with the enzyme 
cyclo oxygenase. This action is also illustrated in Fig. 5.
The principle of this test is that the emergence of new, un­
affected platelets into the circulation is monitored by estim?- 
ating the increase in MDA production in serial blood samples 
obtained over a period of 10 days. This constitutes a measure 
of platelet production time. De Haas e t . a l . (195) modified 
this method by using arachidonic acid to stimulate platelet 
lipid peroxidation. Again, this test, although not involving 
expensive and specialised equipment, requires monitoring of the 
patient for 10 consecutive days.
-2 7 -
In order to tes t a large number of subjects on a survey 
basis, i t  was desirable to introduce a test that could be used 
in a hospital laboratory utilising the apparatus already 
available and with the minimum of inconvenience to the patients 
involved. The test developed was based on the aggregation 
patterns obtained when platelets are stimulated with ADP. The 
original aggregation method was devised by Bom (197) and the 
principle of the test has been detailed on page 5 . I t  is 
known that when a low concentration of ADP is added to a prep­
aration of platelet-rich plasma (prp), the platelets aggregate, 
and because the level is insufficient to stimulate the forma­
tion of thromboxane A2 # the dense granules are not released 
and the platelets exhibit reversible aggregation. This is 
illustrated in Fig. 11. This phenomenon occurs up to a c r i t i ­
cal level of ADP (197), the addition of the aggregating agent 
at a higher concentration results in the formation of throm­
boxane A2 in sufficient quantity to cause the release of the 
dense granules. When this occurs the prp specimen tested 
exhibits irreversible aggregation (see Fig. 11).
A test was developed utilising the above observations.
When the highest possible concentration of ADP that does not 
cause the release of the dense granules, is added to popula­
tions of platelets from normal donors, reversible aggregation 
should be observed. As previously mentioned on page 17, such 
populations of platelets should contain 2 0-25% "active" plate­
le ts . I t  is postulated that if  the same ADP solution is added 
to samples of prp containing an increased percentage of "active" 
platelets, these, by virtue of their greater response to ADP 
(30, 134), will be stimulated to form thromboxane A2 and hence 
the release of the dense granules and therefore irreversible 
aggregation. This degree of irreversible aggregation should 
reflect the activity of the platelet population tested in com­
parison to prp samples from normal donors. The highest possible 
concentration of ADP that allows reversible aggregation in 
normal samples of platelets has been termed "the critica l dose" 
and the degree of irreversible aggregation obtained called the 
"disaggregation pattern".
Fig. 11 showing:-
"A"-reversible aggregation after the addition of
1 tig of ADP to 1 ml of platelet rich plasma
9  '(concentration Of platelets 300 x /^ ).
The OD change to "Y" represents the aggregation 
of the platelet population and the return to “Z* 
demonstrates reversible aggregation.
"B"=irreversible aggregation after the addition 
of 3 Jig of ADP to the same population of platelets
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I t  has already been described how aspirin (acetyl- 
salicylic acid or ASA) prevents the release of the dense 
granules from the platelets by interfering with the enzyme 
cyclo oxygenase and the subsequent formation of thromboxane 
Ag. This phenomenon also interferes with the disaggregation 
patterns obtained with the "critical dose" of ADP by prevent­
ing the release of the dense granules from the "active" plate­
lets. Patients receiving aspirin were excluded from 
surveys and therefore the prp specimens from every subject 
reported in this thesis were all tested against collagen in 
parallel to the "critical dose" of ADP. Collagen was used as 
i t  is the aggregating agent routinely used to demonstrate any 
interference on the aggregation of platelets by ASA (198).
The effect of aspirin on the aggregation patterns obtained 
with collagen is illustrated in Fig. 12.
2.2 Materials and methods
The basis of the test déveloped was to obtain the " c r iti­
cal dose" of ADP. This was achieved by adding varying concen­
trations of ADP to preparations of prp samples from normal 
donors until normal disaggregation no longer occurred.
Platelet rich plasma was obtained by the centrifugation 
of blood at 450 x g for 10 mins. in an I4SE Minor centrifuge. 
The anticoagulant used was 3.13% (w/v) trisodium citrate in 
the ratio of one volume to nine volumes of blood. After re­
moving the prp, the remainder of the blood was centrifuged at 
2,400 X g for 10 mins. to obtain platelet-poor plasma (ppp). 
The platelet count of the samples was standardised using the 
optical density method described by Bom (197). An EEL ag­
gregation meter, model 169 (Evans Electroselium Ltd., Halstead, 
Essex) was used at a temperature of 37°C and at a speed of 
80 on the arbitrary indicator. The aggregation results were 
recorded on a Leeds and Northrup fla t bed recorder set on 
5Mv and a speed of 75cn/hr. The measuring scale on the aggre­
gation meter was marked in arbitrary units of 0-60 which was 
expanded on the f la t bed recorder to 0-100.
Fig. 12 demonstrating the effect of aspirin on collagen 
aggregation.
"A" shows the normal response with collagen.
"B" shows the response after the patient was 
given two 300 mg dose of aspirin 24h prior to 
the blood test.
The concentration of the collagen added was 
standardised as described by O'Brien (199).
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The ppp was placed in the aggregating tubes supplied by 
EEL, positioned in the well of the meter and the scale ad­
justed to zero using the 'se t meter* control. The ppp was 
removed and replaced by the prp specimen. This was. adjusted 
by the addition of ppp until a reading of between 38 and 42 
was obtained on the measuring scale. One ml amounts of the 
adjusted prp specimens were placed in the aggregation tubes 
and le ft at room temperature. The prp specimens were warmed 
to 37°C for 5 mins. prior to testing and then placed in the 
well of the aggregation meter and the s tirre r positioned in 
the tube. After 2 mins., 0.1 ml of the "critical dose" of 
ADP (pre-warmed to 37°C) was added and the aggregation pattern 
observed on the recorder.
2.2.1 Correlation of platelet numbers. The total platelet 
count using the Coulter Counter (Coulter Electronics, Luton, 
Beds.) and the optical density (OD) method of Bom (197) were 
compared. The scale on the aggregating meter was set to zero 
using ppp, this was removed and replaced with varying concen­
trations of prp. The readings on the meter scale were noted 
and recorded. Platelet counts were also performed on the same 
preparations of prp using the Thrombocounter-C available from 
Coulter Electronics. The OD readings were compared with the 
total platelet counts.
2.2.2. Estimation of the 'c ritica l dose" of ADP. A stock sol­
ution of ADP (Sigma, Poole, Dorset) was prepared by dissolving 
lOOmg in 200ml 0.06 M phosphate buffered saline (pH 7.4). 
Dilutions of this stock solution were prepared in this diluent 
and are listed in Table 2. To estimate the "critical dose" of 
ADP, 0.1 ml aliquots of the diluted stock were added to 1 ml 
volumes of prp preparations from normal healthy donors using 
the method already described. The "critical dose" was the 
highest concentration of ADP that showed a normal disaggrega­
tion patte m. •*
2.2.3 Collagen induced aggregation. The collagen was prepared
Table 2 showing the dilutions of the stock ADP solution in
0.06 M phosphate buffered saline (pH 7.4).
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from homogenised, filtered human tendon and standardised as 
described by O'Brien (199).
2.2.4 Population survey using platelet aggregation patterns.
The technique has been used in a preliminary investigation of 
the normal population. In a Carmarthen community survey car­
ried out by the Medical Research Council Epidemiological Unit 
(Cardiff), 65 apparently normal healthy men were examined and 
platelet samples were also obtained from 23 confirmed myocardial 
infarction patients. In addition, 23 hospital based control 
patients were studied. Both groups were part of a larger 
study (200) and diagnosis had been established.
Subjects referred to as myocardial infarction patients 
(MI patients) were males up to the age of 65 who had suffered 
what is variably known as "heart attack", coronary thrombosis 
or myocardial infarction. (Its significance in relation to 
coronary heart disease has already been detailed in Section
1.1.2 page 22). The only patients included in this work were 
investigated and diagnosed by a doctor of consultant status.
The diagnosis was based upon typical clinical history, unequi­
vocal electro-cardiographie changes and changes in circulating 
myocardial enzymes diagnostic of infarction following clinical 
occurrence. The medical consultants involved maintained s tr ic t 
criteria  and any cases where the diagnosis was equivocal were 
excluded. The normal controls from the community were chosen 
at random from the electoral l i s t  and the hospital control 
patients included those with a variety of diseases. Exclusion 
in this la tte r group was restricted to patients:-
(a) with a history of, or evidence of an immunological distur­
bance, or a condition known to have an immunological basis 
or relationship,
(b) with any evidence of bleeding.
(c) post operative cases.
(d) clinical evidence of atherosclerosis.
The MI patients in this survey had suffered from the infarction 
at least twelve months prior to the test. This excluded any
-3 1 -
interference from factors present in the circulation which 
can cause abnormal results in the acute state of the condition. 
The significance and importance of this time factor has already 
been discussed on page 15. The tests were performed "blind" 
with regard to the diagnoses which were revealed by the MRC 
after the completion of the survey. Specimens were tested in 
duplicate and the results read and recorded.
2.2.5 Statistical analvses. The following sta tistica l analyses 
are described in this thesis.
Arithmetic mean. This is best known as average and is defined 
by the sum of the separate values in a series, divided by 
their numbers (201). When values of a variable group of num­
bers are represented by x^, X2 , x^....x^^ the mean or average 
is defined by S x. The Greek capital, "sigma", denotes "the 
sum of" and the^arithmetic mean is represented by x. n is the 
total number involved in the calculation.
Standard deviation. This is the measure of dispersion most 
commonly used in sta tistics and is a measure of the spread or 
scatter of the distribution around the mean. In a normal dis­
tribution a departure of one standard deviation (SD or S) on 
either side of the mean will include approximately 68% of the 
values of a given distribution; two standard deviations from 
the mean includes about 95% of a ll values and three standard 
deviations will include almost a ll of the distribution values 
(202). This is illustrated in Fig. 13. When establishing a 
normal range the values between -2 SD are accepted as normal 
(2 03). The formula for calculating the standard deviation is
SD - J  Z (x-x) ^
in which x = mean value
x -x  = deviation from the mean
n = number of specimens tested
The deviations are squared because the problems arising from 
negative signs are dispensed with. There is one refinement 
of the standard deviation. If the observations are only a
F ig .  13 i l l u s t r a t i n g  the p ro p e r t ie s  o f a normal c u rv e .
Reproduced with permission of the publishers. 
Reichmann, W. J . ,  p.215 (202).
Illustrated opposite are four scatter diagrams 
giving different values of r . Each dot represents 
one pair of measurements and the changeover from 
negative correlation through zero to positive 
correlation is shown.
Reproduced with permission of the publishers. 
Moore, P. G. (1969) in Principles of S tatistical 
Techniques, p .262. Cambridge University Press.
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sample (or sub-set) of a larger set of observations then the 
devisor is n - 1 and not n. The change is usually a marginal
one numerically, but may be important if  the sample is small.
Correlation. Correlation techniques in sta tistics are methods 
of examining the relationship of one measure to the other.
There are varying degrees of correlation which range from 
1.0, which is perfect, to 0.0 which represents no correlation. 
Relationship may be negative or positive. The number which 
indicates this correlation between two variables is termed 
"correlation coefficient" which is usually represented by the 
le tte r "r". Therefore the value of r  reflects the degree by 
which two variables are related (204). Most automatic calcu­
lators calculate r  using the following formula:-
r  = n.S XV - % x.S V
y{n.2x2 - (2x)2j | n . S y 2  - (2 y ) 2 j
X represents one set of figures and y the other.
It is advisable to plot the corresponding values of the varia­
bles on a chart. The regression line drawn represents the 
linear equation to which the related behaviour of the two 
variables most closely approximates. I t  is possible to calcu­
late the slope and axial interception of this line using a 
mathematical formula formulated by the French mathematician 
Legendre (2 02). The line may be used to predict the approxi­
mate value of one variable, given the known value of the other.
However, the regression line may be drawn on a chart merely to 
demonstrate that correlation exists between two variables and 
that the correlation is linear and therefore the r  value had 
not been calculated from a narrow range of corresponding 
figures. When the values of the two variables are plotted 
on the chart, one set of figures is represented on the abscissa 
and the other set on the corresponding ordinate. These types 
of charts are referred to as "scatter diagrams" and are illu s­
trated in Fig. 13. When the points are scattered closely about 
the regression line, so that the distances between the points 
and the line are short, there is a clearer possibility of the 
line actually defining a true relationship. If, however, the 
points are scattered all over the chart, no line can be drawn
-3 3 -
to represent any relationship.
Having obtained a value r  for two sets of variables, i t  
is necessary to determine the "degree of significance" of 
the result. This is reported as "probability" (p) which deter­
mines whether the results are not due to chance and is deter­
mined from the appropriate mathematical tables. The table 
used was devised in 1908 by "Student" (the pen name of W. S. 
Gassett) (201) who established the theoretical distribution of 
t  and this discovery made i t  possible to calculate a table 
giving the significant levels of observed values of t .  The 
t-Table used in this thesis is illustrated in Table 3. After 
obtaining the value for r, the degree of significance (or 
probability p) can be obtained by the use of the t-table using 
the following formula.
t  = —  ./n - 2
J x - ê
n represents the number of pairs of observations on which the 
correlation is based, r is the correlation obtained and n - 2 
the degrees of freedom (df)•
The p value can therefore be calculated using Table 3 
and hence the significance that can be attributed to the 
results. When the p value is more than 0.05 i t  means that 
there is a greater than 5% chance that the event or occurrence 
under test could happen by chance alone (p of 0.01 equals a 
1% chance, 0.001 equals 0.1% chance e tc .). A figure of more 
than 0.05 is considered unacceptable and the results fa il to 
show correlation, p values between 0.05 and 0.01 suggest that 
the results should be accepted with some confidence and a p 
value of less than 0.01 can be accepted with greater confidence
The SD, X and the r  values described in the sta tis tica l 
sections of this thesis have been calculated using a "Casio 
Scientific Calculator" (Casio Electronics, 1000 North Circular 
Road, London) model fx 3500p using the formulae described in 
this section.
Table 3 dem o nstra ting  the " t - t a b l e " .
Reproduced by permission of the publishers. 
From Grey, D. E. (1971) in Statistics for 
Medical Students (204).
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2.3. Results
2.3.1 Platelet disaggregation ra tio . On the addition of 
ADP, platelet aggregation occurred and this was measured by 
the reduction in optical density (mark "A" in Fig. 14) which 
rapidly returned to "B" . A ratio of A/B was used to quantify 
the "disaggregation ratio" . Preliminary work using more than 
50 normal subjects and confirmed MI patients showed that a 
normal disaggregation response appears to be a ratio of 1.9 
or less. Prolonged discussions between the MRC statisticians 
took place to consider the most satisfactory means of quanti­
fying the "disaggregation ratio" . I t  was agreed that measuring 
the disaggregation "B" at an arbitrary distance 5 cm from "A" 
provided the most satisfactory discrimination between the con­
firmed MI patients and "normal" controls (See Fig. 14).
2.3.2 ADP titra tio n . Fig. 15 illustrates typical aggregation 
patterns which occur after the addition of the various con­
centrations of ADP. In this illustration a concentration of 
l.O^g/0.1 ml is the highest dilution of ADP that demonstrated 
a normal disaggregation ratio (1.9 or less) with a population 
of platelets from a normal donor. The stock and working
dilutions of ADP were divided into small aliquots and stored 
at -2 0°C. The titration  described was periodically checked 
and performed on every new batch of ADP.
2.3.3 OD and platelet counts. The correlation obtained bet­
ween the total platelet count using the Coulter Counter and 
the optical density method described by Bom is illustrated 
in Fig. 16. The statistical analyses showed that p was 
highly significant (<0.QQ1), r  being 0.73. A reading of 
between 38 and 42 on the aggregation meter scale, referred to 
in the method, corresponded to an actual platelet count of 
between 250 and 350 x 10^/1.
2.3.4 Population survev and platelet aggregation. The disag­
gregation results are tabulated in Table 4. The results can be
F ig .  14 dem o nstra ting  th e  "d is a g g re g a tio n  r a t i o " .
The aggregation is demonstrated by the reduction 
"A" in the optical density which rapidly disag­
gregates to " B" •
A ratio of a/B was used to quantify the "dis­
aggregation ratio". Where the ratio has been 
modified to "percentage disaggregation" the
formula B x 100 was used.
A
(ADP concentration = 1.0 ^g/O.l ml, 
volume added to 1 ml of platelet rich plasma 
= 0.1 ml).
5cm
Fig. 15 demonstrating typical aggregation patterns obtained 
after the addition of the various concentrations of 
ADP.
Response curve "D" shows a ratio of 2.1 and curve 
"F" a ratio of 1.8. Therefore, the highest con­
centration of ADP that shows a normal response of 
1.9 is curve E (ADP concentration of 1.0 ^g/0.1 ml.)
The concentrations of ADP were as follows:-
A = 50 |ig/p.l ml
B = 2.50 jig/0.1 ml
C = 1.67 ^g/0.1 ml
D = 1.25 ^g/0.1 ml
E = 1.00 ^g/0.1 ml
F = 0.83 ^g/0.1 ml
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Fig. 16 demonstrating the correlation obtained between the 
platelet count performed on the coulter Counter and 
the optical density method described by Bom ( 197) , 
n = 64. r  = 0.73p = < 0.001.
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Table 4 showing the distribution of "disaggregation ratios" 
in the community survey.
Ratio Numbers of Patients
Community
Controls
Hospital
Controls
MI
Patients
1.4 13 7 0
1.4 5 1 0
1.5 4 1 1
1.6 6 5 1
1.7 9 2 1
1.8 a 3 0
1.9 8 1 0
2.0 3 1 0
2.1 1 1 0
2.2 1 0 0
2.3 1 0 0
2.4 1 0 1
2.5 0 0 1
2.6 1 1 0
2.7 1 0 0
3.0 - 10.0 2 0 6
11.0 20.0 1 0 0
21.0 - 30.0 0 0 2
31.0 - 100.0 0 0 1
100.0 + 0 0 9
Totals 65 23 23
Only subjects with a normal response to 
collagen are included
-3 5 -
summarised as follows:-
1. Of 65 males in the community survey, 12 exhibited an 
abnormal ratio of greater than 1.9 i.e . 18.5% showed 
abnormal disaggregation.
2. Of the hospital based controls, 3 out of the 23 patients 
tested showed abnormal ratios i.e . 13% showed abnormal 
disaggregation.
3. Of the MI patients who had suffered the infarct at least 
12 months previously, 20 out of 23 subjects exhibited an 
abnormal ratio i.e . 87% showed abnormal disaggregation.
2.4 Discussion
It was found that the sensitivity of the method developed 
was maximal if  the ADP was used at the concentration tentied 
the "critical dose" . This was the highest concentration that 
allowed normal disaggregation in a population of platelets 
from normal donors. I t was obtained by progressively increas­
ing the concentration of aPP until normal disaggregation no 
longer occurred. A ratio was devised to reflect the degree 
of disaggregation and subsequent experiments confirmed that 
a ratio of 1.9 or less discriminated well between known MI 
patients and normal controls. When this "critical dose" of 
ADP was added to platelet rich plasma from certain type of 
donors, i t  was found that irreversible aggregation occurred.
I t  was considered that this phenomenon was due to the presence 
of a higher percentage than normal of "active" platelets in 
the circulation of these subjects.
The disaggregation ratio patterns obtained in the experi­
ments performed to date can be classified into three main 
groups. These are illustrated in Fig. 17. Aggregation (a) 
is a typical pattern found in normal control subjects. Pat­
tern (b) illustrates the disaggregation result found in the 
majority of "long term" confirmed MI patients. I t  will be
F ig .  17 showing ty p ic a l  d is a g g re g a tio n  p a tte rn s .
Pattern "A" is from a normal control subject.
The disaggregation ratio was 1.4 and the percent­
age disaggregation 71.4%.
Pattern "B" is a typical disaggregation pattern 
found in the community based "long term" con­
firmed MI patient. The disaggregation ratio was 
58 and the percentage disaggregation 0%.
Pattern "C" is a typical pattern found in the 
hospital based acute MI patient. The disaggre­
gation ratio was 210. and the percentage disaggre­
gation 0%.
(ADP concentration = 1.0 pg/0.1 ml.
Volume added to 1 ml of platelet rich plasma 
= 0.1 ml).
üCO
N
C/)
LU
LU
J  I I 1 I I I I I I
O
O
oin
A llS N 3 a  n v o lid o
-3 6 -
no ted that the actual aggregation, reflected in the fa ll in 
the OD, is the same as that exhibited by a normal population 
of platelets, however the MI patients differ in the degree of 
disaggregation. (c) illustrates the typical pattern found in 
MI patients in the hospital wards in the acute phase of the 
disease•
I t  has been suggested that the "disaggregation ratio" 
should be changed to "percentage disaggregation" in order to 
facilitate easier sta tistical analyses. However, the author 
believes that the ratio reflects the degree of aggregation 
which appears to relate to the activity of the platelet popul­
ation. This is illustrated in Fig. 17. If percentage disag­
gregation was used, both patients (b) and (c) would be repor­
ted as 0% disaggregation. However, patient (c) was an acute 
case which is reflected in the increased fa ll exhibited. This 
gross abnormality would have been obvious if the results were 
reported as "aggregation ratios". Therefore, where appropriate, 
some of the sta tistica l analyses performed in this study have 
been calculated using the "disaggregation ratio" and "percent­
age disaggregation".
The test was used to investigate community and hospital 
based normal subjects together with "long term" confirmed MI 
patients. All the tests were performed "blind" and the rele­
vant data supplied by the Medical Research Council after the 
completion of the surveys. The surveys described revealed 
the following information which is considered for more detailed 
discussion in the "General Discussion" section which comprises 
the last chapter of this thesis.
1. The test developed detected 87% of the confirmed MI 
patients tested in this "blind" survey performed in 
conjunction with the MRC. This has been repeated 
in subsequent surveys performed in the author's 
laboratory.
2. The community controls were normal healthy males.
examined and interviewed by the MRC staff. Of the 
community based normal subjects 18.7% showed an abnormal 
disaggregation ratio. Morris (205) estimates that approx­
imately 25% of men are "affected by major or minor clinical 
or sub-clinical, chronic-or passing coronary heart disease"
“ 38—
CHAPTER 3
ADP DISAGGREGATION AND "ACTIVE" PLATELETS
3.1 Introduction
This chapter investigates the theory that the abnormal 
dis aggregation results obtained after the addition of a 
"critical dose" of ADP were the result of platelets being 
stimulated to release endogenous ADP. The theory, which has 
been detailed on page 27, relates these abnormal results to 
the presence of an increased number of "active" platelets.
Four different methods were used. Two of these four methods 
were designed to investigate the instrumentation and aggre­
gation method used and the remaining two were to investigate 
the theory.
The results obtained using the EEL aggregation method 
were compared with an aggregation meter loaned by ADG (ADG 
Instruments Ltd., Macon House, 131 High Street, Hitchin, 
Herts.). This aggregation system was also based on the orig­
inal technique described by Bom (197) and the principle of 
the method has been outlined on page 5. The ADG system dif­
fered in many aspects from the EEL aggregation meter and was 
therefore particularly useful for inclusion in this experi­
ment. The differences were dependent upon three main factors:-
(a) The speed and method of stirring. I t  is necessary to 
s t i r  the platelet-rich plasma with the selected ag­
gregating agent for subsequent aggregation to occur 
(42, 2 06). This stirring process potentiates platelet 
collision which results in aggregate formation. Mustard 
and Packard (162) describe how the rate at which aggre­
gation proceeds can be directly related to the rate of 
stirring and Sexina (207) states that a speed greater 
than 1,2 00 revolutions-per-minute (rpm) leads to in­
creased disaggregation. Coller and Gralink (2 08) and 
others (2 09) have studied the mixing of piatelet-rich
—3 9—
plasma specimens and have shown that the relationship
of mixing ability to stir-bar geometry and mixing speed
2is shown in the equation Q ^NL W, where Q is the 
mixing ability, N is the rate of stirring, L is the 
length and W the width of the steel bar. The rate 
and method that the platelets are stirred is there­
fore important and related to the aggregation and 
also disaggregation patterns obtained. The ADG 
system incorporated a small magnetic rod in the 
sample which rotated freely by means of a magnetic 
s tirre r as opposed to a rotating fixed vertical rod 
in the EEL aggregation meter. The EEL meter ag­
gregated platelets using a laminar flow which was 
proportional to the speed of the rod and the former 
induced aggregation using a turbulent current.
(b) The shape and size of the cuvettes used by the two 
systems were different and this is considered to be 
one important factor that influences the rate of 
platelet aggregation (207).
(c) The total volume of prp required for the ADG system 
was 0.2 ml in comparison with 1 ml on the EEL ag­
gregation method.
The effect of a different aggregating agent was compared 
with the results obtained with the "critical dose" of ADP. 
"Active" platelets show a rapid response when stimulated by 
aggregating agents. Therefore, from this hypothesis, abnormal 
results should be observed when the same population of plate­
lets are stimulated by other aggregating agents. One suitable 
agent was adrenaline which has been used by O'Brien (199).
He found that in MI patients the characteristic two-phase 
aggregation response showed an abnormal "lag phase".
The theory that the abnormal disaggregation patterns 
found in certain subjects was due to an increased number of
•40-
"active" platelets present being stimulated to release endo­
genous ADP was also investigated. This experiment was per­
formed by administrating ASA to the patients exhibiting abnor­
mal disaggregation patterns.
As described on page 28, ASA has the effect of blocking the 
formation of thromboxane A^ and therefore no dense granules 
are released from the platelets. Therefore, the administration 
of ASA should prevent the release of endogenous ADP and the 
disaggregation patterns should return to normal.
The theory described above implies that the abnormal dis­
aggregation patterns obtained are the result of platelets 
releasing endogenous ADP. As detailed on page 27, i t  will also 
follow that this reflected the presence of an abnormal number 
of "active" platelets present in the circulation of such pat­
ients. However, all the tests as yet described are " indirect" 
tests where the end results reflect the effect of ADP released 
by the platelets. Electron microscopy studies were performed 
to develop these observations by the "direct" examination of 
the platelet morphology.
The method described in this study was developed from the 
original work of Shatz and Riddle (126). These workers used 
electron microscopy to show that platelets change shape im­
mediately after blood is removed from the circulation and 
demonstrated that these changes were the morphological expres­
sion of platelet activation. I t  was considered that the acti­
vity of the platelet population was reflected in the degree 
of fusion of the pseudopodia after activation by glass. The 
"active" platelets showed this response whereas the less active 
cells remained basically round and compact. This is illu stra­
ted in Fig. 18.
3.2 Materials and methods
3.2.1 Comparison of aggregation meters. The platelet-rich
Fig, 18 showing transmission electron microscope studies
of platelets.
(Top) Response of "active" platelets after 8 mins. 
activation with glass. The fusion of the 
pseudopodia reflects the degree of 
activity.
(Bottom) Platelet preparation showing a normal 
response after activation with glass.
Reproduced with permission of the publishers.
From Shatz and Riddle (1970), p .146, (126).
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plasma specimens were prepared as previously described on 
page 28 and the same procedure of performing the aggregation 
tests was followed. The platelet-rich plasma samples pre­
pared were divided into 1 ml aliquots for the EEL system and
0.2 ml amounts for the ADG meter. The two methods were 
tested in parallel, the. amounts of ADP were added and the 
resulting patterns were read simultaneously on the two-pen 
recorder used. The disaggregation ratios were calculated and 
recorded.
3.2.2 Comparison of aggregating agents. Blood was obtained 
from a number of subjects including some community based con­
firmed MI patients. The ADP disaggregation tests were perfor­
med by the EEL aggregation system using the method outlined on 
page 28. The adrenaline aggregation test followed the method 
of O'Brien (199). Preliminary work showed that the hospital 
based MI patients demonstrated the same type of result as 
described by 0 'Brien (199). The community based MI patients, 
although exhibiting an abnormal ADP disaggregation pattern, did 
not differ from the normal controls in their response to the 
adrenaline.
Further experimental work involved a search for a more 
suitable aggregating agent and i t  was found that satisfactory 
results were obtained using the adrenaline issued by the 
hospital Pharmacy Department. This is commercially available 
and issued in sealed vials in a liquid form containing 1.8 mg/ml 
of adrenaline acid tartarate. This is equivalent to approximately 
1 mg of adrenaline per ml. The ADP and adrenaline were tested in 
parallel on two aggregating meters. The volume of reagents 
used for the adrenaline test was as described on page 28 for the 
ADP aggregation. The results were read simultaneously on a two- 
pen recorder.
3.2.3 The effect of ASA on the ADP disaggregation patterns. 
Blood was obtained from a number of subjects and the ADP dis­
aggregation test was performed as previously outlined. The 
sijbjects showing abnormal disaggregation were investigated
-4 2 -
three days later as also was an equal number of subjects showing 
a normal response. This la tte r group was considered to be a 
control group.
Two 300 mg doses of ASA were given to the group showing the 
abnormal response. The ADP disaggregation and collagen tests 
were repeated on blood samples obtained 24h later.
3.2.4 Electron microscopy studies. The test described on 
page 40 which was developed by Shatz and Riddle involved 
adding blood, anticoagulated with 3.13% (w/v) trisodium c it­
rate, to a glass slide at a temperature of 37^ C, This was 
le f t for exactly 8 min for the glass to activate the platelets 
before the preparations were washed and fixed. The next stages 
involved processing the platelets for examination by the trans­
mission electron microscope.
This study describes the development of a method suitable 
for use using a scanning electron microscope (SEM). Nine volu­
mes of blood was anticoagulated with one volume of 3.13% (w/v) 
trisodium citrate and treated in two ways:-
(1) During development work, 0.3 ml volumes of this whole 
blood were added to a series of glass coverslips (pre- 
warmed) and le ft at 37°C for periods of time which 
varied from 3-30 mins.
(2) The whole blood specimen was immediately centrifuged 
at 450 X g for 10 mins. and 0.3 ml volumes of the 
platelet-rich plasma added to a series of glass cover- 
slips and le ft at 37®C for the appropriate time. It 
was found that a platelet count of approximately
200 X 10^/1 gave satisfactory preparations and there­
fore the prp specimens were diluted with ppp in order 
to achieve the appropriate count.
The platelets were activated by the glass coverslip and 
the degree of activation was demonstrated under the SEM. The
—43 -
method of preparing the platelets for the SEM was based on 
the method used by Wollweber and his co-workers (210). After 
preliminary work, the technique was modified (see page 45 ) and 
the following method was developed and used to examine platelets 
under the SEM.
After incubation at 37°C, the excess blood or platelet- 
rich plasma was carefully removed from the coverslip. Follow­
ing this, the coverslips were:-
1. Transferred directly to 4% (v/v) paraformaldehyde for 
15 mins. at room temperature.
2. Washed in 0.06 M phosphate buffer saline (pH7.2) (PBS).
3. Fixed in 2% (v/v) glutaraldehyde in PBS for 1 h at 4°C.
4. Washed in PBS.
5. Post fixed in 1% (w/v) OSO^  in veronal acetate buffer 
(pH 7.2) for 1 h at room temperature.
6. Extensively rinsed in the veronal acetate buffer.
7. Incubated with 1% (w/v) tannic acid in 0.05 M cocodylate 
buffer (pH 7,2) for 1 h at room temperature.
8. Washed extensively ip 0.9% (w/v) sodium chloride.
9. Incubated in 0.5% (w/v) ura^yl acetate in double dis­
tilled  water for 1 h at room temperature.
10. Rinsed in 0.9% (w/v) sodium chloride.
11. Dehydrated in a graded series of acetone solutions (30%,
50%, 70%, 80%, 90% and twice in 100%).
After dehydration the samples were "critical point" 
dried with COg. The coverslips were mounted on brass stubs, 
gold coated and examined under "Cambridge S150 Scanning Electron 
Microscope.
Blood specimens were obtained from normal controls, MI
patients who had suffered infarction at least 12 months previous­
ly and also hospital based acute MI patients. The platelets 
were prepared and processed for the SEM using the method des­
cribed and the ADP disaggregation test performed as outlined
-4 4 -
on page 28. The platelet disaggregation ratios were calcula­
ted and compared with the platelet activity observed by 
direct examination of the SEM preparations.
3.3 Results
3.3.1 Correlation between the EEL and ADG aggregation meters. 
Examples of the aggregation charts will be seen in Fig. 19.
As illustrated, the aggregation results are similar using both 
systems but i t  is noted that the relative size of the patterns 
obtained on the ADG meter were smaller than those obtained on 
the EEL. The scatter diagram illustrating the correlation 
between the two systems is illustrated in Fig. 20 and the 
results obtained, including the sta tistica l analyses,are listed 
in Table 5.
3.3.2 Correlation between the ADP and adrenaline. Examples of 
the results obtained are illustrated in Fig. 21. The patterns 
demonstrate that, when the ADP disaggregation ratios were normal, 
no response was observed after the platelets were stimulated 
with the commercially available adrenaline used in this experi­
ment. In addition, there appeared to be a correlation between 
the response to this adrenaline and the degree of abnormality 
of the ADP disaggregation ratios. In order to fac ilita te  
sta tistica l analysis, a method was introduced to measure the 
response to adrenaline. This involved measuring the vertical 
fa ll in mm on the chart at an arbitrary distance of 5 cm across 
from the point where the aggregating agent was added. This is 
illustrated in Fig. 22. All the 50 normal ADP aggregation 
ratio results demonstrated no response to the adrenaline. I t  
was observed from the patterns obtained that every abnormal 
ADP disaggregation ratio showed some degree of response to 
this adrenaline. Statistical analyses have only been performed 
on the specimens demonstrating an abnormal disaggregation ratio. 
The scatter diagram showing the ADP disaggregation ratios and 
the response to adrenaline in mm is illustrated in Fig. 23.
Fig, 19 showing the correlation between the response of plate­
let-rich plasma specimens to the "critical dose" of 
ADP tested simultaneously on an EEL and ADG aggre­
gation system.
"X" Aggregation patterns obtained with the ADG 
system.
"Y" Aggregation patterns obtained with the EEL 
system.
(ADP concentration = 1.0 j xg /0 .1  ml.
Volume added to 1 ml of platelet rich plasma 
= 0.1 ml).
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Fig. 20 Scatter diagram illustrating the correlation between 
the EEL and ADG aggregating maters.
n = 24 r  = 0.97 p <  0.001
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Table 5 showing the correlation between the EEL and aDG 
aggregation meters.
Significant correlation was obtained (p =-<.0.001) 
when comparing the ”disaggregation ratio" obtained 
on the two instruments (r = 0.91). Similarly when 
the "percentage disaggregation" results were 
compared r  = 0.97.
DISAGGREGATION RESULTS
EEL ADG
Ratio Percentage Ratio Percentage
1 1.4 73.7 1.4 78.3
2 80.0 0 3.5 2.8
3 4.0 21.4 4.7 21.2
4 150.0 0 98.0 0
5 3.1, 32.6 2.4 42.1
6 80.0 0 47.0 0
7 82.0 0 70.0 0
8 4.1 24.2 3.5 29.0
9 3.5 27.9 2.5 39.0
10 220.0 0 180.0 0
11 125.0 0 140.0 0
12 100.0 0 62.0 0
13 9.0 11.1 8.3 12.0
14 21.0 4.6 20.0 5.0
15 16.4 6.1 24.7 4.1
16 1.9 51.8 1.6 60.1
17 4.7 18.5 4.2 23.8
18 6.0 16.6 7.3 13.6
19 3.3 30.2 2.1 46.7
20 2.1 48.9 1.9 52.0
21 1.9 53.3 1.8 56.6
22 1.5 64.3 1.7 58.0
23 1.9 52.9 1.9 53.3
24 1.3 75.0 1.6 63.8
Mean
Standard
Deviation
34.3
53.5
25.5
24.8
28.8
47.4
27.6
25.3
Correlation (r) between the "percentage disaggregation" 
= 0.97 t  = 14.2 P = < 0.001
Correlation (r) between the "disaggregation ratio"
= 0.91 t  = 10.2 P = < 0.001
F i g #  2 1  s h o w in g  e x a m p le s  o f  t h e  c o r r e l a t i o n  b e t w e e n  t h e  
r e s p o n s e  o f  p i a t e l e t - r i c h  p la s m a  s p e c im e n s  
t h e  " c r i t i c a l  d o s e "  o f  ADP a n d  a d r e n a l i n e .
"X" A g g r e g a t i o n  w i t h  t h e  " c r i t i c a l  d o s e "  o f  ADP.
" Y" A g g r e g a t i o n  w i t h  a d r e n a l i n e .
The ADP was used at a concentration of 1.0 ^ 9/ 0.1 ml 
and the adrenaline 100 pg/0.1 ml.
T h e  v o lu m e  a d d e d  t o  t h e  p l a t e l e t  r i c h  p la s m a  
p r e p a r a t i o n s  w a s  0 . 1  m l .
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Fig. 22 showing the method used to represent the aggregation 
demonstrated by adrenaline. The figure of 5 cm is an 
arbitrary measurement.

Fig. 23. Scatter diagram demonstrating the relationship 
between the ADP disaggregation ratio and the 
response to adrenaline in mm.
n = 21 r  = 0.68 p =<0.001
N 0liV 03d00V S ia%
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The results and sta tistica l analyses are tabulated in Table 6,
3.3.3 ADP disaggregation patterns after the administration of 
ASA. Ten subjects showing an abnormal response to ADP were 
tested after an interval of three days together with the same 
number of controls. The "results are tabulated in Table 7 and 
as can be seen, a ll the results were reproduced.
The abnormal subjects were re-tested 24 h after the ad­
ministration of two 300 mg tablets of ASA. Every subject 
involved showed two changes in aggregation response:-
1. No response was observed when collagen was added to the 
platelets.
2. Every abnormal ADP disaggregation ratio returned to 
normal. The results are tabulated in Table 8.
3.3.4 Electron microscope studies. Two different preparations 
were processed for examination under the scanning electron 
microscope. After the whole blood and the platelet-rich 
plasma preparations were incubated for 5 mins. on a series 
of glass covers lip s , i t  was found that the la tte r gave far 
superior results when processed and examined under the SEM. 
Present in these prp specimens were platelets which had ex­
hibited "activity” shown by extrusion of the pseudopodia.
Some platelets did not show any activity and appeared as round 
cells in the preparations. I t  was also noted that some prepar­
ations contained more of the "active" platelets than others. 
However, when using the method described by Wollweber (210), 
i t  was concluded that the preparations were insufficiently 
washed. This resulted in protein remaining on the coverslips 
and this was not acceptable in electron microscopy studies. 
These results are illustrated in Fig. 24. This problem was 
overcome by modifying the original method by introducing extra 
washing procedures and also including paraformaldehyde in the 
method. However, i t  was noted that the round, less active 
platelets were washed off the coverslip during this procedure.
Table 6 listing the correlation between the ADP dis­
aggregation results and the response to 
adrenaline in mm.
Significant correlation was obtained (p = <0.001) 
when the fa ll of the adrenaline in mm was compared 
with the "percentage disaggregation" (r = 0.68) 
and "disaggregation ratio” (r = 0.83).
No response to the adrenaline was noted in 50 sub­
jects demonstrating normal platelet disaggregation.
No. ADP disaggregation Fall of adrenaline in mms.
Percentage. Ratio.
1 0 150.0 143
2 14.2 7.0 96
3 0 162.0 220
4 0 100.0 67
5 36.6 2.7 38
6 34.2 2.9 60
7 0 80.0 110
8 0 40.0 56
9 43.6 2.3 40
10 30.3 3.3 54
11 0 150.0 110
12 14.2 7.0 86
13 0 86.0 136
14 0 140.0 180
15 0 80.0 100
16 23.3 4.3 60
17 31.0 3.2 52
18 43.4 2.3 29
19 25.0 4.0 40
20 16.3 6.1 82
21 0 40.0 60
Mean
Standard
Deviation
14.8
15.9
51.1
57.6
' 86. 
48.
6
4
Correlation (r) between the "percentage disaggregation" 
and the fall in adrenaline =0.68.
t  = 4.1 p = < .001
Correlation (r) between "disaggregation ratio" and the 
fall  in adrenaline = 0.83,
t  = 6.5 P = < .001
Table 7 showing the ADP disaggregation ratio results after 
an interval of 3 days.
Included are 10 normal and abnormal results.
Patient
ADP Disaggregation 
Results 
Day 1
ADP Disaggregation Results 
After an Interval of 
3 Days
1 36.0 29.2
2 4.0 3.5
3 1 0 0 . 0 74.0
4 26.2 23.0
5 5.3 4.2
6 26.1 18.2
7 4.1 3.4
8 1 0 0 . 0 92.0
9 28.2 24.1
10 2.3 2 . 1
11 1 . 1 1.4
12 1 . 8 1 . 8
13 1.9 1 . 6
14 1.3 1.3
15 1.9 1.7
16 1 . 8 1.9
17 1.7 1.4
18 1 . 6 1.4
19 1 . 8 1 . 6
2 0 1.9 1.9
Table 8 showing the ADP disaggregation ratio results 
after the administration of ASA.
ADP Disaggregation 
Results 
Day 1
ADP Disaggregation 
Results After an 
Interval of 3 Days
ADP Disaggregation 
Results After 
The Administration 
of ASA
1 36.0 29.2 1.9
2 4.0 3.5 1 . 8
3 1 0 0 . 0 74.0 1.9
4 26.2 23.0 1 . 6
5 5.3 4.2 1.4
6 26.1 18.2 1.4
7 4.1 3.4 1 . 6
8 1 0 0 . 0 92.0 1.9
9 28.2 24.1 1.7
10 2.3 2 . 1 1.5
Fig. 24 illustrating the insufficient washing of the
platelet preparation when using the method described 
by Wollweber (210 ).
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The problem was overcome by activating a ll the platelet pop­
ulation present in the preparation. This was achieved by in­
creasing the time that the platelets were in contact with 
the glass and ensuring i t  was sufficient for the less "active" 
platelets to change shape and adhere to the coverslip. Fur­
ther work showed that the modified washing procedure did not 
remove platelets from the coverslip if  the incubation time 
was increased to 10 mins. Identical activity results were 
obtained with incubation times of 15, 20 and 30 mins. although 
these were unsatisfactory because of the drying of the prepar­
ations during incubation resulting in further problems with 
protein precipitation.
The original method of examination after 5 mins. incu­
bation was repeated in parallel with the modified method after 
10 mins. incubation. Examination of the SEM preparations 
showed that the piatelet-rich plasma specimens showed the same 
total number of cells present in both tests . No cells were 
lost. In this modified preparation, with 10 mins. incubation, 
the round cells had changed shape, and although not extruding 
many pseudopodia, had clearly adhered to the surface of the 
glass coverslips.
The platelet activity demonstrated by direct examination 
using the scanning electron microscope is illustrated in 
Figs. 25-2 7. The results are compared with the aggregation 
response after the addition of a "critical dose" of ADP.
Figure 25 shows a normal ADP disaggregation response and 
as can be seen the activated platelets were separate and no 
aggregation was observed on the SEM preparation.
Figure 26 was from a community based MI patient who had 
suffered infarction at least 12 months previously. The ADP 
disaggregation demonstrated an abnormal pattern and the SEM 
preparation showed the platelets grouped in aggregates of 
five to ten.
Figure 2 7 illustrates the grossly abnormal ADP disag­
gregation normally found in acute hospital based MI cases.
Fig. 25 showing a normal ADP disaggregation response. The 
activated platelets are separate and no aggregation 
can be observed.

Fig. 26 showing an abnormal ADP response in the "community" 
based MI patient. The activated platelets are 
grouped in aggregates of 5-10 cells.

Fig. 2 7 showing the grossly abnormal ADP response seen in 
acute cases of MI. The activated platelets are 
grouped in aggregates of 1 0 - 2 0  cells.
n«
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As can be seen the platelet preparation demonstrates platelets 
grouped in aggregates of ten to twenty.
All the platelets in every preparation tested had changed 
shape and adhered to the glass. In the specimens where the 
ADP disaggregation patterns were abnormal gross fusion of the 
pseudopodia were more prominent in the SEM preparation. This 
experiment was repeated using twenty different populations 
of platelets and similar results to those described above 
were obtained.
3.4 Discussion
This chapter describes an experimental programme designed 
to investigate different aspects of the ADP disaggregation 
test developed and described in the previous chapter.
The EEL system used was compared with a basically diffierent s^- 
tem of measuring platelet aggregation. Page 38 l is ts  the 
important differences between the ADG and the EEL aggregation 
meters. Each one of these factors could affect the aggrega­
tion and subsequent disaggregation of the test sample. The 
results show that a satisfactory correlation was obtained 
between the two systems used.
The disaggregation patterns obtained after the addition 
of a "critical dose" of ADP were compared with the response 
in the same platelet population to adrenaline. As discussed 
on page 45/ correlation was obtained between the activity ob­
served when the platelets were challenged with the two aggre­
gating agents. Every preparation that showed an abnormal dis­
aggregation response to the ADP also showed a response to 
adrenaline. Where there was no response in tte latter, the dis­
aggregation ratios were always normal.
T he l a s t  tw o  e x p e r i m e n t s  p e r f o r m e d  i n v e s t i g a t e d  t h e  
h y p o t h e s i s  t h a t : -
1. The abnormal aggregation patterns were due to the platelets
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releasing their endogenous ADP from the dense granules.
2. The abnormal results reflected the presence of an 
excessive number of "active" platelets in the 
circulation of such patients.
The f i r s t  hypothesis (1) was investigated by adminis­
trating ASA to those patients who exhibited abnormal disag­
gregation patterns. This drug has the effect of preventing 
the release reaction of the dense granules by interfering 
with the formation of thromboxane A^ . (This process has been 
detailed on page 28). Therefore, after ASA has been adminis­
tered to such patients, the disaggregation patterns should 
return to normal if  the abnormal results were due to the 
release of endogenous ADP. Every platelet-rich plasma pre­
pared 24 h after ASA, showed a return to normal disaggregation, 
These results support the hypothesis that the abnormal dis­
aggregation ratios were due to the release of the dense gran­
ules containing the endogenous ADP.
The second hypothesis (2), that the blood of subjects 
exhibiting an abnormal disaggregation pattern contained an 
increased percentage of "active" platelets was investigated 
using electron microscopy. I t  was demonstrated that an in­
creased activity was observed when the platelet ADP disag­
gregation ratios were abnormal. Such responses have been dem­
onstrated in Figs. 25-27.
T he i n v e s t i g a t i o n s  c o n f i r m  t h a t  t h e  a b n o r m a l d i s a g g r e ­
g a t i o n  t e s t s  r e f l e c t e d  t h e  a b n o r m a l  p l a t e l e t  a c t i v i t y  i n  t h e  
P a t i e n t s  c i r c u l a t i o n  d u e  t o  a n  e x c e s s  o f  " a c t i v e "  p l a t e l e t s .
The methods described involved "indirect" tests using aggregat­
ing agents, response to ADP after the administration of ASA and 
"direct" examination of platelet activity under the scanning 
electron microscopy after activation with glass.
4-1
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CHAPTER 4
AD? DISAGGREGATION AND COMMUNITY STUDIES 
Introduction
This chapter describes various experiments performed in 
an attempt to find another test reflecting the same platelet 
abnormalities as demonstrated by the disaggregation patterns. 
This was with the aim of performing large scale field work 
in conjunction with the 24edical Research Council Epidemiology 
unit.
Preliminary development work showed that the only d if­
ficulty most likely to be encountered with the ADP aggregation 
test would be the time factor between venepuncture and testing. 
Specimens tested immediately and retested at time intervals 
up to six hours after bleeding gave satisfactory reproducibility, 
Results were unreliable if  the specimens were le ft longer.
This limited the number of tests that was acceptable to the 
laboratory during the working day, additionally the MRC was 
restricted to studies close to Carmarthen. This necessitated 
the development of a method suitable for large scale community 
work in the field.
It was considered that this problem could be overcome 
in two ways : -
1. The technology could be transferrred to the MRC centre 
where the community study was being undertaken and the 
tests performed immediately. However, ADP is unstable 
when made up in solution and requires storage at critica l 
temperatures. The adrenaline solution described on page 41 
could overcome the storage difficulties as this reagent 
is purchased in sealed vials in a liquid form and is 
stable at room temperature. This adrenaline test could 
be used as a complete test with the fa ll in aggregation 
representing the platelet abnormality. Alternatively, i t  
could be used as an in itia l screening test, following
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which, the patients with an abnormal response would be 
requested to attend the Carmarthen laboratory for the 
ADP disaggregation test.
2. A new test capable of being performed in the base 
laboratory could be developed. Certain crite ria  
would need to be met by such a new test.
I t must correlate with the ADP disaggregation 
test and be similarly capable of demonstrating abnormal 
results in a percentage of "normal" controls and the 
community based MI subjects. The ultimate specimen 
prepared should be stable and therefore suitable for 
posting to Ihe base laboratory. In addition, i t  would 
be advantageous if  the test could be automated with 
capability of assaying the large number of specimens ex­
pected when performing large scale community studies.
As the platelet is unstable during storage i t  was decided 
to concentrate this investigation on parameters conse­
quent upon platelet aggregation and measurable in plasma.
Two such factors were considered; platelet factor 4 and 
^ - thromboglobulin.
Platelet factor 4 is a small molecular weight protein 
that is secreted from the oc-granules of platelets during the 
release reaction (211-213). This action is referred to as 
"type II release" and has been detailed on page 6 , This phen­
omenon occurs when the platelets become activated subsequent 
to contact with subendothelia i tissues and a variety of other 
physiological agents including thrombin, ADP and epinephrine 
(212). These have been listed in Table 1. Nath and his co­
workers (214) describe PF4 as a protein that inactivates heparin 
activity. I t  has been suggested that increased levels of 
platelet factor 4 (PF^ ) in the blood could serve as an e s ti­
mate of intravascular platelet aggregation (214). This factor 
is well suited for inclusion in this investigation because 
raised levels have been reported in thrombotic states and also 
in myocardial infarction (215-220). I t  is known that other
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proteins (221/ 222) can neutralise heparin and O'Brien (215) 
refers to this PF^  test as "heparin-thromb in clotting time"
(HTCT). However Nath ‘ and his co-workers (214) conclude that 
"PF^  antigen and antiheparin activity are two properties of 
the same protein".
p-Thromboglobulin was isolated and characterised by 
Moore and his co-workers (223). This factor is located in 
the - granules of platelets and is freed when platelets 
undergo their release reaction (224). I t can be considered 
a platelet specific protein, the presence of which is an ex­
pression of the platelet release reaction. As with PF ,^ an 
increase is present in the blood of MI patients (225). Because 
of these considerations i t  has been included in the investi­
gations .
4.2 Materials and ffethods
4.2.1 ADP disaggregation and p-Throrriboglobulin levels. The 
p)-Thromboglobulin assay has been performed using a radioimmune- 
assay (RIA) kit available from The Radio-chemical Centre, 
Amersham^  Bucks. The RIA method is dependent on competition 
between jS-Thromboglobulin and ^^^I labelled ^-Thromboglo- 
bulin for a limited number of binding sites on a yS-Thrombo- 
globulin specific antibody. The amount of I-labelled yS -
Thromboglobulin bound by the antibody is inversely proportional 
to the concentration of unlabelled g -Thromboglobulin present
T O C
in the plate let-poor plasma samples. The antibody bound I-
labelled ^-Thromboglobulin was separated by precipitation 
with an ammonium sulphate solution. After centrifugation and 
removal of the supernatant, the precipitated radio activity was 
measured in a gamma counter. By measuring the proportion of 
I labelled ^-Thromboglobulin bound in the presence of a 
series of standards, the concentration of^-Thromboglobulin 
in the unknown samples could be calculated from a standard 
curve. In addition, the system employed a mixture of anti­
coagulant and anti-platelet reagent which, combined with
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maintaining the blood sample at 4^C, prevented the release of 
jS -Thromboglobulin from the platelets during processing. In 
this way, the measured jS-Thromboglobulin reflected the 
in vivo circulating level at the time of sampling.
The ADP disaggregation tests were performed as previously 
outlined on page 29. Aliquots of the blood samples were treated 
by the method described in the RIA kit and the 5 -Thromboglo­
bul in level assayed.
4.2.2 ADP disaggregation and platelet factor 4. The levels 
were assayed using two different methods. The original work 
was performed using the "clotting" method developed by Fuster 
(226) and O'Brien (215). The observations made were confirmed 
using an RIA method which only became commercially available 
towards the la tte r stages of the investigations.
The "clotting method of assaying PF^  was basically a 
very simple test. Use was made of two inactivation processes; 
PF^  inactivated heparin and heparin inactivated thrombin.
When thrombin was added to plasma, i t  combined with the fibrin­
ogen to form the fibrin clot. Heparin was added to the test 
plasma and was inactivated by the PF^  present. Thrombin was 
added which was immediately inactivated by the heparin and 
the thrombin remaining combined with the fibrinogen in the 
plasma to form the fibrin clot.
The series of reactions were as follows:-
Plasma (PF^ ) Heparin inactivated according
to the level of PF^  present
in the plasma.
Heparin
Thrombin
+ Heparin remaining after the
above reaction inactivated 
the thrombin.
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+
Fibrinogen in plasma
Fibrin clot
The thrombin remaining 
after the above reaction 
combined with the clot­
ting factors to form 
the fibrin clot.
The more PF^  that was present in the plasma the more 
heparin that was inactivated. Therefore less thrombin was 
neutralised and more was le ft to combine with the fibrinogen 
in the plasma and the fibrin clot formed in a shorter time.
When normal or reduced amounts of PF^  were present, less 
heparin was neutralised and more was le ft to inactivate the 
thrombin. MOre thrombin was therefore inactivated and less 
was le ft to combine with the fibrinogen and the fibrin clot 
took longer to form.
The clotting time after the addition of thrombin there­
fore reflected the level of PF^  present in the plasma. The 
test as described by O'Brien (215) involved adding 0.1 ml of 
heparin to 0 . 1  ml plasma, this was le ft for 1 min and 0 . 1  ml 
thrombin was added. The clotting time was measured and 
recorded. The method described by Fus ter (226) was based on 
the same principle but the coagulation factors were removed 
from the patients'plasma specimens by incubation at 60°C for 
10 mins. The clotting factors for the formation of the fibrin 
clot were made available from pooled normal "substrate" plasma 
added for this purpose. Both tests were found suitable for 
use but the total volume of 0.3 ml in the O'Brien method, com­
pared with 0.7 ml in the Fuster method, made the former the method 
of choice. The main reason for this decision was that the 
relatively small total volume involved made i t  practicable to 
use the Fibrome ter (Beckton-Dickinson, Cavley, Oxford) for the 
detection of fibrin clot. This is a very sensitive electronic 
method of measuring clot formation and is used routinely in 
hospital laboratories for coagulation studies. The thrombin 
was used at a concentration of 10  units/ml and the heparin was 
adjusted with every batch of specimens tested until the clotting
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time after the addition of thrombin was between 30 and 40 secs, 
with "normal' plasma.
Many difficulties were encountered during preparatory 
work and the original method was modified. These aspects are 
discussed in greater detail on page 57. Blood specimens were 
obtained from normal healthy subjects, community and hospital 
based MI patients. A 9 ml volume of the patients* blood was 
prevented from clotting with 1 ml 3.13% (w/v) sodium citrate . 
This was mixed by inversion and, using a plastic pipette,
2 ml was added to each of two plain plastic tubes. One tube 
was centrifuged immediately at 2400Xg for 15 mins. and 0.5 ml 
of plasma removed without delay from the top portion of the 
specimen. This was done in order to minimise contamination 
from the centrifuged platelet layer. The remaining tube was 
le ft at room temperature for 30 mins., centrifuged and 
treated as described for the f irs t  tube. The 6 ml of blood 
remaining in the original specimen tube was centrifuged and 
the ADP disaggregation test performed as previously described 
on page 28.
The plasma specimens were placed at 4°C immediately after 
preparation when using the "clotting" technique and at -20°C 
for the isotope nfôthod. Both the thrombin and heparin solu­
tions were diluted in veronal-acetate-hydrochloric acid buffer 
(pH 7.4). A working dilution of 10 units/ml of thrombin was 
made and divided into 1 ml aliquots and stored at -2 0°C.
Heparin was "titrated" against normal plasma until suitable 
results of between 30-40 secs, were obtained. The correct 
"working" dilution was stored at -20°C but the titra tion  was 
repeated with every batch of specimens tested. The method is 
outlined below and i t  is essential that the incubation times 
stated are followed.
The stored heparin and thrombin were placed at 37°C for 
10 mins. before the f irs t  specimen was tested and then they were only 
used jfer a further 15 mins. The plasma specimens were brought to 
room temperature and maintained at 37°C for exactly two minutes
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before adding the heparin. The system is illustrated below:-
0 . 1  ml plasma
0 . 1  ml heparin
0 . 1  ml thrombin
Fibrin Clot
2 mins. at 37 C
1 min.
Start timer on the 
Fibrome ter
In addition to the PF^  test, the thrombin time was also per­
formed on every specimen tested. This test checks the reaction 
between the thrombin and the coagulation factors in the plasma 
without interference from the heparin. I t  was performed using 
the same method described for the PF^  but the buffer is substi­
tuted for the heparin.
One disadvantage of this test was that i t  was crucial to 
control the time and the temperature at which the reagents were 
tested. Efforts were made to overcome these variables and 
make the test acceptable for field work involving large numbers 
of specimens by using totally automated coagulation systems.
The specimens and reagents on most of these instruments were 
stored in a 4°c compartment and transferred automatically 
to cups maintained at 37^ C. Therefore the time and tempera­
ture variables were stric tly  controlled and every specimen 
including the normal controls for the titration  of the heparin
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were treated in exactly the same manner. The following in­
struments were kindly offered on loan and modified to perform 
the platelet factor 4 test as previously outlined on page 55. 
"Auto-Fi" coagulation instrument (supplied by American Hospital 
Supplies (U.K.) Ltd., Station Road, Didcot, Oxfordshire). 
"Coag-a-Pet" (supplied by General Diagnostics, Ltd., Eastleigh, 
Hants.). "Biomatic 2000" coagulometer (supplied by Walter 
Sorstedt, (U.K.) Ltd., Beaumont Leyes, Leicester).
The RIA method of assaying PF^  was performed on a k it
available from Abbott Laboratories (Abbot Laboratories Ltd.,
Brighton Hill, Basingstoke, Hants.). Again the RIA method
was a "competitive" technique in which the non-radioactive
125PF^  in plasma competed with a constant amount of I-PF  ^ for 
binding sites on a limited amount of PF^  antiserum. Thus the 
percentage of radioactive PF^  bound to the antiserum was 
inversely proportional to the concentration of non-radioactive 
PF^  in the specimen. The antiserum bound (both radioactive 
and non-radioactive) was separated by precipitation with am­
monium sulphate solution. The radio-activity of this complex 
was measured with a well type gamma scintillation counter. The 
concentration of PF^  in the specimen was determined by compari­
son with a group of standards containing measured amounts of 
non-radioactive PF .^
4.3 Results
4.3.1 Relationship between disaggregation ratio and jg-Thrombo- 
qlobulin levels. The comparison between the ADP platelet dis­
aggregation ratios and the yS -Thromboglobulin levels in ng/ml 
is illustrated in the scatter diagram (Fig. 28) and the results 
tabulated in Table 9. S tatistical analyses show no correlation 
(r = 0.23) and the probability (p) was less than 0 . 2  and greatr 
er than 0 . 1 .
4.3.2 Relationship between disaggregation ratio and PF^ . Many 
problems were encountered with the "clotting" method of
Fig, 28. Scatter diagram demonstrating the relation­
ship between the ADP "disaggregation ratio" 
and the Thromboglobul in level in ng/ml. 
S tatistical analyses show a lack of correlation 
between these two parameters r = 0.23 
p = <0.2 >0.1 n = 33.
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Table 9, listing the results obtained when comparing the
disaggregation results and the yff-Thromboglobulin 
levels in ng/ml.
A lack of correlation was observed (p =-<0.2 >0.1) 
when the -Thromboglobulin results were compared
with the "disaggregation ratio" (r = 0.23) and 
"percentage disaggregation" (r = 0.24).
Disaggregation Results &  -Thromboglobulin levels
Ratio. Percentage. in ng/ml.
1 5.3 19.0 21.4
2 1 . 6 61.5 19.7
3 30.0 0 2 1 . 2
4 1 . 6 64.0 22.9
5 1 . 8 54.0 25.9
6 1 . 8 56.3 33.3
7 29.0 0 38.0
8 1 0 . 8 92.3 26.0
9 1 . 8 56.3 19.8
10 2.3 44.4 32.0
11 1 . 8 55.2 6 8 . 2
12 2 . 1 49.7 140.0
13 2 . 2 44.7 58.0
14 1.7 57.6 20.3
15 1.7 57.1 63.0
16 6.9 14.5 19.6
17 1.9 48.7 1 2 0 . 0
18 1.7 58.3 24.3
19 32.0 0 27.6
20 3.3 30.7 34.0
21 14.3 69.8 26.2
22 2 . 0 50.0 32.0
23 1 . 8 55.5 1 2 0 . 0
24 2.3 42.9 19.8
25 3.5 29.0 24.6
26 25.0 0 18.2
27 1 . 8 56.5 98.2
28 6 8 . 0 0 28.2
29 1 . 6 62.1 26.9
30 1 . 8 57.1 34.2
31 150.0 0 2 1 . 6
32 44.0 22.5 32.0
33 160.0 0 18.9
Mean 18.7 36.7 40.5
Standard 3 7 , 7 25.0 32.0
Deviation
Correlation (r) between "disaggregation ratio" and the 
^-Thromboglobulin levels = 0.23 t  = 1.35 p =<0.2>0.1.
Correlation (r) between "percentage disaggregation and 
the yS - Thromboglobul in levels = 0.24 t  = 1.4 p = <0.25^0.1
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performing the platelet factor 4 test. I t  was found that the 
time and temperature at which the reagents were stored and 
tested v^ re c ritica l. This problem was overcome by stric tly  
controlling these variables and the sensitivity was also 
improved by the use of the veronal acetate4iydrochloric acid 
buffer as the diluent. A further change to the PF^  test was 
also introduced. This involved the testing of the blood speci­
men twice. One specimen was prepared immediately after bleed­
ing the patient and the other aliquot of blood was prepared 
after 30 mins. incubation at room temperature. This modifica­
tion resulted in a conpletely new aspect being introduced into 
the PF^  test and was developed as the result of problems en­
countered when standardising the heparin solution to obtain a 
result of between 30-40 secs, with normal plasma. I t  was ob­
served that, after the heparin concentration was adjusted to 
give a satisfactory clotting time with one normal plasma, the 
next normal tested could vary from a normal to a very abnormal 
result. Further work showed that these results on the normal 
plasma specimens were related to the time the bloods were le ft 
at room temperature before centrifuging. Typical examples of 
the results obtained with the different blood specimens separ­
ated into 2 ml amounts^  and these aliquots centrifuged at 
controlled time intervals,, are illustrated in Fig, 29. I t  was 
observed that some blood specimens, although showing a normal 
result with the sample centrifuged immediately after bleeding 
the patient, showed a marked increase (decrease in clotting 
time) in the subsequent samples le ft at room temperature. 
Provisional investigations showed that the difference was 
maximal after 30 mins. I t  was noted that, although this in­
crease could be demonstrated in the PF^  test, the thrombin 
times on all these samples from the same patient, remained 
the same. The specimens were numbered (centrifuged immed­
iately) and 9q  (centrifuged after 30 mins.). Similarly the 
thrombin times on the same specimens were numbered and 1^ ,
No correlation was observed when comparing the ADP dis­
aggregation ratio and the platelet factor 4 levels (1^ , Stat­
istical analyses are listed in Table 10 and n = 41 r  = 0,26 
p =<.0,1 >,0,05, The scatter-diagram is illustrated in Fig, 3CL
Fig. 29 demonstrating the difference in the PF^  levels 
after different time intervals. One blood 
specimen was separated into eleven different tubes 
and each sample centrifuged at the time intervals 
shown on the chart. Patient X was a normal • 
control and the difference in the PF^  levels 
between this specimen and conf irmed MI patients Y and 
Z after 30 mins. incubation can be clearly seen.
The normal control and confirmed MI patients 
demonstrate the same PF^  levels after an inter­
val of 3-4 h.
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Table 10 listing the results obtained when comparing the
disaggregation results with the "clotting" method 
of estimating PF .^
A lack of correlation was observed when the PF^  
levels were compared with the "disaggregation 
ratio" (p = <0.I> 0,05 r  = 0.26) and the 
"percentage dis aggregation" (p = >0.9 r  = 0.02).
Disaggregation Results PF. results 
in secs.Ratio Percentage
1 1 . 8 56.5 27.3
2 44.5 22.5 34.4
3 1.7 57.8 2 0 . 2
4 2.3 44.4 40.4
5 1 . 6 64.0 30.2
6 5.3 19.0 43.2
7 3.5 29.0 29.4
8 1.7 57.6 36.2
9 1.7 57.1 27.3
10 1 . 8 55.5 29.4
11 32.0 0 34.8
12 44.0 22.5 29.4
13 1 . 6 62.1 30.8
14 32.0 0 45.2
15 160.0 0 2 1 . 2
16 1.9 48.7 15.2
17 1.9 46.2 30.4
18 2.3 42.9 26.3
19 118.0 0 15.3
2 0 38.0 0 34.4
21 1 . 2 83.3 28.2
22 1 . 6 63.8 38.4
23 42.0 0 29.3
24 2 . 1 47.6 28.2
25 1 . 6 60.5 32.4
26 2 . 8 35.4 46.2
27 1.7 59.4 30.2
28 182.0 0 29.4
29 2.4 41.4 18.5
30 91.0 0 27.5
31 2 . 6 38.3 25.0
32 3.4 29.0 33.0
33 1.9 48.8 37.6
34 1.4 60.3 44.0
35 1 . 8 53.6 39.4
36 1.3 76.9 32.0
37 6.4 15.5 31.8
33 1 . 2 78.0 24.0
39 4.2 23.8 35.9
40 3.3 30.3 29.2
41 1.5 6 6 . 6 31.0
tleem
Standard
Deviation
2 0 . 8
42.0
38.9
24.7
31.0
7.24
Correlation (r) between the "disaggregation ratio" and the 
PF^  levels = 0.26 t  = 1.7 p = <■ 0.1>0.05.
Correlation (r) between the "percentage disaggregation" 
and the PF^  levels = 0.02 t  = 0.12 p =>0.9.
'ig, 30 Scatter diagram illustrating the relationship 
between the ADP disaggregation patterns and 
the PP.level in seconds.
4
Statistical analyses show a lack of correlation 
r = 0.26 p = <0.1 >0.05 n = 41
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However, examination of the data revealed that 7 out of a 
total number of 10 acute hospital based MI patients showed 
abnormally high (shorter clotting time) PF^  levels. No 
abnormal results were seen in any of the normal controls or 
the "community based" MI patients.
When the disaggregation ratio results were compared 
with the and the values from the same patients, the 
difference between these two la tte r tests could be related 
to the disaggregation patterns. Three examples of such 
results are illustrated in Fig. 31. These three patterns 
show the importance of the modified PF^  test:-
Pattem (a) was from a normal control and the value 
was normal and the P^ result showed a reduction (increase in 
PF^ ) of only 1 . 8 -secs.
Pattern (b) was from a community based confirmed MI
patient, the ADP disaggregation pattern was abnormal, the
P^  value normal, but there was a marked reduction in the 
clotting time of ^  (a decrease of 14.3 secs..).
Pattern (c) was from a hospital based acute MI patient 
and both the aggregation and ^  levels were abnormal.
The stringent criteria related to time and temperature
introduced to improve reproducibility resulted in the problem 
that only a few duplicated tests could be performed in one 
batch. Attempts to automate the test using three different 
automatic coagulation methods were not successful. Not one 
of the three instruments tested was found to be as sensitive 
as the Fibrometer used in the original experiments. I t  was 
considered that the reason for this was that the electronic 
method of detecting the clot was more efficient than the 
optical density or vibrating rod system used by the automated 
methods. These methods were not sensitive enough to measure 
the weak, friable clot formed when the heparin was used at the
Fig. 31 demonstrating examples of the correlation between 
the ADP disaggregation patterns and the difference 
between the PF^  levels in the P^  and P2 plasma 
specimens.
Subject "A" shows a normal aDP disaggregation 
ratio
The PF^  results were:-
P^  = 30.4s 
P^  = 28.6s
The thrombin times were:- 
T^  = 1 1 .2 s 
T2 = 1 1 . 1 s
Subject "B" shows the typical abnormal APP dis­
aggregation ratio shown by "long term" MI patients 
The PF^  results were:-
P^  = 32.5s 
P2 = 18.2s
The thrombin times were:- 
Tj_ = 11.4s 
T2 = 11.4s
Subject "C" was. an acute MI patient.
The PF^  results were:-
P^  = 1 2 .2 s 
^2 = 1 2 . 0 s
The thrombin times were:- 
T^  = 1 2 . 0 s 
Tg = 11.9s
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same c o n c e n t r a t io n  a s  w as p r e p a r e d  and t i t r a t e d  on  th e  F ib r o ­
me t e r .  H ow ever , t h e y  f u n c t io n e d  s a t i s f a c t o r i l y  when th e  
h e p a r in  c o n c e n t r a t io n  w as r e d u c e d . T h is  r e s u l t e d  i n  th e  form ­
a t i o n  o f  a s t u r d i e r  f i b r i n  c l o t  b u t  th e  d i f f e r e n c e s  b e tw e e n  
th e  and P ^  v a lu e s  w ere  n o t  a s  g r e a t  a s  fo u n d  w i t h  th e  
F ib r o m e t e r .  The same l o s s  o f  s e n s i t i v i t y  w as e n c o u n t e r e d  
when th e  t e s t s  w ere  p er fo rm ed  m a n u a lly . In  a d d i t io n  th e  r e s u l t s  
c o u ld  n o t  b e r e p r o d u c e d  th e  f o l l o w i n g  d a y  b e c a u s e  o f  th e  l o s s  
o f  l a b i l e  c l o t t i n g  f a c t o r s  w h ic h  a f f e c t e d  t h e  fo r m a t io n  o f  th e  
f i b r i n  c l o t .
The m o d if ie d  p l a t e l e t  f a c t o r  4 t e s t  in c o r p o r a t in g  and  
^  d i f f e r e n c e s  n o t  o n ly  d e t e c t e d  a b n o r m a l i t ie s  i n  th e  a c u te  MI 
c a s e s  b u t  w as c a p a b le  o f  sh o w in g  an a b n o r m a lity  in  th e  com m u nity  
b a s e d  MI p a t i e n t s  and a lso  in a p e r c e n t a g e  o f  norm al c o n t r o l  su b ­
j e c t s .  T h ese  abnorm al g ro u p s show ed a n orm al P ^  v a lu e  b u t  th e  
a b n o r m a lity  w as d e t e c t e d  in  th e  in c r e a s e  s e e n  a f t e r  in c u b a t io n  
a t  room te m p e r a tu r e  f o r  30 m in s . . O ver 80 s u b j e c t s  h a v e
b e e n  t e s t e d  c o m p r is in g  o f  com m unity  b a se d  norm al and c o n f ir m e d  
MI p a t i e n t s .  E xam p les o f  th e  r e s u l t s  o b t a in e d  a r e  i l l u s t r a t e d  
in  T a b le  11.
The p l a t e l e t  f a c t o r  4 RIA m ethod w as a l s o  p e r fo r m e d .  
P r e l im in a r y  t e s t s  show ed t h a t  p la sm a  sp e c im e n s  r e q u ir e d  d i l u ­
t i o n  1 :3  w i t h  th e  d i l u e n t  p r o v id e d  in  t h e  k i t .  T h is  f a c i l i t a ­
t e d  th e  r e a d in g  o f  th e  t e s t  r e s u l t  from  th e  m ost s e n s i t i v e  
p o r t io n  o f  th e  " s ta n d a r d  g r a p h " . The g ra p h  and some o f  th e  
r e s u l t s  o b t a in e d  c a n  be s e e n  i n  F i g . 32 and e x a m p le s  o f  th e  
r e s u l t s  o b t a in e d  a r e  l i s t e d  i n  T a b le  1 2 .  I t  ca n  b e s e e n  t h a t  
t h i s  m ethod c o n f ir m s  t h a t  m arked d i f f e r e n c e s  in  t h e  and  
r e s u l t s  e x i s t  in  some o f  th e  s u b j e c t s  t e s t e d .  O n ly  l i m i t e d  
d a t a  h a s  b e e n  o b t a in e d  t o  d a t e  from  e x p e r im e n t a l  w ork  in c o r p o r ­
a t i n g  t h i s  m eth o d . H ow ever, i t  a p p e a r s  t h a t  a s i m i l a r  s i g n i f i ­
c a n t  r e l a t i o n s h i p  b e tw e e n  th e  d i s a g g r e g a t i o n  r a t i o  and th e  p l a t e ­
l e t  f a c t o r  4 l e v e l s  in  th e  and P^ s p e c im e n s  d e s c r ib e d  u s in g  
th e  c l o t t i n g  m ethod ca n  be r e p r o d u c e d  u s in g  th e  RIA t e c h n iq u e .
Table 11 showing examples of the ADP disaggregation
patterns and the platelet factor 4 levels after 
centrifuging immediately and after incubation 
at room temperature for 30 mins.
The PF^  levels are reported in seconds.
The pairs of results indicate the P^  and Pg 
values and the thrombin times are similarly rep­
orted. (a) denotes abnormal platelet disag­
gregation results and (N) a normal response.
Platelet disaggregatim 
ratio
PF^  levels 
reported 
in seconds
Thrombin times 
reported 
in seconds
2.6 (A) 25.0 1 2 . 016.0 11.9
3.4 (A) 33.0 11.7
2 0 . 0 - 1 1 . 6
1.9 (N) 37.6 1 1 . 834.0 1 1 . 8
1.4 (N) 44.0 11.741.0 • 1 1 . 8
1.8 (N) 39.4 1 1 . 634.0 1 1 . 6
1.3 (N) 32.0 11.931.0 11.9
6.4 (A) 31.8 11.719.0 11.7
1.2 (N) 24.0 11.924.0 11.7
4.2 (a) 35.9 1 1 . 817.3 1 1 . 8
3.3 (a) 29.2 1 2 . 014.0 11.9
1.5 (N) 31.0 1 1 . 828.2 11.7
100 (acute MI) 1 2 . 0 11.9
1 2 . 0 1 2 . 0
Fig. 32 demonstrating the "standard graph" and ex­
amples of the way in which the data was pres­
ented. The "conc." are the PF^  values in 
ng/ml.
The gamma counter used was an LKB (LKB Instru­
ments Ltd ., Addington Rd., Selsdon, Croydon) 
model "Rockgamma 11". A Texas Instrument 
(St. James House, Wellington Rd;, North, 
Stockport) "silent 700 electronic data terminal" 
was programmed with the appropriate information 
and the data was presented as shown.
PL PM 
PEFP 
TDTP
rpM 
1 9 9 3 .  I,
4 6 7 3 . 0  
1 4 5 4 3 . 0
-TPOl  
■TI'Oc- 
"TP 03 
'TP 04
CDMC 
1 0 . 0 0 0 
3 0.  0 0 0 
5 0 . 0 0 0  
1 0 0 . 0 0 0
B BO 
. 9 4 3
. 491
. 393  
. 3 5 6
P.-PO E 00
1 . 3 0 1  
I 
I
1 . 0 9 1  
I 
1
. 9 6 1  
I 
I
. 9 4 1  
I 
I
. 7 3 1  
I 
I
.601 
I 
I
. 4 9 1  
I 
I
. 3 6 1  
I 
I
. 3 4 1  
I 
I
. 131 
I 
I. 0 0 1---
. 00 15 . 3 0  . 4 5  . 6 0  . 7 5  . 9 0  1 . 0 5  1 . 3 0  1 . 3 5  1 . 5 i
PD? CDPE TIME CDUMTl CPMl PPTID CDMC.
0009 UMKS 006 0 0 04 0 33 3 0 9 9 1 . 6 . 4 4 7 3 9 . 9 5 5
0009 0 0 1'l 0 0 06 0 0 0 5 969 3 9 7 6 1 . 3 . 93  0 1 0 . 7 1 9
0010 0 0 0 0 0060 00 4 7 9 0 3 9 0 5 1 . 4 . 6 0 0 3 3 . 7 7 3
0011 0 0 0 0 0060 0 019 33 3 .  3 . 0 0 0 1 9 4 . 1 7 3 !
0013 0 0 0 0 006 0 0059 75 3 9 9 3 1 . 3 . 9 31 1 0 . 6 4 6
0013 0 0 0 0 006 0 0039 30 1937 1 . 6 . 393 4 9 . 7 4 1
0 014 0 0 0 0 0 06 0 0 019 36 3 . 3 . 0 0 0 1 9 4 . 1 7 3 !
0 015 0 0 0 0 0 06 0 0 039 31 1939 1 . 6 . 4 1 5 4 5 . 3 7 9
0016 0 0 0 0 0 06 0 0 035 1544 1 . 7 . 33 0 7 3 . 5 9 9
0017 0 0 0 0 0O6O 0 045 3 5 4 5 1 . 5 . 5 4 5 3 6 . 9 4 1
0019 0 0 0 0 0 06 0 0 037 31 739 1 . 9 . 156 1 3 6 . 9 5 0 !
Table 12 listing examples of the PF^  RIA results. The 
data indicate that some of the patients tested 
showed the significant marked increase between 
and that was observed when using the 
"clotting" method.
The pairs of results describe the 
and ^  values in ng/ml.
Platelet Factor 4 results 
on P^  and P2 specimens 
reported in ng/ml
10.7
23.7
26.9
2 2 0 . 0
30.4
45.2
18.2
33.0
1 2 . 0 ,
24.4
33.7
38.0
20.3
96.4
26.6
283.0
25.7 
117.9
26.3
40.1
60.
4.4 Discussion
This chapter describes investigations performed in 
order to replace the ADP disaggregation patterns with a test 
suitable for Medical Research Council field work. Investi­
gations were concentrated on the platelet factor 4 and the 
jS-Thromboglobulin levels in the patients' plasma. These 
factors have been well documented and are knowntDplay a role in 
the platelet release reaction. The tests available were re li­
able and capable of investigating large numbers of requests 
expected from a population survey. Denham and his co-workers 
(225) showed that jS-Thromboglobulin was abnormal in some MI 
patients and suggested that the results might be of practical 
value in the care of such patients. Similar results were ob­
tained in this study and abnormal results were found in 6 out 
of 10 acute MI patients. However, normal values were obtained 
with the community based "long-term" MI patients and no cor­
relation was found between the ADP disaggregation ratio and 
the ^-Thromboglobulin levels. In the PF^  studies, 7 out of 
10 acute MI cases were abnormal. No correlation was obtained 
between this test and the ADP disaggregation ratio. Not one 
of the community based MI patients demonstrated an abnormal 
PF^  result. The only test performed that was capable of 
showing abnormal results in these community based MI patients 
and showed a correlation with the ADP disaggregation was the 
modified PF^  method. This was achieved by using a very sensi­
tive system of detecting the clot formed and also by centri­
fuging a portion of the blood immediately and after 30 mins. 
at room temperature. I t was found that the disaggregation pattern 
was related to the difference in the PF^  level between these 
two plasma specimens. Pairs of patients' plasma specimens 
showing abnormal results were fully investigated. Coagulation 
screenings for Jevels of clotting factors as well as individual 
factor assays were performed. No difference in any of the 
coagulation factors was found in the pairs of plasma specimens 
tested. I t has been reported (22i 222) that other proteins can 
inactivate heparin. The utilisation of two specimens from the 
same patient excludes this phenomenon as the explanation for 
the results obtained; proteins should show no increase in
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concentration during incubation at room temperature for 30 
mins. Therefore, the only possible source of this increase 
in PF^  levels must be attributed to the platelets. I t  was 
demonstrated that a good correlation existed between abnormal 
ADP disaggregation tests and a marked increase in the PF^  
levels. The f irs t  tests confirmed that an increased percentage 
of "active platelets" was present in these subjects and i t  is 
suggested that the same phenomenon accounts for the increase 
in the PF^  levels. This view is based on the observation that 
a ll the blood specimens tested were found to have a normal 
whole blood platelet count (the majority having a total count 
within the range 250-350 x 10^/1). Therefore, the only d if­
ference between the normal and abnormal results was that the 
la tter group released in 30 mins. the same level of PF^  that 
the normal subjects released in 3-4 h. Therefore, the abnormal 
group released their platelet factor 4 at a faster rate than 
the normal subjects. Karpatkin (30, 134) has demonstrated that 
"active" platelets release PF^  more readily than the less active 
cells. I t must be assumed that platelets release some of their 
-granules during the 30 mins. incubation at room temperature. 
However, the amount released is relatively small and only de­
tected because of the sensitive techniques used. The PF^  
levels assayed by the RIA method demonstrated an increase from 
approximately 16 ng/ml ( l^  to 40 ng/ml (]^ g^  . In comparison, 
when PF^  was assayed in serum, results of greater than 400 
ng/ml were obtained. The time factor variable (up to six hours) 
has been shown (227) to have no influence on the ADP disag­
gregation test.
The modified platelet factor 4 tes t fulfilled the criteria  
demanded for a test that could replace the ADP disaggregation 
patterns. The problem of returning large numbers of blood 
samples to the base laboratory was therefore overcome. The 
samples can be centrifuged and stored by the MRC staff and 
returned to the laboratory for the platelet factor 4 assay 
using the RIA method.
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1. The previous chapters have shown that in the apparently 
normal healthy male population is a sub-group demonstra­
ting abnormal platelet behaviour when exposed to ADP
as shown in disaggregation tracings. These patterns 
were similar to those found in patients recovered from 
MI. I t  was subsequently demonstrated that such abnormal 
patterns reflected an increased number of "active" plate­
lets present in the circulation of these subjects.
2. The MRC Epidemiology Unit wished to identify individuals 
in the population " at risk" , that is , those most likely 
to develop thrombosis and coronary heart disease.
3. Platelets cannot be stored and therefore this resulted in 
technical and field work d ifficulties.
4. Two different approaches were:-
a. to consider a test and related apparatus that could 
be used by the MRC in the field.
b. to study a stable product in plasma released by the
platelets.
5. Work was performed on jS-Thromboglobulin and Platelet 
Factor 4. The primary objective was to determine a para­
meter suitable for field work giving results correlating
with the ADP disaggregation patterns. I t was observed 
that if  a specimen of blood was separated into two a li­
quots, one centrifuged immediately and one after 30 mins. 
incubation; PF^  results were obtained which
correlated with the ADP disaggregation patterns.
6 . I t is considered that this represents an advance in both 
the knowledge of platelet behaviour and the technological 
methods of studying them. The relevance of the results 
obtained in relationship to the study of coronary heart 
disease is discussed in the "General discussion" chapter 
of this thesis.
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CHAPTER 5
THE AUTOMATION OF THE COATED TANNED RED CELL 
HAEMAGGLUTINATION TECHNIQUE
5.1 Introduction
In addition to the work on platelets already described, 
this thesis is also concerned with the immunological theory 
of coronary heart disease and, in particular, immunelogical 
explanations of platelet disorders related to this disease.
The studies described are based on the work of Davies and 
his CO-workers (178) who found a relationship between anti­
body levels to whole dried milk and patients with confirmed 
CHD. This observation initiated the interest and co-operation 
of the Medical Research Council Epidemiology Unit, Cardiff.
The main objective became the testing of this original report 
using large numbers of MI patients and community "control" 
subjects from a wide area of South Wales. It became essential 
that sera be tested as quickly and efficiently as possible 
maintaining quality control. The method employed in the orig­
inal work was the manual tanned red cell haemagglutination 
technique and this chapter describes the automation of this 
test to meet the MRC requirements.
5.2 Materials and Methods
The technique which was automated was the coated tanned 
red cell haemagglutination method developed by Boyden (228) 
and modified by Gunther (172) • The antigen which was related 
to coronary heart disease in the original experiments was a 
soluble preparation of commercially available whole dried milk 
This was therefore the antigen of choice used in developing 
the automated technique.
5.2.1 Manua1 Method. The reagents used were:- 0.06M phosphate 
buffered saline (pH 7.4) (PBS) Stock solution of 1% (w/v) 
tannic acid in distilled water. The working solution was
— 64—
prepared by diluting the stock with PBS.
The group 0 Rhesus positive cells used in this work
were preserved and anticoagulated with acid citrate dextrose
and obtained from the Blood Transfusion Service.
The principle of the method was that group O cells were 
"tanned'with tannic acid. Reiner and Fischer (229) describe 
how tannic acid alters the surface properties of the red cell, 
changing them from a hydrophilic to a hydrophobic state. This 
results in the absorption of proteins on to the red cell sur­
face.
Group 0  Rhesus positive cells from the acid citrate 
dextrose anticoagulated blood were washed three times in the 
phosphate buffered saline (PBS). The cells were tanned by 
adding 0.5 ml of packed cells to 5 ml PBS, mixing and adding 
a further 5 ml of V]^ 5 oqo dilution of tannic acid. The cells 
were mixed and le ft at room temperature for 30 mins. after
which they were centrifuged and washed once in PBS. To the
washed cells obtained by centrifugation, 5 ml of PBS was added 
and also an equal volume of the soluble antigen solution, 
which in this development work was prepared from whole dried 
milk. This was mixed and le ft at room temperature for 45 mins. 
when the cells were centrifuged and washed twice in the PBS.
The suspension of the antigen coated cells for the titra tion  
were diluted in PBS.
In the titration , serial dilutions of the tes t sera were 
made in neutral rabbit serum and an equal volume of the sens­
itised cells added. The titra tion  trays were le ft at room 
temperature for 1 h followed by overnight incubation at 4 *^C. 
The results were read by noting the pattern formed by the 
settled cells (230). Negative results were denoted by a sharp 
round button of cells at the bottom of the well. In contrast, 
a positive result showed the cells settled in an uniform 
pattern covering the base of the well. This is illustrated 
in Fig. 33.
Fig. 33 demonstrating the cell patterns observed with
the tanned red cell haemagglutination technique. 
The results of the sera demonstrated in the 
haemagglutination tray illustrated in this 
figure are listed below. The results are read 
from right to le f t and the f irs t  row contains 
sera only to facilitate  automatic dilution by 
the Dinateck system. The results are recorded 
as the number of wells demonstrating a positive 
result (see page 67)•
Row Number Result
1 2
2 2
3 6
4 5
5 6
I
8 <1
9 <1
10 ^1
II 2
12 3
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The protein solution of whole dried milk was prepared by 
dissolving 3g of the milk in 15 ml PBS. The suspension was 
shaken for 10 mins. and centrifuged at 2400Xg for a further 
10 mins. The supernatant was carefully removed, care being 
taken in removing the soluble portion only. The total protein 
concentration of this soluble whole dried milk was assayed 
using the method of King and Hazlewood (231). In this method, 
the protein concentration was proportional to turbidity dev­
eloped with a 3% solution (w/v) of sulphosalycilic acid in 
7% (w/v) sodium sulphate. The protein solution of whole dried 
milk was adjusted with the PBS to give a protein concentration 
of 500mg/100ml.
The rabbit sera were prepared by inactivating rabbit 
serum at 56^ C for 30 mins. Washed 0 Rhesus positive cells 
were added to the inactivated serum and le f t for 20 mins. The 
suspension was centrifuged and a working dilution of 1 ml of 
serum to 200 ml of PBS prepared.
5.2.2 The automation of the coated tanned red cell haemagqlu- 
tination technique. Cells were tanned and sensitised as 
described in the manual method. The method was automated 
using the equipment and tubes available from Technicon, (Technicon, 
Hamilton Close, Basingstoke). The principle of the method 
developed was based on agglutination occurring in a glass coil 
and, using a system of *T' pieces, these agglutinated ceHs 
were removed. After separation from the main "flow", these 
cells were haemolysed and the colour developed represented the 
degree of agglutination present in the original specimen. The 
manifold developed for the automation of the tanned red cell 
haemagglutination technique is illustrated in Fig. 34.
Using the manifold described, undiluted sera were added 
to the sensitised cells. After mixing, the antigen/antibody 
reaction occurred in a 10 mins. glass "time delay coil". A 
volume of 1.5% (w/v) sodium chloride solution was added after 
this reaction. This has the effect of destroying any false 
agglutination caused by abnormal proteins present in the sera
Fig. 34 showing the manifold developed for the automation 
of the coated tanned red cell haemagglutination 
technique.
The figures quoted relate to the flow capacity of 
the tubes used e.g. 0.32 denotes that that size 
tube was capable of pumping 0.32 ml of fluid per 
minute.
Reproduced by permission of the publishers.
Rees, B. W. G. (1973) Medical Laboratory 
Technology, 30, p .168.
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(rouleaux formation). The suspension of cells was again mixed 
and the cells allowed to settle in another coil for 1 min>
The agglutinated cells being heavier, settled out faster and 
were removed by a *T* piece together with a standard amount 
of unagglutinated cells. This phenomenon is illustrated in 
Fig. 35. These decanted agglutinates were haemolysed using 
2% (w/v) saponin and the colour developed was measured using 
a 550 or 535nm f i l te r  (See Fig. 36). The peaks observed were 
therefore in proportion to the colour developed which were 
directly related to the amount of agglutination present in the 
specimens.
The detailed procedure is as follows
1. Insert 550 nm or 535 nm f i l te r  in the colorimeter.
2. Turn on the colorimeter lamp. Allow 20 mins. for 
lamp to warm up.
3. Place all the reagent lines and sample lines in 
buffered saline. Start pumping.
4. After 10 mins., check the bubble pattern and connections.
5. Place a ll reagent Ihes in their respective reagents.
L eave th e  sam p le  l i n e  p ic k - u p  in  b u f f e r e d  s a l i n e .
6 .  F i l l  sa m p le  cu p s  and p la c e  on  c o v e r  t r a y  t o  i n h i b i t  
e v a p o r a t io n .  A cu p  c o n t a in in g  b u f f e r e d  s a l i n e  s h o u ld  
be p la c e d  b e tw e e n  th e  l a s t  s ta n d a r d  and th e  f i r s t  
sp e c im e n .
7. When the baseline is established, set recorder at 
90-95% transmission (T) also check 0%T and recorder 
again.
8. Decide on the necessary speed of testing and insert the 
correct cam.
9. Start the samples and standards through the system.
10. The system should be washed with IM sodium hydroxide for
5 mins. and distilled water for 25 mins. after testing.
Fig, 35 demonstrating the cells being decanted by the 
”T” piece. I t  is important that the ”settihg 
out coil" allows the complete sedimentation of 
the agglutinated cells and leaves the unag­
glutinated cells in suspension.
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( L e f t )  A g ra p h  d e m o n s tr a t in g  t h e  p e a k  h e i g h t s  o f  
t h e  s ta n d a r d s  when d i f f e r e n t  f i l t e r s  w ere i n s e r t e d  
i n  t h e  c o l o r i m e t e r .  U s in g  th e  4 2 0  nm f i l t e r  th e  
b a s e l i n e  c o u ld  n o t  b e  a d j u s t e d  t o  z e r o .
( R ig h t )  A s o l u t i o n  o f  h a e m o ly se d  c e l l s  w as sca n n e d  
o n  a  Pye U nicam  " S P 8 -1 0 0  u l t r a v i o l e t  s p e c t r o ­
p h o to m eter* * . The v e r t i c a l  in c r e a s e  r e f l e c t s  th e  
a b so r b a n c e  a t  t h e  a p p r o p r ia t e  w a v e le n g t h s .
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5 . 2 . 3  C om p arison  b e tw e e n  m anual and a u to m a ted  m e th o d s . The 
r e s u l t s  o b t a in e d  u s in g  th e  m anual and a u to m a ted  m eth o d s w ere  
com pared  b y  t i t r a t i n g  th e  same s e r a  u s in g  th e  tw o d i f f e r e n t  
t e c h n iq u e s .  T h is  c o m p a r iso n  w as p er fo rm ed  on r e l a t i v e l y  
s m a ll  b a t c h e s  a t  d a i l y  i n t e r v a l s .  D i f f e r e n t  p r e p a r a t io n s  
o f  c e l l s  w ere  ta n n ed  and s e n s i t i s e d  on  th e  d i f f e r e n t  d a y s  
and in  a d d i t i o n ,  v a r y in g  b a t c h e s  o f  c o m m e r c ia l ly  a v a i l a b l e  
d r ie d  m ilk  w ere  a l s o  p u r c h a se d  and p r e p a r e d  in  o r d e r  t o  v a r y  
th e  s o u r c e  o f  th e  a n t i g e n i c  s o l u t i o n s .  A t o t a l  o f  202 s e r a  
w ere  t e s t e d  on  d i f f e r e n t  d a y s  and a l l  th e  r e a g e n t s  w ere  ch a n g ed  
w it h  e a c h  b a t c h  t i t r a t e d .
5 . 2 . 4  R e c o r d in g  th e  r e s u l t s . U s in g  th e  m anual m eth od  th e  
s e r a  w ere  d o u b le  d i l u t e d  from  n e a t  and t h e  r e s u l t s  r e c o r d e d  
a s  th e  num ber o f  tu b e s  e x h i b i t i n g  a p o s i t i v e  r e s u l t  ( i . e .  
n e a t  = 1 t u b e ,  Vj^q = 2 t u b e s ,  V 20 “ 5 t u b e s . . . . ) .  When 
d e v e lo p in g  th e  a u to m a ted  t e c h n iq u e  i t  w as r e a l i s e d  t h a t  a  
p e a k  h e i g h t  e x t e n d in g  th e  f u l l  l e n g t h  o f  a c h a r t  r e c o r d e r  
( i . e .  100% h a e m o ly s is  o r  c o m p le te  a g g l u t i n a t i o n  o f  th e  serum  
sp e c im en ) w as o b t a in e d  w it h  s e r a  e x h i b i t i n g  an e q u i v a l e n t  
m anual r e s u l t  o f  V q q  ( i . e .  5 t u b e s  p o s i t i v e ) ,  a  b a t c h  o f  
s e r a  w as t h e r e f o r e  t i t r a t e d  m a n u a lly  and a l l  t h o s e  sh o w in g  
a t i t r e  o f  V q q  w ere p o o le d  and d i l u t e d  a s  f o l l o w s  f o r  th e  
a u to m a ted  s y s t e m : -
D i l u t i o n  T i t r e
80N e a t 5 tu b e s  ( V o n )
V 2 4 tu b e s  (V ^ q )
V 4 3 tu b e s  ( V 2 0 )
V g  2 tu b e s  (V j^q)
The " s ta n d a r d  graph" w as drawn by  sa m p lin g  th e  a b o v e  s e r a  
f i r s t  and in  a d d i t io n  known " c o n tr o l"  sp e c im e n s  w ere  t e s t e d  
e v e r y  t e n t h  s p e c im e n . The p e a k  h e i g h t s  o f  th e  unknown s e r a  
w ere com pared w it h  th e  " s ta n d a r d  graph" and th e  r e s u l t s  r e ­
c o r d e d . S e r a  sh o w in g  p ea k  h e i g h t s  e x t e n d in g  th e  f u l l  l e n g t h
—6 8 —
o f  th e  c h a r t  w ere  d i l u t e d  w i t h  PBS and th e  t i t r a t i o n  r e p e a t e d ,
5 , 2 . 5  A d d i t io n a l  c o n t r o l  . t e s t s  p e r fo r m e d . I t  w as c o n s i ­
d e r e d  t h a t  th e  c o lo u r  o f  th e  s e r a  c o u ld  i n f l u e n c e  th e  r e s u l t ­
in g  p ea k  h e i g h t s  and t h e r e f o r e  60 s e r a  w ere t e s t e d  a g a i n s t  
u n s e n s i t i s e d  c e l l s .  The r e s u l t s  w ou ld  d e m o n str a te  th e  i n t e r ­
f e r e n c e  i n  th e  t o t a l  p ea k  h e i g h t s  from  t h e  c o lo u r  o f  th e  s e r a .
The r e p r o d u c i b i l i t y  o f  th e  s y s te m  w as t e s t e d  b y  t i t r a t i n g  
t h e  same sp e c im e n  50  t im e s  and a l s o  by  r e p e a t e d ly  t e s t i n g  
sp e c im e n s  o f  d i f f e r e n t  t i t r e s .
The optim um  sp e e d  f o r  t e s t i n g  w as i n v e s t i g a t e d  b y  t i t r a ­
t i n g  40 s p e c im e n s  m a n u a lly  and r e p e a t in g  th e  t i t r a t i o n  u s in g  
th e  au to m a ted  s y s te m . The s p e e d  o f  sa m p lin g  w as v a r ie d  on  
th e  au to m a ted  s y s te m  from  50  sa m p le s  p e r  h o u r  t o  100  sa m p le s  
p e r  h o u r .
The optim um  p r o t e i n  c o n c e n t r a t io n  o f  th e  a n t i g e n i c  
m a t e r ia l  w as i n v e s t i g a t e d  b y  t e s t i n g ,  a g a i n s t  40 s e r a ,  th e  
same b a tc h  o f  ta n n ed  c e l l s  s e n s i t i s e d  w it h  v a r y in g  d i l u t i o n s  
o f  th e  a n t i g e n i c  m a t e r i a l ,  a  s i m i l a r  e x p e r im e n t  w as p er fo r m ed  
t o  f in d  th e  optim um  c o n c e n t r a t io n  o f  s e n s i t i s e d  c e l l s  s u i t a b l e  
f o r  u se  on  t h e  a u to m a ted  s y s t e m . In  t h i s  e x p e r im e n t  th e  
ta n n e d  c e l l s  w ere  s e n s i t i s e d  w i t h  5 0 0  m g/100  ml o f  th e  a n t i ­
g e n ic  m a t e r ia l  and d i f f e r e n t  c o n c e n t r a t io n s  o f  t h e s e  c e l l s  
w ere  made and t e s t e d  in  tu r n  a g a i n s t  40  s e r a .
5 .3  R e s u l t s
E xam p les o f  th e  "peaks" o b t a in e d  w i t h  th e  a u to m a ted  s y s ­
tem  a re  i l l u s t r a t e d  in  F i g .  3 7 .  E xam p les o f  th e  c o m p a r iso n  
b e tw e en  th e  a u to m a ted  and th e  m anual r e s u l t s  a r e  l i s t e d  i n  
T a b le  1 3 . The t o t a l  number o f  sp e c im e n s  t e s t e d  in  t h e s e  
d i f f e r e n t  b a t c h e s  w as 2 02 and when a l l  th e  r e s u l t s  o b t a in e d  
w ere  com p ared , th e  c o e f f i c i e n t  o f  c o r r e l a t i o n  r  w as 0 . 9 4  w h ic h  
was h i g h l y  s i g n i f i c a n t  (p <  . 0 0 1 ) .  T h ese  r e s u l t s  ca n  b e  s e e n  
in Table 1 4 .
F i g .  37  d e m o n s tr a t in g  th e  r e s u l t s  o b t a in e d  u s in g  th e  
a u to m a ted  s y s t e m . S p ec im en s  w ere  t e s t e d  a t  
60 t e s t s  p e r  h o u r .
1 /8 0
1 /4 0
1/20
l/IO
1/5
— Standards—
T a b le  13 d e m o n s tr a t in g  sorr^ e x a m p le s  o f  th e  c o m p a r iso n  
b e tw e e n  t h e  m anual and th e  a u to m a ted  s y s t e m s .
S p eed 60 Wash 1 /2 S p eed 70 Wash 1 /2
M anual A utom ated M anual A u tom ated
8 . 0 0 0 6 . 0 0 0 2 . 0 0 0 2 . 0 0 0
7 . 0 0 0 6 . 0 0 0  . 3 . 0 0 0 3 . 0 0 0
1 . 0 0 0 2 . 0 0 0 5 . 0 0 0 " 5 . 0 0 0
7 . 0 0 0 7 . 0 0 0 5 . 0 0 0 3 . 5 0 0
2 . 0 0 0 2 . 0 0 0 5 . 0 0 0 5 . 0 0 0
1 . 0 0 0 2 . 0 0 0 3 . 0 0 0 4 . 0 0 0
6 . 0 0 0 6 . 0 0 0 3 . 0 0 0 3 . 0 0 0
1 . 0 0 0 2 . 0 0 0 2 . 0 0 0 2 . 0 0 0
7 . 0 0 0 5 . 0 0 0 2 . 0 0 0 2 . 0 0 0
3 . 0 0 0 4 . 0 0 0 3 . 0 0 0 2 . 0 0 0
2 . 0 0 0 2 . 0 0 0 2 . 0 0 0 2 . 0 0 0
6 . 0 0 0 6 . 0 0 0 3 . 0 0 0 4 . 0 0 0
3 . 0 0 0 2 . 0 0 0 3 . 0 0 0 5 . 0 0 0
8 . 0 0 0 7 . 0 0 0 2 . 0 0 0 2 . 0 0 0
2 . 0 0 0 2 . 0 0 0 6 . 0 0 0 6 . 0 0 0
6 . 0 0 0 6 . 0 0 0 2 . 0 0 0 2 . 0 0 0
3 . 0 0 0 2 . 0 0 0 3 . 0 0 0 4 . 0 0 0
2 . 0 0 0 2 . 0 0 0 4 . 0 0 0 4 . 0 0 0
2 . 0 0 0 2 . 0 0 0 3 . 0 0 0 3 . 5 0 0
4 . 0 0 0 4 . 0 0 0 6 . 0 0 0 5 . 5 0 0
2 . 0 0 0 2 . 0 0 0
1 . 0 0 0 2 . 0 0 0
3 . 0 0 0 2 . 0 0 0 X 3 . 3 5 0 3 . 4 7 5
7 . 0 0 0 7 . 0 0 0 SD 1 . 3 4 76 . 0 0 0 5 . 0 0 0 1 . 3 4 2
1 . 0 0 0 2 . 0 0 0 r . 8 4 9
2 . 0 0 0 2 . 0 0 0 = 20 p = - < 0 . 0 0 16 . 0 0 0 6 . 0 0 0 n
4 . 0 0 0 3 . 0 0 0
2 . 0 0 0 2 . 0 0 0
6 . 0 0 0 4 . 0 0 0
6 . 0 0 0 6 . 0 0 0
3 . 0 0 0 3 . 0 0 0
X 3 . 9 3 9 3 . 7 2 7
3D 2 . 3 5 8 1 . 9 4 1
r . 9 3 8
n = 33 p  = w c:o .oo i
T a b le  14 d e m o n s tr a t in g  th e  s t a t i s t i c a l  a n a ly s e s  b e tw e e n  
th e  a u to m a ted  and m anual t e c h n iq u e s .
A t o t a l  o f  2 02 sp e c im e n s  w ere com pared and  
t h e  r e s u l t s  d e m o n s tr a te  th e  c o m p a r iso n  b e tw e en  
th e  b a t c h e s .  E ach  b a t c h  w as t e s t e d  u s in g  com­
p l e t e l y  new r e a g e n t s  in c lu d in g  t h e  a n t i g e n i c  
s o l u t i o n .
S p eed  o f  S a m p lin g  
(S p e c im en s  p e r  m in u te ) Wash
Number o f  
S p ec im en s
L in e a r  c o e f f i c i e n t  
o f  c o r r e l a t i o n
50 1 / 1 20 0 . 9 2
60 1 / 1 30 0 . 9 6
60 1 / 2 33 0 . 9 4
70 1 / 2 27 0 . 9 5
70 1 / 2 20 0 . 8 5
80 1 / 1 15 0 . 9 2
90 1 / 1 37 0 . 9 5
100 1 / 1 20 0 . 8 9
C om p arison  o f  a l l  in d i v i d u a l  p a i r s  o f  r e s u l t s
n = 202 r  = 0 . 9 4  p = < 0 . 0 0 1
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When a sam p le  w as t e s t e d  50  t im e s  u s in g  a s p e e d  o f  60  
p e r  h o u r  th e  mean (x ) o f  th e  sp e c im e n  w as 4 4 . 5  in c r e a s e  in  
p e r c e n t a g e  t r a n s m is s io n  (%T), and th e  s ta n d a r d  d e v i a t i o n  (SD) 
0.9% T.  The r e p r o d u c i b i l i t y  o f  th e  s y s te m  u s in g  s e r a  w it h  
d i f f e r e n t  t i t r e s  i s  i l l u s t r a t e d  in  F i g .  3 8 .
The e x p e r im e n t  p er fo rm ed  in  o r d e r  t o  f i n d  th e  i n f l u e n c e  
o f  th e  c o l o u r  on th e  p e a k  h e i g h t  show ed t h a t  when s e r a  w ere  
t e s t e d  a g a i n s t  u n s e n s i t i s e d  c e l l s  th e  mean in c r e a s e  w as 8%T 
and SD 1.4% T.
I t  w as fo u n d  t h a t  c e l l s  c o u ld  be s e n s i t i s e d  w it h  a  
s o l u t i o n  o f  m i l k  p r o t e i n  r a n g in g  from  2 0 0  t o  800 m g/100  m l, 
s i m i l a r l y ,  c e l l  c o n c e n t r a t io n s  r a n g in g  from  1 .8  t o  3.0%  g a v e  
i d e n t i c a l  r e s u l t s .  C e l l  c o n c e n t r a t io n s  g r e a t e r  th a n  3% w ere  
n o t  p r a c t i c a b l e  due t o  th e  r a i s e d  b a s e l i n e  on t h e  r e c o r d e r .  
S a t i s f a c t o r y  r e s u l t s  w ere  o b t a in e d  when th e  sp e e d  o f  sa m p lin g  
w as v a r ie d  from  50 sp e c im e n s  p e r  h o u r  t o  100  s p e c im e n s  p e r  
h o u r  b u t  th e  s p e e d  u se d  in  r o u t in e  w ork w as 60 s p e c im e n s  p e r  
h o u r .
5 . 4  D i s c u s s io n
The a u to m a ted  p r o c e d u r e  d e v e lo p e d  show ed c o r r e l a t i o n  w i t h  
th e  e s t a b l i s h e d  m anual t e c h n iq u e .  The in f l u e n c e  o f  t h e  c o l o u r  
o f  th e  s e r a  on th e  t o t a l  p ea k  h e i g h t  w as i n v e s t i g a t e d  and fo u n d  
t o  b e c o n s i s t e n t l y  l e s s  th a n  a t i t r e  o f  and w as t h e r e f o r e
c o n s id e r e d  t o  be o f  no p r a c t i c a l  s i g n i f i c a n c e .  The o p e r a t o r  
c a n  d e c id e  on  th e  sp e e d  o f  t e s t i n g  a s  a ra n g e  o f  s a m p lin g  
s p e e d s  and w a s h - r a t io s  show ed c o r r e l a t i o n .  A c e l l  c o n c e n t r a t i o n  
o f  3% w as u se d  r o u t i n e l y  and th e  c e l l s  w ere  c o a te d  w i t h  a  
s o l u t i o n  o f  w h o le  d r ie d  m ilk  w i t h  a  p r o t e i n  v a lu e  o f  5 0 0  m g/
100 m l.
I t  w as c o n s id e r e d  t h a t  t h i s  a u to m a ted  m ethod w as s u i t a b l e  
f o r  p r a c t i c a l  u s e .  I t  was r e a l i s e d  t h a t  w i t h  a c o n t i n u a l  s c a l e  
o f  r e a d in g ,  r e s u l t s  c o u ld  be p r o v id e d  w h ic h  w ou ld  be s u p e r io r  
t o  th e  s t a g e d  l e v e l s  o b t a in e d  by  th e  m anual d o u b le  d i l u t i o n  t e s t  
T h is  i s  i l l u s t r a t e d  and e x p la in e d  in  F i g .  39 and new u n i t s  w ere
F i g .  38 d e m o n s tr a t in g  th e  r e p r o d u c i b i l i t y  o f  th e  au to m a ted  
c o a t e d  ta n n ed  r e d  c e l l  h a e m a g g lu t in a t io n  te c h n iq u e  
The maximum p e a k  h e i g h t  r e p r e s e n t s  a  ch a n g e  o f  
o p t i c a l  d e n s i t y  o f  a p p r o x im a te ly  70 u n i t s .

F i g .  39 d e m o n s tr a t in g  th e  l i m i t a t i o n s  o f  th e  d o u b le ­
d i l u t i o n  n o n -c o n t in u o u s  s c a l e .  U s in g  th e  m anual
d i l u t i o n  m ethod a p o s i t i v e  a g g l u t i n a t i o n  a t  a
1 1 d i l u t i o n  of / qq and n e g a t iv e  a t  s u g g e s t s
t h a t  th e  r e s u l t  i s  V q q . H ow ever, th e  r e s u l t
c o u ld  be 1 / ^ 2 0  ^ ^ 140' w it h o u t  f u r t h e r  tim e
c o n su m in g  d i l u t i o n s  i t  i s  im p o s s ib le  t o  g iv e  an
a c c u r a t e  t i t r e .
When th e  t i t r e s  a re  c o n v e r t e d  t o  th e  r e c i p r o c a l  
o f  th e  t i t r e s ,  th e  " u n its "  g iv e  a c o n t in u o u s  • 
and more s e n s i t i v e  s c a l e  o f  r e a d in g  th e  r e s u l t s .  
The s ta n d a r d s  a r e  a l s o  c o n v e r t e d  t o  t h e s e  u n i t s  
and t h e r e f o r e  th e  s ta n d a r d  g rap h  drawn u s e s  th e  
f u l l  p o t e n t i a l  o f  th e  s y s te m .
CO
5
LU
g
o
lO
g
g
o o
o
O)
o
00
O
N
O
(O
O
10
o
o
co
O
CM
O
<30
LU
ÛC
z
LUf i
.  I
-70
b a s e d  u p o n  c o n v e r t i n g  t h e  t i t r e  i n t o  t h e  r e c i p r o c a l  o f  t h e  
t i t r e .  T h i s  m e th o d  o f  r e p o r t i n g  t h e  r e s u l t s  u s e d  t h e  f u l l  
p o t e n t i a l  o f  t h e  i n s t r u m e n t  an d  t h e  l i m i t a t i o n s  o f  t h e  n o n -  
c o n t i n u o u s  s c a l e  d o u b l i n g  d i l u t i o n s  w e r e  o v e r c o m e .  S u b ­
s e q u e n t l y  t h e  " s t a n d a r d  g ra p h "  w a s  d r a w n  fr o m  p e a k  h e i g h t s  
r e p r e s e n t i n g  8 0 ,  4 0 ,  2 0  a n d  10  u n i t s  an d  t h e  r e s u l t s  o f  t h e  
t e s t  s e r a  c o u l d  t h e r e f o r e  b e  r e a d  w i t h  g r e a t e r  a c c u r a c y .
I t  w a s  c o n c l u d e d  t h a t  t h e  a u t o m a t e d  m e th o d  c o u l d  r e p l a c e  
t h e  m a n u a l h a e m a g g l u t i n a t i o n  t e s t  an d  i t  w a s  u s e d  i n  t h e  
c o l l a b o r a t i v e  s u r v e y  w i t h  t h e  MRC. T h is  i s  d e s c r i b e d  i n  
C h a p t e r  7 ,  p a g e  8 0 .
-7 1 -
C H A P T E R  6
A STUDY OF AGGLUTINATING ANTIBODIES TO FOOD 
IN THE NORMAL POPULATION
6.1 Introduction
This chapter describes the immunological response in 
normal individuals to some commonly eaten foods. A large 
number of sera from healthy males were available from a pop­
ulation suirvey performed in conjunction with the MRC and the 
automated procedure enabled these specimens to be efficiently 
and accurately titrated . The normal ranges obtained could be 
referred to and compared with the data obtained in subsequent 
"case-control" studies.
I t has been demonstrated by Schloss (232), Sussman et. aL 
(233), Lippard (334) and others (235-237) that intact dietary 
protein derivatives can cross the mature mammalian intestine 
in sufficient amounts to result in an immunological response 
and the subsequent production of specific antibodies. This 
antibody response to various foods, sometimes to a high titre , 
has been demonstrated in the sera of patients by many workers 
(172-177).
Proteins are broken down in the intestines to facilita te  
their absorption and subsequent utilisation by the body. The 
mechanism by which proteins or protein derivatives are ab­
sorbed to stimulate an immune response is reviewed in detail 
by Muir (183). It would appear that in normal conditions 
protein derivatives reach the small intestine epithelium as 
oligopeptides containing 2-3, or probably more, amino acids 
(238) . Kabat (239) has shown that the optimal size of anti­
genic determinants is 3-6 amino acids which is consistent 
with these oligopeptides being antigenic. Warshaw and Walker 
(2 36) have shown that dietary protein derivatives can be ab­
sorbed in antigenic quantities. This occurs in the mature mam­
malian intestine (237, 240) and i t  appears that 2% remain anti- 
genically intact (2 41). The absorption of antigens by the small
-72
intestine is inhibited by antibodies present either on the in­
testinal surface or possibly within the intestinal lumen (242- 
243). These antibodies act as receptors to link the antigen 
to the cell surface proteases, thus immobilising the oligo­
peptides and aiding their breakdown into amino acids. They 
are IgA in nature and are considered to be produced by lymph­
oblasts populating the lamina propria of the intestine. These 
lymphoblasts are derived from the gut associated lymphoid 
tissues and are probably precommitted to IgA production before 
being distributed along the mucosal surface. I t  has been 
proposed that specialised epithelial cells, called M cells, 
provide one route by which antigens from the lumen of the gut 
are sampled and transported to the lymphoid tissue. After 
stimulation by the antigen the lymphoblasts are committed to 
IgA synthesis and they ultimately return to the epithelial 
surface. The review by Muir (183) also suggests that a 
partial deficiency in the intestinal antibodies may result 
in increased absorption of intact antigenic oligopeptides into 
the blood stream. This could cause the formation of antigen/ 
antibody complexes which would ultimately result in localised 
inflammation and therefore increased permeability of the gut. 
This would result in further uptake of antigens reaching the 
serosal side of the intestine and eventually causing an immune 
response with the appearance of the specific antibody in the 
circulation, '
The appearance of antibodies in the circulation is related 
to the method of feeding newborn babies, a newborn infant is 
deficient in IgA but when i t  receives colostrum from its  mother, 
i t  receives antibodies against antigens in the maternal diet, 
small amounts of antigen and immunocompetent cells. I t  is 
therefore immunised both actively and passively to prepare i t  
for its eventual introduction to antigenic food. If, however, 
the infant is bottle-fed, the antibodies in the cow's milk are 
destroyed by the heating and drying process and the antigens 
are given to the infant unopposed. It is known that increased 
permeability occurs at this time and the antigens can reach 
the circulation and stimulate antibody response. In this case, 
re-exposure to minute quantities later in life will result in
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a marked increase of the antibody t i t r e . Clearly the presence 
of antibodies to food in the sera of the adult population 
warrants further investigation. Lowell (244) states that 
"there is perhaps no field in medicine in which more divergent 
views are held than that of response to foods. I t  would seem 
worthwhile, therefore, to outline some procedure by which 
better understanding of the subject be obtained".
This chapter describes experiments performed using the 
automated tanned red cell haemagglutination technique to in­
vestigate the level of antibodies to milk, egg white, meat and 
gluten in 6 00 normal healthy males and females.
6.2 Materials and Methods
The investigations were performed on sera from three 
hundred normal males obtained by the Medical Research Council 
Unit. These subjects were selected at random from the elec­
toral roll and resided in an area of south Wales covering 
apprximately 5000 sq. miles. A similar survey of the level 
of serum antibodies in 300 normal adult females up to the age 
of 65 was made. These were ambulatory females attending the 
hospital laboratory for routine blood tests.
Cells were prepared, tanned and sensitised as previously 
described in Chapter 5, page 64. All the tests were performed 
using the automated system and the results read in the new 
units. Preliminary work determined the concentrations for 
each of the different foods. In this process a wide range of 
antigenic food concentrations were used to sensitise tanned 
red ce]]s. Specificity of a positive result was demonstrated 
by absorbing positive sera with the corresponding antigenic 
food preparation and repeating the titra tion . Only after 
specificity was demonstrated by the reduction of the titre  to 
zero was the test considered specific. Every positive t itre  
reported in this chapter was reduced to zero with the corres­
ponding antigen.i-
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The above development work was performed on random sera 
available in the laboratory and only after the above criteria  
were fulfilled were the techniques subsequently used for the 
population survey. The following sections describe the pre­
paration of various antigenic solutions.
6.2.1 Preparation of milk antigen. The preparation of this 
antigen has been described in detail in Chapter 5, page 65.
6.2.2 Preparation of gluten antigen. After preparatory work 
5 gm of "crude gluten" (Sigma, Poole, Dorset) was added to
15 ml of 0.06M phosphate buffered saline (pH 7.2) (PBS). The 
solution was stirred and shaken for 15 mins. The mixture was 
centrifuged at 2400Xg for a further 15 mins. and the super­
natant removed and used as the soluble protein solution of 
gluten. Using the sulphosalicylic acid method (described on 
page 65) the protein concentration was 300mg/100ml. The sen­
sitised cells demonstrated spontaneous agglutination which 
was overcome by diluting the final concentration of cells in 
1:100 solution of normal serum in PBS.
Random sera were titrated against cells sensitised with 
the solution of gluten. The negatives were discarded and 
sera exhibiting positive results were divided into five a li­
quots and the following added to these tubes containing 1 ml 
of specimen.
a. 50 mg gluten powder
b. 100 mg white bread
c. 100 mg brown bread
d. 100 mg gluten free bread (Waifare Foods, Stockport, Cheshire.
e. 50 mg whole dried milk as a control
The above were left to react with the sera for 30mins, at room 
temperature, removed by centrifugation and the sera retitrated 
against the gluten sensitised cells.
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Only after this experiment demonstrated specificity were 
the 600 normal sera tested for the distribution of antibodies 
to gluten in the normal population.
6.2.3 Egg-white antigenic preparations. Antigenic prepar­
ations were prepared from raw and boiled egg white.
The raw egg whites were separated from the whole eggs 
and diluted 1:5, 1:10, 1:20, 1:50 and 1:100 with the PBS 
pH 7.2. Preparatory work showed that the antigenic solution 
of raw egg could be used at a dilution between 1:5 and 1:100 
but for the experiments described in this thesis a dilution of 
1:10 was used. This dilution of raw egg was prepared in PBS, 
shaken for 10 mins., centrifuged and the soluble protein 
solution removed. Using the sulphosalycilic acid method 
(described on page 65) the protein value of this antigen 
solution was approximately 300mg/l00ml.
The cells were tanned and sensitised with this antigenic 
solution using the same method as described for the milk 
antigen.
In addition to the raw egg, solutions of boiled egg 
antigens were also prepared. One egg was boiled for 10 mins. 
and the white separated from the yellow. The egg white was 
chopped into small pieces, placed in a liquidiser and 20 ml 
of the PBS added. After liquidising for 5 mins. the solution 
was transferred to a suitable tube and centrifuged at 2400Xg 
for 15 mins. The supernatant was removed and this soluble 
proteinof egg white was found to have, on average, a protein 
concentration of 280mg/l00ml. The tanned cells were prepared 
and sensitised with this antigen as previously described.
6.2.4 Preparation of meat antigens. Protein solutions pre­
pared from raw and cooked beef, lamb and pork were tested in 
this experiment.
When p r e p a r i n g  a  s o l u t i o n  o f  raw  m e a t ,  t h e  s u r f a c e  b l o o d
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was recovered by washing in PBS. The meats were liquidised with 
varying amounts of PBS, the solutions centrifuged and the super­
natants used as the solutions of protein. The cells were sen­
sitised with these preparations using the method previously 
described.
For the cooked meat antigen the meat was roasted in the 
oven in the usual manner and when cold, a portion was removed 
and a solution of antigens prepared as described for the raw 
meat.
Raw and cooked protein solutions were obtained from all 
the different meats listed and a wide range of protein con­
centrations prepared from each individual solution. Cells were 
sensitised with these different concentrations and each batch 
tested against the 300 normal male and the 300 normal female 
sera using the automated method.
6.3 Results
6.3.1 The distribution of antibodies to whole dried milk in 
the normal population. The results from the 300 sera of healthy 
males can be seen in the histogram illustrated in Fig. 40. The 
mean titre  was 15.4 units and the standard deviation 24.7.
The distribution of antibodies to whole dried milk in the 
300 females tested is seen in the histogram showing in Fig. 41. 
The mean titre  was 29.5 units and the standard deviation 42.5.
These two figures (40 and 41) illustrate that a higher 
percentage (67% with a titre  greater than 10 units) of females 
have antibodies to dried milk when compared with normal males 
(36% with a titre  greater than 10 units). The actual antibody
level was also higher in the female (mean level was 2 9.5 units
compared with 15.4 units in males). The correlation ' r ' between 
these two groups was 0.50. This compared with values of greater
than 0.94 for all the other foods tested.
t i g .  40 showing the distribution of antibodies to whole
dried milk in the sera of 300 normal healthy males
The mean titre  = 15.4 units and the standard 
deviation 24.7 units.
fig . 41 demonstrating the distribution of antibodies to 
whole dried milk in the 300 normal female sera 
tested.
The mean t i t r e  = 2 9 .5  u n its  and th e  standard
d e v ia t io n  4 2 . 5 .
sioarans dO udawnN
sioarans do aaawAN
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6.3.2 The distribution of antibodies to gluten in the normal 
population. The experiment involving the absorption of sera 
demonstrating a titre  to gluten with different preparations 
of bread showed a reduction in titre  in many of the prepara­
tions tested. The titres  were reduced to less than 10 units 
with the gluten powder, white bread and brown bread but antibody 
remained in the sera absorbed with the gluten-free bread 
and the control tube of dried milk. This demonstrated the 
specificity of the method. Histograms demonstrating the 
distribution of antibody to gluten in 300 normal males are 
illustrated in Fig. 42 and normal females in Fig. 43. The 
mean titre  for the male sera tested was 13.8 units and the 
standard deviation 20.9. S tatistical analyses on the sera 
from the normal females showed that the mean value was 13.9 
units and the standard deviation 22.3. Analyses to compare 
the two groups showed a correlation (r) value of 0.95 which was 
highly significant (p =<0.001).
6.3.3 The distribution of antibodies to egg white in the 
normal population. The distribution of antibodies to boiled 
egg white in 300 normal males can be seen in the histogram 
illustrated in Fig. 44 and the normal females in Fig. 45.
The mean titre  for the male sera was 10.0 units and the stan­
dard deviation 3.6. A mean value of 10.0 was also obtained 
for the female sera tested and the standard deviation was 3.5.
A correlation of 0.97, which was highly significant (p=^ 0.001), 
was obtained when the two groups were compared.
The antibody distribution to raw egg white in the normal 
males can be seen in Fig. 46. The mean titre  was 9.2 units 
and the standard deviation 2.9. The histogram showing the 
distribution of antibodies to raw egg white in the females is 
illustrated in Fig. 47. The mean value in this group was 9.1 
units and the standard deviation 2.8. A correlation (r) of 
0.94 was obtained when the two groups were compared. This was 
highly significant (p = <  0.001).
Fig. 42 demonstrating the distribution of antibodies to 
gluten in 300 normal males.
The mean value was 13.8 units and the standard 
deviation 20.9.
Fig. 43 demonstrating the distribution of antibodies to 
gluten in 300 normal females.
The mean v a lu e  was 13 .9  u n its  and th e  standard
d e v ia t io n  2 2 . 3 .
sioarans dO aaawoN
sioarans dO uaawnN
Fig. 44 demonstrating the distribution of antibodies 
to boiled egg white in 300 normal males.
The mean value was 10.0 units and the 
standard deviation 3.6.
Fig. 45 demonstrating the distribution of antibodies 
to boiled egg white in 300 normal females.
The mean v a lu e  was 1 0 .0  u n its  and th e  standard
d e v ia t io n  3 . 5 .
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s i o a r a n s  j o  uaaw nN
sioarans ao aaawnN
Fig. 46 demonstrating the distribution of antibodies to 
raw egg white in 300 normal males.
The mean value was 9.2 units and the standard 
deviation 2.9.
Fig. 47 demonstrating the distribution of antibodies 
to raw egg white in 300 normal females.
The mean va lu e  was 9 .1  u n its  and th e  standard
d e v ia t io n  2 . 8 .
: 9
fî I
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sioarans ao waawnN
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6.3.4 The distribution of antibodies to meat in the normal 
population. No antibody response was obtained in the 300 
normal males and the 300 normal females to antigenic prepar­
ations from raw and cooked beef, pork or lamb.
The summary of the results obtained in this section is 
illustrated in Table 15.
6.4 Discussion
This chapter describes the antibody response in the normal 
population to various foods. The foods chosen for testing in­
cluded some of the most commonly consumed. They were milk, 
gluten, egg and meat. The subjects used to determine the 
distribution consisted of healthy males chosen by the MRC from 
an extensive area of south Wales and 300 normal females at­
tending the laboratory out-patients' department.
The results obtained when testing the antibody level in 
response to whole dried milk demonstrated that the female 
population appears to show a considerably higher t itre  than 
those observed in the normal males tested. Many factors could 
explain this difference. Preliminary work showed that one 
factor was pregnancy and further experiments are warranted 
on this aspect. However, the investigation of the sex related 
difference is beyond the scope of . this thesis. I t  does, how­
ever, underline how essential i t  is to confine, at this stage, 
related work to males only.
Despite the differences now demonstrated, females of 
child bearing age have a lower incidence of coronary heart 
disease than males (245). A  review in the "Lancet" (245) 
suggested that one possible explanation was that the increased 
endogenous oestrogen production from an early age might prevent 
the development of the disease. However, the incidence of 
CHD disease in females increases after the menopause (246, 247), 
While some protective mechanism from CHD may exist in the 
younger female, the incidence of venous thrombosis in this group
Table 15 summarising the correlation between the dis­
tribution of antibodies to milk, egg and 
gluten in 300 males and 300 females. The 
titrations were performed using the automated 
tanned red cell haemagglutination technique.
Antibody titrated Males Females
Whole Dried Milk
Mean
S.Dv
r
15.4
24.7
29.5
42.5
0.56
Gluten .
Mean
S.D.
r
13.8
20.9
13.9
22.3
0.95
Boiled egg white
Mean
S.D.
. r
1 0 . 0
3.6
1 0 . 0
3.5
0.97
Raw egg white
Mean
S.D.
r.
9.2
2.9
9.1
2 . 8
0.94
No antibodies wecre detected 
meat antigens tested.
against the
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is far higher than in men from the same age group (248).
The experiment involving gluten showed that some of 
the normal population produce antibodies to this antigen.
No significant difference was encountered between the res­
ponse in the 300 male and 300 female sera tested.
The response to raw and cooked egg white in the normal 
population demonstrated that some subjects produce an anti­
body to these antigens. No difference was encountered between 
the response of the male and female population to raw egg or 
boiled egg white. However, there was no obvious relationship 
between the raw and boiled egg white titre s  in individual 
subjects. Further experiments demonstrated that the raw egg 
antigen did not absorb the boiled egg antibody and the reverse 
of this was also true. This suggested that these two anti­
bodies are produced by different antigens, one to raw egg 
white and the other to boiled egg white.
No antibody response to raw and cooked meat antigens was 
found. But i t  may remain possible that the procedure used 
for antibody determination is not suitable for the demonstra­
tion of antibodies to meat.
The results described in this chapter demonstrate that 
a percentage of the normal population produce antibodies
to food antigens. All the sera were tested with the automated 
tanned red cell haemagglutination method, developed and 
described in the previous chapter.
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CHAPTER 7
FOOD ANTIBODIES AND CORONARY 
HEART DISEASE -
7.1 Introduction
This chapter describes a survey performed primarily to 
test the observation that coronary heart disease is related 
to the development of antibodies to whole dried milk when 
compared with controls matched for age (178). This survey was 
performed with the co-operation of the MRC Unit. A large 
number of confirmed MI patients and control subjects were invest- 
gated from a wide area (approximately 5,000 square miles) 
of South Wales. Use was made of the automated procedure for 
titrating the sera. In addition to whole dried milk, gluten 
and egg white were investigated.
A small sub-sample of paired sera was investigated for 
antibodies to various preparations of soya bean. This was the 
result of the observations of Taylor (249) who used rabbits to 
investigate the immunological theory of coronary heart disease. 
The report by Muir et. a l . (249) stated "preliminary experi­
ments are consistent with the view that the formation of anti­
bodies to dietary proteins may indeed constitute a risk factor 
in the development of atheroma in rabbits".
7.2 Materials and Methods
All the sera tested were received from the staff of the 
r-îedical Research Council Epidemiology Unit, Cardiff. A total 
of 216 patients who had suffered a myocardial infarction and 
144 control subjects were tested. The sera were tested "blind" 
with regard to diagnoses and the results were returned to the 
MRC for sta tistica l analyses. S trict diagnostic criteria , 
detailed in Chapter 2 , page 30, were maintained by one medical 
consultant physician under the direction of the MRC. Technical 
proecedures have been described in detail in Chapter 6 page 73.
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7.2.1 Preparation of soya bean antigen. The soya bean prep­
arations tested were obtained from Professor Taylor (Depart­
ment of Science and Nutrition, University of Southampton). 
Five preparations were tested; proteinate, soyolk, soygold, 
promine D and bronsoy 100.
Preliminary work showed that suitable solutions ; could 
be prepared by dissolving 3 grm of the soya bean preparations 
in 20 ml 0.06M phosphate buffered saline (pH 7.4) (PBS).
This was shaken for 10 mins. and centrifuged at 2400Xg. The 
tanned cells were sensitised with these preparations of 
protein and every positive result obtained was absorbed with 
the specific antigen. The subsequent titration  showed the 
reduction of the titre  to less than 10 units, confirming spec­
ific ity .
7.3 Results
The antibody titres  to whole dried milk, gluten, egg 
white and soya bean were assayed "blind" and the results sent 
to the MRC Unit for sta tistica l analyses. The data was pro­
cessed and subsequently published in the Lancet (200). In 
brief, the conclusions were : -
1. I t was confirmed that a higher percentage of men who 
had suffered a myocardial infarction possessed anti­
body to whole dried milk when compared with control 
subjects.
2. Mortality within six months after infarction in the 
group of patients possessing milk antibody was 28% 
compared with 10% in patients with no antibodies.
3. Antibodies to egg white also appeared to have a rela­
tionship with CHD. This observation is discussed 
further in the "General Discussion" chapter of this 
thesis.
4. No difference between the two groups was observed in
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antibodies to gluten.
5. No detailed analyses were received from the MRC on 
the small sub-group tested with the five different 
preparations of soya bean. However i t  was stated 
by the MRC statisticians that there were no signifi­
cant findings. I t  is considered that no firm con­
clusions can be made from this investigation and a 
further, larger study is indicated.
This chapter describes the confirmation of the original 
observations of Davies and his co-workers (178), showing that 
a relationship exists between the presence of antibody to 
whole dried milk and coronary heart disease. I t  was also 
concluded that the presence of this antibody was related to 
mortality in such patients.
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CHAPTER 8
INVESTIGATIONS CONCERNING ANTIBODY TO 
"WHOLE DRIED MILK"
8.1 Introduction
The previous chapter describes investigations performed 
in conjunction with the Medical Research Council Epidemiology 
Unit which confirmed the earlier work of Davies e t. a l . (178) 
in which i t  was shown that antibody to whole dried milk was 
related to coronary heart disease. Prior to that stage i t  had 
been considered essential to study the original antigenic pre­
paration used by Davies (178) although i t  was known that i t  
contained a mixture of many milk proteins. This chapter 
describes investigations performed attempting to identify and 
isolate the individual protein(s) responsible.
The investigations commenced by testing patients' sera 
against cells sensitised with the three main protein fractions 
of milk; casein, ^ -lactalbumin and ^ ^^-lactoglobulin. The 
possibility of the antigen involved being the result of the 
dénaturation of milk proteins during the drying process was 
tested by comparing the antibody titres  obtained with cells 
sensitised with fresh whole milk. The effect of the cream 
portion of milk was investigated by centrifuging whole fresh 
milk and removing the cream. The tanned cells were sensitised 
with the fresh milk with the cream removed.
These investigations suggested that the antigen(s) res­
ponsible for the production of the antibody, previously loosely 
described as "milk antibody", was located in the cream portion 
of milk. I t  is the aim of this chapter to isolate and identify 
the fraction of cream implicated in coronary heart disease. 
Because of the nature of milk-fat globule-membrane (250), i t  
was thought possible that this could be the antigen responsible 
for the production of the "milk antibody". These investigations 
and their significance are detailed in this chapter.
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8.2 Materials and >fethods
8 . 2 . 1  Comparison between the antibody levels to dried whole 
milk and the three main protein components. Solutions of 
casein,c>d-lactalbumin and ^5-lactoglobulin (kindly supplied by 
Dr. Cheeseman, Institute for Research in Dairying, Reading 
University) and whole dried milk were prepared in 0.06 phos­
phate buffered saline (pH 7.2) (PBS) and the protein concen­
trations adjusted to 500 mg/100 ml. Cells were tanned and 
sensitised with solutions of these proteins. A total of
1 0 0  sera were titrated using the automated system and the 
results compared.
Absorption experiments were also performed. Sera exhibi­
ting a titre  to dried whole milk were divided into 5 aliquots 
of 0.5 ml. A volume of 0.1 ml of the antigenic preparations 
from the dried whole milk, casein,cnC-lactalbumin and^-Iacto- 
globulin were added to each of four tubes. The same amount of 
saline was added to one further aliquot, as a control. The 
sera were mixed, le ft at room temperature for 30 mins. and 
tested against cells tanned and sensitised with whole dried 
milk using the automated system already outlined.
8 .2 . 2  Comparison between the antibody levels to whole dried 
milk and whole fresh milk. Whole fresh milk was obtained from 
a local farm. A portion of this milk was centrifuged at 
2400Xg for 2 0 mins. and the cream portion removed. Cells were 
tanned and sensitised with (a) a solution of reconstituted 
whole dried milk; (b) whole fresh milk; and (c) freshly pre­
pared skimmed milk. A total of 12 0 sera were tested. In 
addition, absorption experiments were performed. A suspension 
of cream was added to the sera exhibiting a titre  to both the 
whole dried milk and the fresh whole milk antigens. After 30 
mins. at room temperature the titrations were repeated against 
cells sensitised with the whole dried milk and the whole fresh 
milk.
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8.2.3 Comparison between the antibody levels to whole dried 
milk, washed fresh cream and commercially available skimmed 
milk. Fresh milk was obtained from a local farm, allowed to 
settle and the supernatant cream removed. This was washed 
three times in PBS and cells were tanned and sensitised with 
this antigenic suspension. A solution of commercially pre­
pared skimmed milk was prepared by dissolving 3 grm of the 
powder in 2 0 ml PBS. This was centrifuged at 2400Xg for 20 
mins. and the clear solution removed and used to sensitise 
the tanned red cells.
All subsequent tanned red cell haemagglutination tests 
described in this chapter were performed using a commercially 
available automated method - the Dynateck Rotator System 
(DynatecJc Laboratories Ltd., Danx Road, Billingshurst, Sussex). 
Sera were double diluted from neat and the sensitised cells 
added automatically. Micro-haemagglutination trays were used 
and the results read and recorded as previously described in 
detail for the manual method (page 63).
8.2.4 Comparison between the antibody levels to whole dried 
milk and milk-fat globule-membrane. The method of preparing 
the bovine milk-fat globule-membrane was based on that des- 
^^^bed by Newman (251), Briefly, fresh cream was washed with 
large volumes of PBS and this washed cream placed at 40°C.
After 30 mins. the butter oil was removed and the milk-fat 
globule-membrane used to sensitise tanned cells.
Comparison between the tanned red cell haemagglutination 
t echnique and another method of antibody detection. All the 
observations made and subsequently published were based on 
results obtained with the sensitised tanned red cell haemag­
glutination technique. This section describes experiments 
designed to validate these findings using the enzyme-immuno 
assay (EIa/^  method of antibody detection. This was performed 
in collaboration with Flow Laboratories (Flow Laboratories, 
Second Avenue Industrial Estate, Irvine). The principle of
s u b s e q u e n t l y  r e t i t l e d  E L I S A  o r  e n z y m e - l i n k e d  i m m u n o s o r b e n t  
a s s a y .
—8 6 —
the EIA method depends on the fact that antigen can be absorbed 
and bound to an inert carrier surface, such as the wells of 
micro-titration plates, without losing activity. Subsequently, 
after washing, the test sera are added to these trays. The 
specific antibody attaches to the 'prepared* antigenic surface. 
After washing, enzyme labelled antiglobulin of the relevant 
species is added to these trays. The specific antiglobulin 
antibody attaches itse lf  to the antiglobulin and after further 
washing a substrate is added which changes colour in proportion 
to the enzyme remaining. Therefore the amount of antibody 
present is directly proportional to the optical density of 
the final colour.
Sera were titrated in the author's laboratory using 
tanned cells sensitised with solutions of whole dried milk and 
also milk-fat globule-membrane. An aliquot of the same sera 
and the antigenic solutions were sent to Flow laboratories 
and the antibody levels were assayed there using the EIA 
method.
8.3 Results
8.3.1 Comparison between whole dried milk and the three main 
milk protein fractions. Examples of the results obtained are 
illustrated in Table 16. The total number of sera tested was 
1 00  and the correlation between the titires of dried whole milk 
and casein was r  0.22 p = 0.9, dried milk and oC-1 act albumin 
r 0,22 p = 0.9 and dried milk and Æ -lac to globulin r*0.22 
p = 0.9.
Absorption experiments showed that of the 20 sera exhibi­
ting a titre  to dried whole milk; an antigenic solution of dried 
whole milk reduced the level to less than 10  units in all the 
specimens tested. No reduction of the t itre  of the antibody 
to whole dried milk was observed after solutions of casein,
- 1  actalbumin or ^-lactoglobulin were added to the sera;
Table 16 showing examples of the results obtained when 
the same sera were tested against whole dried 
milk and the three main proteins of milk:- 
casein, - 1 actoglobulin and lactalbumin.
A lack of correlation (r = 0.22, n = 100) was 
observed between the whole dried milk and the 
three fractions. This was reflected in a p value 
of 0.9 (t = 2.2)
Serum
Number
Whole 
Dried Milk Casein -Lactoglobulin Lactalbumin
1 11 8 8 8
2 8 9 12 9
3 20 12 11 12
4 11 8 8 8
5 9 8 8 9
6 9 8 7 7
7 15 8 6 6
8 100 10 9 9
9 100 9 10 10
10 1 20 15 11 8
11 15 8 8 5
12 10 9 6 8
13 10 8 7 ■' 8 ;. .
14 6 8 8 8
15 10 8 8 8
16 8 8 8 8
17 35 10 8 6
18 15 10 8 6
19 20 8 18 7
2 0 10 8 16 12
21 10 8 10 8
22 10 9 10 8
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these results were the same as those obtained when the sera 
were 'absorbed* with saline.
8.3.2 Comparison between dried whole milk and fresh whole 
milk. Examples of the comparison between the whole dried milk 
and the whole fresh milk titres can be seen in Table 17. A 
total of 120 sera were tested and r = 0.99 p = 0.001. Cross
absorption experiments confirmed that whole dried milk absorbed 
to less than 10 units the antibody to whole fresh milk. The 
antibody to whole dried milk was also absorbed to less than 10  
units by whole fresh milk.
Some examples of the results obtained with sera tested 
against cells sensitised with dried whole milk and fresh whole 
milk with the cream removed are also illustrated in Table 17.
A total of 120 sera were tested and r  = 0.28 and p = 0.7.
Investigations into the effect on the titre  of antibodies 
after the addition of cream showed that antibodies to whole 
dried milk and whole fresh milk were reduced to less than 10  
units after absorption with cream. Examples of these results 
can be seen in Table 18.
8.3.3 Comparison between the antibodv titre s  to whole dried 
milk, washed cream and dried skimmed milk. The distribution 
of the results of 50 sera tested against whole dried milk and 
washed cream can be seen in Fig. 48. Correlation "r" was 
0.96 which is highly significant (p = <1 0.001). The results 
obtained with skimmed milk showed r = 0.50. This is illustrated 
in Fig. 49.
Absorption experiments confirmed that washed cream reduces 
the level of antibody to whole dried milk to zero. The antibody 
titre s  obtained with washed cream were also reduced to zero 
with whole dried milk.
Tab le  17 showing examples o f the c o r r e la t io n  between the
whole d r ie d  m ilk  and the whole fre s h  m ilk .
A significant correlation (r = 0.99, n = 120) 
was observed between these two preparations.
A p value of 0.001 (t = 76) was highly
significant. ,
Also included are the results obtained when 
tanned cells were sensitised with whole fresh 
milk but with the cream removed. A lack of cor­
relation (r = 0.28, p = 0.7, t  = 3.0) is ob­
served between the results for this antigenic 
solution and those for whole dried milk.
specimen No.
Whole
dried
milk
Fresh whole milk
Fresh whole 
milk with 
cream removed
1 26 24 10
2 6 . ^ 6
3 30 28 10
4 40 42 10
5 6 6 6
6 160 152 36
7 7 8 7
8 7 8 7
9 320 340 80
10 16 : 16 8
Table 18 showing examples of the results obtained when 
sera exhibiting a titre  to whole dried milk 
were "absorbed" with saline and also absorbed 
with the same volume of cream.
Every specimen was absorbed to less than 10 units 
with the cream when the sera were tested with 
cells sensitised with an antigenic solution of 
whole dried milk.
specimen No. absorbed with saline
Sera
absorbed with cream
y 1 26 9
2 ■ 46 ■
3 30 : ' e: :?:; : :
4 40 6
5 16 8
6 160 9
7 27 7
8 17 7
9 320 9
10 16 ■ 8 :
F ig .  48 showing the c o r r e la t io n  ob ta ined  when te s t in g  sera
f o r  a n tib o d ie s  to  whole d r ie d  m ilk  and washed cream.
A correlation (r) of 0.96 was obtained and this was 
highly significant (p ^0.001).
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Fig. 49 showing the scatter diagram obtained when the
same sera were titrated for antibodies to whole 
dried milk and skimmed milk.
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8.3.4 Comparison between the antibody titre s  to whole dried 
milk  and milk-fat globule-membrane. Titration of 2 00 sera was 
performed and sera showing a negative result to both antigens 
have been excluded from the sta tistica l analyses. The correl­
ation between the remaining 48 paired results is demonstrated 
in Fig. 50 and r  = 0.95 p = <0.001.
Cross-absorption experiments showed that the bovine milk- 
fat globule-membrane antigen reduced the level of the antibody v 
to whole dried milk to zero. The antigenic solution of whole 
dried milk had the same effect on the antibody titre  to the 
bovine milk-fat globule-membrane•
8.3.5 Comparison between the antibodv titre s  to whole dried 
milk and milk-fat qlobule-membrane using the EIA method. The 
results of the collaborative study with Flow Laboratories are 
illustrated in Fig. 51. Shown are the levels obtained with
the EIA method of sera tested against whole dried milk and bovine 
milk-fat globule-membrane. Correlation 'r* of 0.97 (p = L^O.OOl) 
was obtained.
8.3.6 Comparison between the haemagglutination technique and 
the EIA method. Specimens were tested for levels of antibodies 
against bovine milk-fat globule-membrane, using the tanned red 
ce ll’haemagglutination technique, in the author's laboratory.
The same sera were tested by Flow laboratories using the EIA 
method. The EIA results were reported in optical density (OD) 
units. The data from the preliminary experiment is listed in 
Table 19. I t  appeared from the data that when the haemag­
glutination result was or greater, the EIA test was always
higher than 0.10. This was also found in five out of nine of 
the haemagglutination results of ^/g. However, in the lower 
dilutions, i t  was obvious that many sera exhibiting a negative 
haemagglutination result showed the presence of an antibody 
with the EIA method. In a lower percentage, the reverse of 
this was found. In the second collaborative study performed, 
i t  was decided to examine the data in terms of positive/negative 
results. CDs of < 0.100 were accepted as negative, 0.100-0.150 
as positive/negative and >0.150 as definite positives. This
Fig, 50 demonstrating the correlation between the results 
of sera tested against whole dried milk and bovine 
milk fa t globule-membrane. A correlation *r' of 
0.95 was obtained, (p <  0.001).
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B O V IN E  M IL K - FAT G LO B U LE -M E M B R A N E  A N T IB O D Y  LEVELS (T U B E S )
F i g .  51 d e m o n s tr a t in g  th e  c o r r e l a t i o n  o b t a in e d  when t e s t i n g  
s e r a  u s in g  th e  EIA m eth od . The c o r r e l a t i o n  ' r  ' 
o b t a in e d  when co m p a r in g  th e  a n t ib o d y  l e v e l s  a g a i n s t  
w h o le  d r ie d  m ilk  and b o v i n e - f a t  g lo b u le -m em b ra n e  
w as 0 . 9 7  (p * < 0 . 0 0 1 ) .
12
10
0  9
0 8OO
Î3lU
>UJ 0 7
o
§
I-z
<
0 6
S
2 0 5
cco
0
1  0 4
0 3
0 2
01
0 0 801 0 2 070603 0 4 0 5
BOVINE M IL K -F A T  GLOBULE-MEMBRANE ANTIBODY LEVELS (O D)
T a b le  1 9  e x h i b i t i n g  t h e  r e s u l t s  o b t a i n e d  b y  E IA  an d
t a n n e d  r e d  c e l l  h a e m a g g l u t i n a t i o n  t e c h n i q u e s  
T h e a n t i b o d y  t e s t e d  w a s  m i l k - f a t  g l o b u l e -  
m em brane an d  t h e  r e s u l t s  a r e  g r o u p e d  i n  
h a e m a g g l u t i n a t i o n  t i t r e s .
EIA results 
in OD
Haemagglutination 
results in titres
EIA results 
in OD ; ,
Haemagglutination 
results in titre s
0 . 0 1 0 0 . 0 1 1 / 8
0 . 0 1 0 0 . 0 2 1 / 8
0 . 0 2 0 0.03 1 / 8
0 . 0 2 0 0.07 1 / 8
0 . 0 2 0 0 . 1 0 1 / 8
0 . 0 2 0 0 . 1 2 1 / 8
0.03 0 0 . 1 2 1 / 8
0.03 0 0.15 1 / 8
0.03 0 0.29 1 / 8
0.05 0 0 . 1 2 1/16
0.05 0 0 . 1 2 1/16
0.06 0 0.13 1/16
0.06 0 0.17 1/16
,0.06 0 0 . 2 1 1/16
0.06 0 0 . 2 2 1/16
0.06 0 0.24 1/16
0.08 0 0.47 1/16
0.09 0 0.16 1/32
0.09 0 0.15 1/32
0.09 0 0.15 1/64■■
0 . 1 0 0 0.16 1/64
0 . 1 2 0 0.32 1/64
0.13 . 0 0.44 1/64
0.14 0
0.14 0
0.03 1/4
0.04 1/4
0.04 1/4
0.05 1/4
0.06 1/4
0.06 1/4
0.09 1/4
0 . 1 0 1/4
0 . 1 0 1/4
0 . 1 0 1/4
0 . 1 2 1/4
0 . 2 2 1/4
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experiment was performed using a freshly prepared batch of 
milk-fat globule-membrane and the optimum dilutions of the 
various reagents were carefully monitored. The results returned 
from Flow laboratories and the comparison with the haemag­
glutination results are reported in Table 20. As can be 
seen an improved correlation was obtained, most of the
2haemagglutination titres  of greater than V 9 exhibited a 
positive EIA titre .
8.4 Discussion
This chapter describes investigations attempting to 
identify and isolate the antibody previously referred to as 
"antibody to whole dried milk". I t  was found that casein,
0 ^ - 1  act albumin and jff-lactoglobul in showed no correlation 
between antibody levels to these three main proteins of milk 
and that to whole dried milk. The absorption experiments 
confirmed that these three antigens were not related to or 
responsible for the "whole dried milk" antibody.
I t  was shown that a highly significant relationship 
existed between the levels of antibody to whole dried milk and 
to fresh whole milk. This excluded the possibility that the 
responsible antigen was related to dénaturation of proteins 
during preparation of the dried milk or to any additives to 
the commercial product. The absorption experiments with cream, 
and the lack of correlation in results when fresh milk, with 
the cream removed, was tested, suggested that the antigen 
responsible resided in the cream portion of milk. This ob­
servation was confirmed when the results of sera tested with 
whole dried milk were compared with cells sensitised with 
washed cream. The correlation 'r '  was 0.98 which was highly 
significant.
This knowledge that the responsible antigen was located 
in the cream portion of fresh whole milk formed the basis for 
further studies. Cream consists of fat globules. Borgmann and 
his co-workers (252), Harrison and Lunt (253) and Patton and
Table 20 demonstrating the comparison between the EIA and 
the haemagglutination method. The EIA results 
of 0.100 were accepted as negative. When 
"absorption" experiments were performed on the 
positive sera, the levels were reduced to OD 
readings of <0.100. This was considered to be 
equivalent to the "background" level. OD readings 
between 0.100-0.150 were reported as positive/ 
negative. This level appeared to be an "inter­
mediate range" where the haemagglutination results 
were negative or demonstrated a low titre . Most 
OD readings of > 0.150 correlated with a haemag­
glutination titre  of > V 2 *
In this table the negative results are reported 
as -, postive/negative as -, positive results 
as +, and "strong" positive results as ++.
The tanned red cell haemagglutination results 
are reported as titre s .
OD
+
+
+
+
+
T i t r e
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0
OD T i t r e
-  1 /2  
-  1 /2
-  1 /2  
-  1 / 2
OD T i t r e
- 1/4
+ 1/4
+ 1/ 4
+ 1/4
t  1 /4
— 1/ 4
+ 1/4
OD T i t r e
-  1 /8  
+  1 /8  
+ 1/8  
+  1 /8  
-  1/8  
+ 1/  8
+  1 /8  
+  1/8
OD T i t r e
+ 1/16 
+ 1/16 
++ 1/16
OD T i t r e
++ 1/32
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Keenan (254), describe how the fat-globules are synthesised 
in the acinar cells of the mammary gland and, upon reaching a 
critical size, project into the duct pushing the acinar cell 
membrane around them. Eventually the cell membrane is separa­
ted and completely encases the milk-fat globule and is referred 
to as the "milk-fat globule-membrane". This is illustrated 
in Fig. 52. McKenzie (250) described this membrane found 
in cream as "highly antigenic and differs immunologically 
from all other recognisable milk proteins".
Sera tested against whole dried milk and also the bovine 
milk-fat globule-membrane showed a h i^ ly  significant correla­
tion in antibody levels (r =0.96). Extensive cross-absorption 
studies confirmed that the antibody related to coronary heart 
disease, previously referred to as an antibody to "whole dried 
milk", is an antibody formed to an antigenic fraction of 
cream called "milk-fat globule-membrane". This finding made 
using the sensitised tanned red cell haemagglutination 
technique, was confirmed in collaboration with Flow Laboratories 
using the enzyme immuno-assay method. After further develop­
ment work using this EIA technique, both Flow Laboratories and 
the author considered that an EIA method had been established 
with results comparable to those obtained by the tanned red 
cell haemagglutination technique which had provided the basic 
published data. In addition, this EIA method confirmed that 
the sera of some healthy adult males possessed an antibody to 
milk-fat globule-membrane. Flow Laboratories have now reported 
(255) that studies have shown that the structure of this anti­
body is consistent with the IgG class of immunoglobulins.
Patton and Keenan (254) describe the bovine milk-fat glob­
ule-membrane as being suitable for use as a "model system for 
the investigation of bio-membranes". Many sim ilarities were 
observed by Dowben and his co-workers (256) between the be­
haviour of intact milk fat-globules and erythrocytes; one 
example is that they are both lysed by repeated freezing and 
thawing, sonication and by sapogenins. I t  is of interest that 
in 1674 van Leeuwenhoek (257) observed that butterfat in milk
F ig .  52 show ing:-
(Top) The appearance of the principal microstructures 
involved in lactation. On the le ft is a single 
alveolus showing arrangement of lactating cells and 
(hollow) lumen area into which the milk is secreted.
On the right is an enlarged version of a single 
lactating cell illustrating the mechanism of 
protein and fat secretion and showing the principal 
membrane system of the cell.
Reproduced by permission of the publishers. From 
Patton, S. (1969). Scientific American, 221, 58-68.
(Deft) An electron micrograph of a section of goat 
mammary tissue showing milk fat globules (MFG). The 
globules approach the plasma membrane (PM) of the 
secretory cell (SC) and bulge through i t .  The globule 
forms a protuberance, which pinches off, forming a 
free milk^fat globule with a boundary membrane (GM). 
Small crescents of cytoplasm (C) are sometimes 
trapped in the globules.
(Right) At a higher magnification, i t  can be seen hew the 
plasma membrane (PM) of the secretory cell (SC) is 
continuous with the globule membrane (GM).
Reproduced by permission of the publishers. From 
Harrison and Lunt (1980), p.50 and 51 (253#
Also by permission of Dr. F. B. P. Wooding, Agri­
culture Research Council, Institute of Animal 
Physiology, Babraham who supplied the original 
micrographs.
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was dispersed as "granules" approximately 2^ in diameter and 
likened the microscopic appearance of a film of milk to that 
of blood. Electron microscopy studies (256) of milk-fat 
globule-membrane "ghosts" showed the structure of this 
membrane to be similar to other membranes and chemical 
analyses of the enzymes present showed similarities to those 
present in the erythrocyte membrane. The results of these 
and other tests, provided further data to confirm similarities 
in the properties and functions of the two membrane prepar­
ations. Dowben et. a l . (256) after extensive investigations 
concluded that the bovine milk-fat globule-membrane was "a 
true biological membrane generically related to other membranes". 
The function and structure of the membrane has been described 
by Harrison and Lunt (253) , These authors describe how the 
main function of the plasma membrane is to protect. I t  main­
tains a constant internal environment irrespective of changes 
that may occur outside. The plasma membrane is also involved 
in complex transfer systems where i t  controls the passage of 
nutrients into the cell and the removal of waste products from 
i t .  Plasma membranes have a basic structure of a double 
layer of lipid molecules with hydrophilic heads and hydrophobic 
ta ils . Also associated with the membrane are protein mole­
cules which penetrate the membrane and others of which are 
embedded in one side or the other. This is illustrated in 
Fig. 53.
I t is known that membranes throughout phylogeny are 
basically similar, Bjerrum (258) demonstrated cross-reactivity 
of antibodies to membranes against the same antigenic deter­
minants in the membranes of other species. Comparable findings 
have been made by other workers (259-264). Bjerrum and B/g- 
Hansen (265) commented that there was "a much closer immunolo­
gical relationship between membrane proteins of different 
cell types than hitherto suggested".
Evidently the bovine milk-fat globule-membrane can be 
considered a biological membrane. This thesis, therefore, 
considers the possibility of cross-reaction between an anti­
body to this bovine membrane and antigenic determinants on
Fig. 53 showing the structure of the cell membrane. I t  
is shown schematically according to current con­
ceptions. The basic structure is a double layer 
of lipid (fat) molecules with their hydrophilic 
heads pointing outward and their hydrophobic 
ta ils  pointing inward. Also associated with the 
membrane are protein molecules, seen here as large 
bodies some of which penetrate the membrane and 
others of which are embedded in one side or the 
other. Most of the movement of ions into and 
out of the membrane is by way of channels in 
the various proteins.
Reproduced with permission of the publishers.
From Tosteson,D.C.(1981) in Scientific American, 
244, p .132.
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human membranes. Chapter 9 (page 93) describes investigation 
into the relationship between the antibody to bovine milk- 
fat globule-membrane and human platelets - both of which 
have been implicated in coronary heart disease.
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CHAPTER 9
BOVINE MILK-FAT GLOBULE-MEMBRANE 
and human PLATELET MEMBRANE
9.1 Introduction
In the previous chapter i t  has been discussed how anti­
bodies developed against one membrane can cross-react against 
membranes of other species. This chapter describes experiments 
demonstrating that the antibody to bovine milk-fat globule- 
membrane reacts with human platelets.
9.2 Mate rials and Ptethod s
9.2.1 Production of antibody to bovine milk-fat globule- 
membrane « The bovine milk-fat globule-membrane was prepared, 
using sterile precautions, as described on page 85. Antibody 
to this preparation was raised in laboratory rabbits. Pre- 
and post-injection rabbit sera were tested for the presence 
of antibody to bovine milk-fat globule-membrane using haemag­
glutination and EIA methods.
9.2.2 Preparation of platelets. Platelets were obtained from 
ten normal healthy males and washed in 0.06M phosphate buffer 
saline (pH 7.2). After washing, the individual preparations 
of washed platelets were pooled. For testing, the final count 
was adjusted to 250 x 10 /^1
9.2.3 Reactivity between antibody to bovine milk-fat globule- 
membrane and platelet membrane. This was demonstrated using 
(1) the EEL aggregation system, (2) a fluorescence method.
1. The procedure followed was similar to that described for 
ADP aggregation on page 2 8 . One ml aliquots of platelet
— 9 4 —
suspension were placed in tubes supplied with the EEL 
aggregation meter. After one minute, 0.1ml samples of 
the rabbit sera were added and the aggregation patterns 
recorded.
2. The fluorescence technique used was based on the method 
described by Von Bem Borne et. a l . (266). To.0.1ml a li­
quots of pooled platelets, 0 .1ml samples of rabbit sera 
were added. These were incubated at 37°C for 30 mins. 
After washing, they were treated with anti rabbit immuno­
globulin FITC, After further incubation and washing, 
examination for fluorescence was made using a Leitz Dialux 
20 Microscope (Leitz Instruments Ltd., 48, Park Street, 
Luton).
9.3 Results
Both the pre- and post-injection sera were tested in 
parallel on the aggregation meter. I t was found that volumes 
down to 0 . 1ml of the post-injection specimens induced strong 
platelet agglutination. The sarr^  volume of the pre-injection 
sera exhibited no agglutination. This is illustrated in 
Fig. 54. The post-injection sera showed marked membrane- 
bound fluorescence and also caused clumping. The pre-injection 
sera showed slight background fluorescence only and the plate­
lets remained discrete.
The tanned red cell haemagglutination technique showed 
that the pre-injection sera possessed antibodies to a titre  of 
/ g and the post injection specimens a titre  of approximately 
/4000* The EIA results showed optical density readings 
equivalent to the haemagglutination titre s . Extensive cross­
absorption studies showed that an antigenic solution of 
^^ole dried milk reduced the titre  of the antibody to bovine 
milk-fat globule-membrane to zero and vice-versa.
9.4 Discussion
The i n v e s t i g a t i o n s  in  t h i s  c h a p t e r  d e s c r i b e  w o r k  p e r f o r m e d
Fig. 54 demonstrating platelet response after the addition 
of rabbit sera.
Tracing 'A* shows a lack of response to the pre­
injection sample of rabbit serum.
Tracing *B* reflects the agglutination observed 
after the addition of the post-injection specimen.
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with antisera, raised in rabbits, and establish that antibody 
to bovine milk-fat globule-membrane reacts with human plate­
le t membrane. The theory of cross reactivity between mem­
branes of different species has been described in Chapter 8 , 
page 92. There is published evidence that antigenic deter­
minants of human platelets membrane may bind with antibodies 
formed against bovine milk-fat globule-membrane. Thus, Bjerrum 
and By6g-Hansen (265) describe how antibodies can be used for 
verifying that the same molecular structures (antigenic deter­
minants) exist on the membranes of different cell types, when 
using cross- immunoelectrophoresis of berol-solubilised membranes 
and appropriate antisera, precipitation lines are obtained.
These can be standardised and identified using a reference 
method. Fig. 55 demonstrates the precipitation lines obtained 
when testing solubilised human erythrocyte membrane against 
antibodies to this membrane. The numbers indicate and are used 
to identify the proteins involved. Although these numbers are 
allocated arbitrarily and the identity of the proteins are 
unknown, when the same method of identification is employed, 
and experimental conditions are identical, they should represent 
the same antigenic determinants, irrespective of the membrane 
system or species involved.
Bjerrum and Be5g-Hansen (265) demonstrated that antibodies 
raised in rabbits against bovine milk-fat globule-membrane 
cross-reacted with some of the major proteins of the bovine 
erythrocyte membrane. These were identified as numbers 5, 6 and 
16. Immunoelectrophoresis studies of solubilised human eryth­
rocyte membrane and antibodies to bovine erythrocyte membrane 
demonstrated that these three determinants were also common 
to these two membranes (258, 265) . This suggests bovine milk- 
fat globule-membrane and human erythrocyte membrane share three 
common antigenic determinants; 5, 6 and 16. Hagen and his co­
workers (267) extensively examined human platelet membrane using 
the same method. They found that these three antigenic deter­
minants were also present on the platelet membrane. I t  there­
fore follows that antibody to bovine milk-fat globule-membrane 
should also react specifically with the same determinants 
shown to be present on the human platelet membrane.
Fig. 55 showing crossed immunoelectrophoresis of 
solubilised human erythrocyte membrane 
proteins and an antibody to this antigenic 
preparation. The numbers on the precipitation 
lines denote particular proteins.
Reproduced with permission of the publishers. 
From Bjerrum, O. J and B^g-Hansen, T. C* (1975), 
p .388 (265).
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Another possible means of activity is now considered.
It has been demonstrated that antibody to bovine milk-fat 
globule-membrane is a IgG class immunoglobulin (255). When 
an immunoglobulin is treated with papain, the molecule is 
sp lit into three parts (268). Two of these are identical 
and capable of combining specifically with the related anti­
gen (269) . These fragments are termed Fab (Fragment antigen 
binding). The third fragment crystallises after purification 
and so is referred to as Fc fragment (Fragment crystallizable)• 
This fragment has not the ability to combine with the antigen. 
However, the Fc fragment can react with "Fc-receptors" present 
on certain cell membranes. This phenomenon could also explain 
the reaction between antibody to bovine milk—fat globule-membrane 
and platelet membrane. But such an alternative explanation 
for the phenomenon demonstrated would not detract from its  
significance in the reaction between these two membranes.
In summary, work described in this chapter has demonstrated 
that antibody to bovine milk-fat globule-membrane reacts with 
human platelet membrane. This forms the basis for further 
discussion which will be included in the "General Discussion" 
section of this thesis.
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CHAPTER 10 
ŒNERAL DISCUSSION '
The fireiings presented in this thesis confirmed the 
involvement of platelets in the development of atheros­
clerosis and coronary heart disease (CHD). Emphasis was 
placed on the role of "active" platelets in these conditions.
I t  was explained how individuals with a higher percentage 
than the normal 2 0-25 per cent "active" platelets could be 
susceptible to atherosclerosis. A test was developed, 
based on the "disaggregation ratio" after the addition of 
a "critical dose" of ADP, and was used in a "blind" survey 
performed in conjunction with the Medical Research Council 
Epidemiology Unit at Cardiff. Analyses of the results 
showed that abnormal results were demonstrated in approxi­
mately 90% of MI patients who had suffered the infarction 
at least twelve months previous to the test. The normal 
population exhibited approximately 19% abnormal results and 
the hospital based controls 13%. This test therefore offers 
a means of identifying individuals who have a predisposition 
to coronary heart disease.
The findings of these investigations need to be con­
sidered in relation to the two theories which are current 
in this particular subject. The f irs t  being the increased 
platelet activity is an effect of atherosclerosis and the 
second is that i t  plays a role in the initiation of ather­
osclerosis and coronary heart disease.
Examination of the data highlights one of the problems 
of investigating this disease. The presence of abnormal results 
in approximately 19% of the normal population demonstrates 
that the abnormality in the confirmed MI patients is not 
likely to be secondary to the infarct. Atherosclerosis is one
—9 8 -
condition where the patients show no clinical evidence 
whatsoever of its  presence (142). Under these circumstances 
i t  is d ifficu lt to define "normal" controls because "healthy" 
males may have atherosclerotic arteries. Myocardial infarc­
tion is only a clinical manifestation of coronary heart 
disease (90). This thesis therefore examines the data 
presented for evidence of the "active" platelets being the 
result of coronary heart disease against them being the 
cause.
The abnormal results in 90% of the confirmed MI cases 
demonstrate that most confirmed patients have a higher than 
normal number of "active" platelets present in their circu­
lation. Although this is highly significant, i t  does not aid 
in elucidating the question of their presence being primary 
or secondary. I t  is therefore important to examine the 
abnormal results in the approximately 19% of the "normal" 
population. These results may have an influence on the 
important question of cause and effect.
Those investigated were a ll healthy adult males as 
determined by the Medical Research Council staff. I t  is 
noted that the percentage of abnormal results found in this 
normal population approximates that of men reported to be 
affected by clinical or sub-clinical coronary heart disease 
(205).
This data may well suggest a predisposition to CHD in 
some apparently normal healthy subjects. This could be due 
to premature build-up of atheromatous lesions caused by 
factors such as life  style, heredity, possibly premature 
ageing or to others of unknown aetiology, similarly, i t  
could be argued that the presence of these platelets could 
be primary and are actively involved in initiating the 
process which terminates in clinical coronary heart disease. 
Their presence could reflect the ability of some individuals 
to produce antibodies against certain immunological factors
-9 9 -
that influence platelet turnover (see page 2 0 ). Genetical 
factors could conceivably influence and result in an in­
creased production of thrombopoietin and subsequently in 
an increased turnover of platelets.
The data presented in the platelet section offers no 
conclusive evidence to support the two theories discussed. 
Therefore, the more controversial theory that the "active" 
platelets play a role in the development of atherosclerosis 
cannot be excluded at this stage. This should not detract 
from the fact that the test developed was capable of detect­
ing the majority of confirmed Ml subjects and could play an 
important role in detecting individuals predisposed to 
coronary heart disease.
The evidence presented to elucidate the exact role of 
"active" platelets appears to attribute equal importance to 
both the cause and effect theories. To develop the theme 
of crucial importance to our understanding of the primary 
or secondary nature of these platelets, investigations were 
performed on the immunological aspect of coronary heart disease.
This section described investigations performed to 
elucidate the role of antibodies to whole dried milk in CHD 
and the distribution of other food antibodies in the popula­
tion. It was found that the antibody which was originally 
related to coronary heart disease was produced in response to 
an antigen present in the cream portion of milk. I t  was 
subsequently demonstrated that this antigen resided in the 
bovine milk-fat globule-membrane, of bovine cream.
Using the EIA nfôthod (page 85), i t  was confirmed that 
a relationship existed between the antibody to whole dried 
milk and bovine milk-fat globule-membrane. The correlation 
between the haemagglutination and the EIa methods was satis­
factory, considering that the methods utilised completely 
different systems of antibody detection. A similar method,
•j p  c
but using isotope ( ^^I) to determine antibody level has
~  1 0  0 —
subsequently been developed in the Biochemistry Department 
of the West Wales General Hospital. This test was introduced 
by Mr. N. M. De adman and Mr. J . D. Evans of the Isotope 
Unit. The results obtained, using this isotope method, 
confirmed allthe observations made by Flow Laboratories; 
the relationship between the antibody to whole dried milk 
and the bovine milk-fat globule-membrane was again confirmed.
The development of an automated system (see page 63) 
enabled the investigation to demonstrate that normal males 
and females produce antibodies to milk, egg and gluten.
No response was shown, using this method, to meat either 
cooked or raw form. I t  was discovered that the antibody 
levels to egg and gluten demonstrated a similar distribution 
in the male and female populations. But antibodies to milk 
did not, for more females possessed antibodies to whole 
dried milk and the levels were also higher. Although the 
milk antibody level is higher, the incidence of coronary 
heart disease is lower in the younger female than in males 
of the same age group. This aspect has been considered in 
the text (page 78) and evidence exists which suggests that 
this apparent protection can be attributed to oestrogen (245).
The discovery that the antibody implicated in atheros­
clerotic coronary heart disease is directed towards a 
fraction of cream called bovine milk-fat globule-membrane 
offers an explanation of why this work on milk antibody and 
coronary heart disease was refuted by certain workers (270, 
271). One (270) used "fat-free" milk and the other (271) 
"National Dried Milk", a preparation which was low in its  
contents of cream. Oster (2 72), using an antigenic prepar­
ation consisting of whole dried milk, independently con­
firmed the original work of Davies e t. a l . (178).
One observation was made which is important in relation 
to the use of the tanned red cells haemagglutination tech­
nique for estimating membrane antibodies. From January to 
September, 1982, the isotope method has given consistent
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results. The haemagglutination technique however, demon­
strated unsatisfactory results with the standard sera during 
the winter months, returning to the expected values during 
the spring. The volume and the consistency of the membrane 
preparations were strikingly different during these two 
seasons. The unsatisfactory variability in the results 
with the tanned red cell haemagglutination technique was 
probably due to the physical state of the membrane and its  
capability of being absorbed on the surface of the tanned 
red cells. This observation may also be of dietary signifi­
cance. I t  was fortuitous that the original observation, 
describing the relationship between the antibodies to whole 
dried milk and bovine milk-fat globule-membrane, was made 
during the summer months. In the author's laboratory future 
work on membranes will be performed using the enzyme (or 
isotope) immuno assay method.
Published evidence describes the bovine milk-fat globule- 
membrane as a "true biological membrane" (256). I t  is also 
known that cross-re activity exists between the membranes of 
different species (258-264). An experiment was designed to 
investigate whether any reactivity occurred between an anti­
body to bovine milk-fat globule-membrane and the platelet 
membrane. I t  was discovered that reactivity did occur. I t 
is important to consider the significance of such a reaction 
and the possible mechanism by which such an antibody could 
attach itse lf  to the platelet membrane. I t has been described 
in the text how an antibody produced to bovine milk-fat globule- 
membrane contains antibodies to antigenic determinants 5 , 6 
and 16. These determinants were shown by Hagen and his co­
workers (267) to be present on the human platelet membrane. 
Relevant to this, Hagen et. a l . (267) showed that the human 
platelet membrane contains twenty antigenic determinants.
Six of these were shown to be glycoproteins, the main one 
present, which was "probably exposed at the outer platelet 
surface" was demonstrated to be number 16. Therefore, if  
this is the case, antigenic determinant is easily accessible
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to the effect of circulating antibodies to bovine milk-fat 
globule-membrane. The cross-reactivity between these two 
membrane preparations could be demonstrated using the 
cross immuno electrophoretic method, which would involve 
testing the antibody to bovine milk-fat globule-membrane 
against solubilised platelet membrane.
The possibility of this antibody reacting via the 
Fc receptor (page 96) should also be considered. This could 
be performed by digesting the antibody with pepsin (2 73). As
a result the Fc fragment is destroyed, but the Fab fragments
remain capable of reacting specifically with the antigen 
involved. The influence in the test of a non-specific "anti­
human" antibody can be disregarded as the test was controlled 
with pre-injection samples from the rabbits. However, the 
action on the platelets by milk-fat globule-membrane antigen/ 
antibody complexes warrants consideration but the presence 
of these can be demonstrated by many techniques routinely
used for the detection of complexes.
I t  is now evident that a percentage of the normal male 
population, and a greater percentage of confirmed myocardial 
infarction patients, have an excess of "active" platelets. 
There is also a correlation between confirmed MI patients 
and the presence of antibody to bovine milk-fat globule- 
membrane. I t  has been demonstrated that this antibody will 
aggregate platelets. One explanation for the presence of 
the increased percentage of "active" platelets can therefore 
be the reaction between the antibody to bovine milk-fat 
globule-membrane and the human platelet membrane.
Such a reaction will inevitably be followed by their 
removal from the circulation (137, 143-153) resulting in 
increased platelet turnover and explain the excess "active" 
form present in the blood. I t  therefore follows that the 
presence of an increased number of "active" platelets in the 
circulation of the normal controls, points to the possibility 
that they are actively involved in the process terminating
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in clinical coronary heart disease.
Relevant to the investigations described in this thesis, 
is the work of Butler and Osking (274). These workers have 
shown reactivity between an antibody to bovine associated 
mucoprotein and various human tissues. This mucoprotein is 
a constituent of the milk-fat globule-membrane. This work 
(2 74) involved cancer, IgA deficiency and auto-immunity. 
Platelets were not tested in this experiment, but the results 
showed reactivity between an antibody to a portion of the 
bovine-milk fat-globule membrane and human epithelial membrane 
antigen and other human cell antigens. Antibodies to human epith­
elia l membrane has also been shown to react with human milk- 
fat globule-membrane-derived glycoproteins (2 7 5 ).
This thesis has demonstrated that interaction between 
an antibody to bovine membrane and human platelets may play a 
role in the development of atherosclerosis. The phenomenon 
by which the body is stimulated to produce antibody against 
"self", resulting in a clinical condition, should be considered. 
Group A streptococcal antigen has been shown to cross-react 
with the myocardium (276, 277). Some workers believe that 
group A beta-haemolytic streptococci of types 12, 4 or 49 
could have a similar action on the kidney (2 76). Welsh and 
his co-workers (2 78) found cross-reactivity between ankylosing 
spondylitis, HLA-B2 7 and Klebsiella. There are 13 antigenic 
determinants (258) on the bovine milk-fat globule—membrane.
I t  will be highly significant to discover whether the body 
produces antibodies to all these and the cross-reactivity 
discussed is caused by a small number of antigens which happen 
to be common to the bovine milk-fat globule-membrane and the 
platelet membrane.
Certain conclusions have been drawn from the work 
described in this thesis. I t  is important to consider 
possible new lines of investigations. These are outlined 
below:-
1. Comparison between the ADP disaggregation patterns and
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antibody levels to bovine milk-fat globule-membrane 
using the isotope immuno-assay method.
2. Electron microscopy studies (2 79) to ascertain whether 
the platelets circulate in the "active" form or whether 
this activity is only important after they have been 
stimulated to undergo their "release reaction".
3. Absorption of the bovine milk-fat globule-membrane 
antigen into the blood stream utilising the inhibition 
method and using the isotope immuno-assay technique.
4. Isolation of the fraction of this antigen in relation 
to coronary heart disease patients.
5. The immunological theory could be pursued by measuring 
the various complement levels and also circulating 
antigen/antibody complexes.
6 . Platelet material can be added to trays (280) and the 
isotope immuno-assay method performed to detect antibody 
in sera directed against platelets. This sensitive 
method could demonstrate a cross reactivity in some 
normal subjects.
In conclusion, this thesis describes the significance 
of detecting the increased percentage of "active" platelets 
in coronary heart disease. Evidence is given to demonstrate 
how antibodies to bovine milk-fat globule-membrane can result 
in the appearance of such platelets. I t  is therefore pro­
posed that interaction between membranes should be considered 
as one important contributory factor in the development of 
atherosclerosis and coronary heart disease.
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